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Abstract 
 
Evaluation of acid ceramidase as response predictor and therapeutic target in 
neoadjuvant chemoradiotherapy for rectal cancer. 
Bowden D, Sutton P, Wall M, Parsons J, Kitteringham N, Vimalachandran D 
 
Introduction 
Colorectal cancer represents the second commonest cause of cancer-related mortality in the 
UK, with one-third of cases involving the rectum.  Response to chemoradiotherapy (CRT) in 
rectal cancer varies from pathological complete response (pCR, with associated survival 
benefit) to disease progression.  Predicting response is not currently possible but biomarkers 
to do this would facilitate personalised treatment, minimise morbidity from CRT and prevent 
delays in the systemic and local management of the disease in non-responders.  Therapeutic 
targets may also be revealed to improve the efficacy of CRT, and further facilitate non-
operative or rectal-preservation strategies.  Initial proteomic profiling of rectal cancer has 
revealed differential expression of acid ceramidase (AC) between relative responders and 
non-responders to CRT. 
 
Aims 
1) Validation of initial proteomic findings. 
2) Confirmation of biological manipulation of AC in vitro. 
3) Subsequent assessment of cell survivability post-irradiation. 
 
Methods 
Tissue microarrays (TMAs) were constructed, comprising pre-CRT biopsies and post-CRT 
resection specimens from 111 rectal cancer patients, and used to correlate 
immunohistochemical expression of AC with pathological response to CRT (χ2). 
Genetic (siRNA) and pharmacological (carmofur) manipulation were used independently to 
inhibit AC expression and activity in a colorectal cancer cell line.  Cells were subsequently 
irradiated, and survival measured by clonogenic assay. 
Results 
TMA analysis demonstrated low AC expression in tumour stroma to correlate with pCR 
(p=0.003) and relative responders to CRT (p=0.048), whereas high AC expression in normal 
colonic epithelium correlated with a non-response (p=0.012).  High AC expression in residual 
cancer epithelium post-CRT also correlated with an increased risk of local disease recurrence 
(p=0.031). 
Preliminary in vitro modelling demonstrated no irradiation specific benefit to 
pharmacological or genetic inhibition of AC activity.  Genetic manipulation of AC resulted in 
reduced cell viability and higher caspase activity, suggesting an apoptotic mechanism. 
Conclusions 
This study supports a role for AC in the response to CRT, implicating tumour-stromal 
interaction and apoptosis as potential mechanisms of action.  Inhibition of AC, by drugs such 
as carmofur, may yet provide a promising therapeutic strategy as an adjunct to CRT in 
patients with rectal cancer.  Further prospective analysis of AC in a wider clinical dataset and 
further evaluation of the potential mechanism of AC-dependent radio-resistance in rectal 
cancer and apoptosis is required. 
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results, and then normalised to the non-coding siRNA value for each time point.  
Data points represent the mean of triplicate samples, with error bars 
representing one SD. 
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4.1 A schematic demonstrating the experimental process undertaken to assess 
irradiation response in the HCT116 cells across all treatment groups.  The process 
was designed to facilitate irradiation delivery at the point of maximal AC activity 
inhibition.  Cells were initially seeded in individual 35mm cell culture dishes and 
incubated overnight to adhere.  siRNA (final concentration 10nM) transfection 
was undertaken (siRNA3 and non-coding control) after 24 hours in relevant cell 
groups by adding the transfection mix to the dishes, whereas pharmacologically-
only treated groups (not undergoing transfection) remained in culture.  At 72 
hours the respective pharmacological treatments (including 0.05% DMSO vehicle 
controls) were applied to the cells in both groups, undertaken by exchanging the 
existing culture medium for dosed DMEM.  In those groups where a 
pharmacological treatment was not applied, the culture medium was equally 
exchanged at this point.  Following incubation with the pharmacological 
treatments for two hours, the cells in the dishes were placed on ice and irradiated 
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across the range of experimental doses, then re-seeded into 6-well cell culture 
plates for the clonogenic assay.  Formed cell colonies were fixed and stained in 
the plates after incubation for 9 days, and subsequently counted. 
4.2 Haemocytometer cell counting performed for the determination of accurate 
plate seeding.  The left side of the figure depicts the haemocytometer grid 
(adapted from https://en.wikipedia.org/wiki/File:Haemocytometer_grid.svg), 
with a corner square representing 1x1mm (and containing a further 4x4 grid) 
highlighted in red.  The right side of the figure demonstrates a near-complete 
image of this 1x1mm square taken from a performed cell count.  An aliquot of 
cells in suspension and appropriately mixed, is mixed 1:1 with 0.4% trypan-blue 
and applied to the haemocytometer under a cover slip at 0.1mm depth.  Cells are 
counted in each of the four corner 1x1mm squares, the total count divided by 4, 
and this number (representing the number of cells in 100nL) multiplied by 20,000 
(as the original cell solution was diluted 50:50 with trypan-blue) to give the cell 
count per mL of the original suspension.  In the demonstrated image, 7 live cells 
(seen as white dots, where trypan-blue has not permeated the cell membrane) 
can be observed. 
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4.3 Colony detection using the GelCount™ automated colony counter.  The image on 
the left depicts the digitally acquired image obtained by the system and 
demonstrates a single well from one of the 6-well experimental plates used.  The 
section of the area highlighted by the red box (as magnified in the right side of 
the figure) demonstrates the automated analysis of the digital image.  A ‘mask’ 
is applied to the image (as demonstrated by the circumferential green line) to 
determine the areas for analysis in relation to the specification of the plate 
loaded, encompassing the area of each well individually.  CHARM™ settings are 
then optimised based primarily on cell colony density and for the size of colonies 
for detection, and the system identifies the colonies (as demonstrated by the red 
triangles, with each triangle counting as one colony) within the designated ‘mask’ 
for each experimental well. 
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4.4 Dose-response to capecitabine in HCT116 cells, evaluated on MTS proliferation 
assay.  Absorbance at 490nm was quantified from triplicate samples in three 
independent experiments, 72 hours after dosing with the demonstrated range of 
concentrations of the drug.  Data was adjusted to account for background 
absorbance and has been normalised to absorbance of vehicle control samples 
(0.05% DMSO).  Mean values are plotted with error bars representing one SD. 
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4.5 Dose-response to 5-FU in HCT116 cells, evaluated on MTS proliferation assay.  
Absorbance at 490nm was quantified from triplicate samples in five independent 
experiments, 72 hours after dosing with the demonstrated range of 
concentrations of the drug.  Data was adjusted to account for background 
absorbance and has been normalised to absorbance of vehicle control samples 
(0.05% DMSO).  Mean values are plotted with error bars representing one SD. 
172 
4.6 Dose-response to carmofur in HCT116 cells, evaluated on MTS proliferation 
assay.  Absorbance at 490nm was quantified from triplicate samples in five 
independent experiments, 72 hours after dosing with the demonstrated range of 
concentrations of the drug.  Data was adjusted to account for background 
absorbance and has been normalised to absorbance of vehicle control samples 
(0.05% DMSO).  Mean values are plotted with error bars representing one SD. 
172 
4.7 Dose-response to combining carmofur and 5-FU in HCT116 cells, evaluated on 
MTS proliferation assay.  Absorbance at 490nm was quantified from triplicate 
samples in five independent experiments, 72 hours after dosing with the 
demonstrated range of concentrations of the drugs in combination.  Data was 
adjusted to account for background absorbance and has been normalised to 
absorbance of vehicle control samples (0.05% DMSO).  Mean values are plotted 
with error bars representing one SD. 
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4.8 Dose-response profiles of 5-FU, carmofur, and carmofur & 5-FU, evaluated on 
MTS proliferation assay.  The graph depicts the data presented in figures 4.5, 4.6 
and 4.7 to facilitate direct comparison. 
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4.9 Whole membrane film of a Western blot performed on a 10% SDS-PAGE gel, with 
ab198599 (Abcam, RabMAb®, rabbit monoclonal) anti-TS primary antibody at a 
concentration of 1:5000.  The green dots represent the position of the bands 
from the molecular weight marker, as per the weights depicted to the right of 
the film.  The grouped bands from 0.05% DMSO vehicle control samples, 2µM 
carmofur treated samples, and 2µM 5-FU treated samples, were obtained at 2, 8 
and 24 hours following incubation in each group from left to right respectively in 
HCT116 cells.  M represents untreated cells incubated in culture medium only. 
175 
4.10 Band specific films of Western blots performed on a 10% SDS-PAGE gel, with 
ab198599 (Abcam, RabMAb®, rabbit monoclonal) anti-TS primary antibody at a 
concentration of 1:5000.  The top film represents TS expression (at 36kDa) in 
HCT116 cells at 1, 2, 4, 8, 16, and 24 hours (from left to right respectively in the 
yellow bracketed bands) subsequent to incubation with 2µM 5-FU, compared to 
expression subsequent to incubation with 2µM carmofur at the same time points 
(from left to right respectively in the green bracketed bands) in the middle film.  
The 0.05% DMSO vehicle control treated cell samples and untreated culture 
medium only cell sample (M) are those as described in figure 4.9.  Can represents 
a rectal cancer sample obtained from the original proteomic profiling known to 
have relatively high AC expression.  A β-actin reference band was obtained for 
the carmofur treated samples blot. 
176 
4.11 HCT116 cell colonies observed after irradiation (0-4Gy) in the pharmacological 
manipulation arm of the AC dependent model of sensitivity to CRT.  Colony 
formation was assessed 9 days after plate seeding, subsequent to irradiation and 
prior pre-irradiation manipulation of AC activity with carmofur.  The treatment 
groups are those as defined in table 4.1.  The surviving fraction for each 
irradiation dose has been normalised to the non-irradiated (0Gy) control for the 
respective pre-irradiation treatment, to facilitate direct comparison of any 
radiation specific effect.  Results are the means of three independent 
experiments. 
177 
4.12 HCT116 cell colonies observed after irradiation (0-4Gy) in the genetic 
manipulation arm of the AC dependent model of sensitivity to CRT.  Colony 
formation was assessed 9 days after plate seeding, subsequent to irradiation and 
prior pre-irradiation manipulation of AC activity with siRNA3.  The treatment 
groups are those as defined in table 4.1.  The surviving fraction for each 
irradiation dose has been normalised to the non-irradiated (0Gy) control for the 
respective pre-irradiation treatment, to facilitate direct comparison of any 
radiation specific effect.  Results are the means of three independent 
experiments. 
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4.13 Box-and-whisker plots demonstrating the surviving fraction at 1Gy irradiation, 
across all experimental treatment groups investigated on clonogenic assay.  
Results have been normalised to the non-irradiated (0Gy) control for the 
respective pre-irradiation treatment to facilitate direct comparison of any 
radiation specific effect.  The treatment groups are those as defined in table 4.1. 
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4.14 Box-and-whisker plots demonstrating the surviving fraction at 0.5Gy irradiation, 
across all transfected treatment groups investigated on clonogenic assay.  Results 
have been normalised to the non-irradiated (0Gy) control for the respective pre-
irradiation treatment to facilitate direct comparison of any radiation specific 
effect.  The treatment groups are those as defined in table 4.1. 
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4.15 Images acquired by the GelCount™ automated colony counter of two of the 6-
well experimental clonogenic assay plates.  The comparison demonstrated is to 
illustrate a representative outcome following transfection with siRNA3 (left side) 
against non-coding siRNA (right side).  The cells on both plates were incubated 
with media only following the respective transfection and are the non-irradiated 
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(0Gy) control group for their pre-irradiation treatment.  Cell seeding densities 
were identical between the plates, with each well in the top rows seeded with 
200 cells, and 400 cells seeded into each well in the bottom rows. 
4.16 Box-and-whisker plots demonstrating the observed surviving fraction across all 
experimental treatment groups investigated on clonogenic assay, for the non-
irradiated (0Gy) control group of the respective pre-irradiation treatment.  The 
treatment groups are those as defined in table 4.1. 
182 
4.17 Box-and-whisker plots demonstrating the grouped observed surviving fraction at 
baseline (non-irradiated, 0Gy controls) on clonogenic assay between cell 
populations that had undergone ASAH1 siRNA transfection (siRNA3), non-coding 
siRNA transfection (siRNA-NC) and non-transfected cells.  The grouped results 
originate from the data presented in figure 4.16; siRNA3 combines 3,M, 3,D and 
3,5; siRNA-NC combines NC,M, NC,D and NC,5; non-transfected combines M, D, 
5, C and C,5. 
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4.18 HCT116 cell proliferation after irradiation (0-4Gy) as observed on MTS assay in 
siRNA transfected populations.  Cell populations had undergone pre-irradiation 
ASAH1 transfection (or non-coding siRNA transfection as control) +/- 5-FU dosing 
(or respective control).  MTS assay was performed 72 hours following the seeding 
of 2,500 cells from each population in triplicate in 96-well plates, with three 
independent experimental replicates performed.  Absorbance at 490nm was 
measured, data adjusted according to background control samples, then 
normalised to the 0Gy value for each treatment group to facilitate direct 
comparison.  The treatment groups are those as defined in table 4.1. 
184 
4.19 HCT116 cell proliferation after irradiation (0-4Gy) as observed on MTS assay in 
pharmacologically treated populations.  Cell populations had undergone pre-
irradiation treatment with 5-FU, carmofur, combined treatment or vehicle 
control.  MTS assay was performed 72 hours following the seeding of 2,500 cells 
from each population in triplicate in 96-well plates, with three independent 
experimental replicates performed.  Absorbance at 490nm was measured, data 
adjusted according to background control samples, then normalised to the 0Gy 
value for each treatment group to facilitate direct comparison.  The treatment 
groups are those as defined in table 4.1. 
184 
4.20 Box-and-whisker plots representing the live cell counts observed prior to seeding 
in the clonogenic plates, according to respective grouped treatment.  2x105 cells 
in 2mL culture medium were seeded in each 35mm cell culture dish at the outset, 
prior to transfection of coding (siRNA3) and non-coding (siRNA-NC) siRNA.  Some 
cell groups were exposed to pharmacological treatment only (non-transfected), 
and control groups were incorporated across the range of treatments as 
described in table 4.1.  All cell groups underwent a change of culture medium (to 
facilitate pharmacological treatment) 2 hours prior to exposure to 0-4Gy 
irradiation.  The cell counts were observed immediately subsequent to 
irradiation (74 hours following initial seeding) upon re-seeding into the 
clonogenic plates. 
185 
4.21 Box-and-whisker plots representing the crude absorbance values observed on 
MTS assay from non-irradiated cell populations exposed to; siRNA transfection 
coding for AC (siRNA3), non-coding siRNA transfection (siRNA-NC), and non-
transfected cells.  Transfection or control treatment was undertaken prior to re-
seeding the cells in 96-well plates at 2,500 cells per well, and MTS was applied 
after incubation for 72 hours.  The values have been adjusted according the 
background absorbance observed from an equivalent volume of media in wells 
on the plates and represent triplicate values from three independent 
experiments. 
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4.22 Luminescence observed in luciferase-expressing HCT116 cells comparing ASAH1 
siRNA transfected (siRNA3), non-coding siRNA transfected (siRNA-NC) and non-
transfected (Media) cell populations, using VivoGlo™ Luciferin assay (Promega).  
Transfection or control treatment was undertaken prior to re-seeding the cells in 
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white-bottomed 96-well plates at 2,500 cells per well.  Luminescence (as a 
surrogate for cell proliferation) was observed at time points over the subsequent 
72 hours following the application of VivoGlo™ Luciferin.  Triplicate wells were 
seeded for each time point for each population, with three independent 
experiments performed.  Mean fluorescence values observed are plotted with 
error bars representing one SD. 
4.23 Luminescence observed in HCT116 cells subsequent to undertaking the Caspase-
Glo® 3/7 assay (Promega) in ASAH1 siRNA transfected (siRNA3), non-coding 
siRNA transfected (siRNA-NC) and non-transfected (Media) cell populations.  
Transfection or control treatment was undertaken prior to re-seeding the cells in 
white-bottomed 96-well plates at 10,000 cells per well.  Luminescence (as a 
marker of caspase 3/7 activity) was observed at 0, 2.5, 7 and 24 hours following 
the application of Caspase-Glo® reagent.  Triplicate wells were seeded for each 
time point for each population, with three independent experiments performed.  
Mean fluorescence values observed are plotted, with error bars representing one 
SD. 
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General Introduction 
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1.1 Colorectal Cancer 
 
 
1.1.1 Epidemiology of Colorectal Cancer 
 
Colorectal cancer (CRC) represents the second commonest cause of cancer related mortality 
in the United Kingdom, according to the Cancer Research (UK) dataset from 2011, despite 
crude 5-year survival more than doubling from 24.4% to 58.7% over the last 40 years.  It is 
the fourth most commonly diagnosed malignancy in the country overall, with 41,581 new 
cases reported in 2011 but is the third commonest malignancy in men and women 
individually (behind prostate and lung cancer, and breast and lung cancer respectively).  The 
national incidence of the disease has increased by 6% over the last decade, likely with the 
introduction and gradual roll out of the UK bowel cancer screening programme since 2006, 
and 95% of cases occur in those over the age of 50.  Males are more frequently affected 
(55.7% vs. 44.3%), and approximately one third of cases involve the rectum or recto-sigmoid 
junction.  These figures are representative of global disease burden, with 447,000 and 
1,360,000 new cases diagnosed in Europe and worldwide respectively in 2012.  
(http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type/bowel-cancer) 
The overall five-year relative survival of CRC patients in England is 50.7% but there is 
significant variation according to disease stage at diagnosis.  According to National Cancer 
Intelligence Network (NCIN) data published in 2009, 93.2% of patients with Dukes A disease 
at diagnosis survive at least five years, in comparison with only 6.6% of those with Dukes D 
disease (table 1.1).  
(http://www.ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_wor
k/colorectal_cancer) 
Survival between patients with colon cancer and those with rectal cancer is comparable, as 
is longer-term survival between sexes.  The latest data from EUROCARE-5 (De Angelis et al, 
2014) demonstrates that five-year age-standardised relative survivals for colon and rectal 
cancer in England are 51.3% and 53.7% respectively.  Whilst most recent data from Cancer 
Research (UK) demonstrates better one-year age-standardised survival in the UK for men 
with colorectal cancer (77.4% vs. 73.9%), survival at five years is equivalent (59.2% vs. 58.2%) 
for men and women respectively. 
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Dukes Stage Cases (%) Five-year survival (%) 
A 8.7 93.2 
B 24.2 77.0 
C 23.6 47.7 
D 9.2 6.6 
Unknown 34.3 35.4 
 
Table 1.1 – Percentage of cases and five-year relative survival by Dukes stage at diagnosis for CRC 
patients diagnosed 1996-2002 in England.  (Adapted from NCIN data briefing – CRC Survival by 
Stage, June 2009) 
 
 
1.1.2  Risk Factors for Colorectal Cancer 
 
It is considered that lifestyle and environmental risk factors are associated with 54% of CRC 
(Parkin et al, 2011).  A meta-analysis of prospective studies assessing meat consumption and 
CRC risk demonstrated the relative risks of cancer development to be 1.28 (95% confidence 
interval (CI) 1.15-1.42) and 1.20 (95% CI 1.11-1.31) for those with the highest intake of red 
meat and processed meat respectively against those with the lowest intake (Larsson and 
Wolk, 2006).  An increased intake of dietary fibre and whole grains reduces the risk of CRC 
(Aune et al, 2011). 
Colonic cancer risk was observed to be 18% and 48% higher in men who are overweight or 
obese respectively, compared with men of a normal weight on meta-analysis (Xue et al, 
2017).  The same study demonstrated a 12% higher risk of colonic cancer in obese women 
but did not demonstrate any association with rectal cancer with a raised BMI in women.  The 
rectal cancer risk was 6% and 25% higher in overweight and obese men respectively 
compared with men of a normal weight.  Another meta-analysis observed the risk of 
colorectal adenoma to be 47% higher in an obese population compared to those of a normal 
weight (Omata et al, 2013).  Complimentary to this is the association of a sedentary lifestyle 
to colon (but not rectal) cancer risk in a meta-analysis of observational studies (Cong et al, 
2014). 
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Alcohol has also been associated with CRC on meta-analysis (Bagnardi et al, 2015), with a 
relative risk of 1.44 in those who drink more than 6 units of alcohol per day, and a 17% higher 
incidence in those who consume 1.5-6 units daily, compared to non- or occasional drinkers.  
A daily consumption of 3 units of alcohol also contributes to a 27% higher incidence of colonic 
(but not rectal) adenoma (Ben et al, 2015).  Smoking confers a 20% increased risk of CRC 
compared to non-smokers (Huxley et al, 2009), with twice the risk of adenomatous polyp in 
smokers against non-smokers (Botteri et al, 2009). 
There is an increase in the relative risk (1.28, 95% CI 1.19-1.39) of developing CRC in people 
with diabetes mellitus compared to those without (Luo et al, 2011).  A diagnosis of 
inflammatory bowel disease also predisposes to CRC, with increased disease extent and 
duration contributing to a 5% risk after 20 years (Lutgens et al, 2013). 
The risk of CRC is more than doubled with a first degree relative affected by the disease and 
increases in those with more than one affected relative or a relative diagnosed at a younger 
age (Butterworth et al, 2006).  Having an adoptive parent with a CRC does not increase an 
individual’s risk, suggesting genetic rather than environmental factors underpin the familial 
risk (Zöller et al, 2014).  The genetics of CRC and associated familial syndromes is therefore 
discussed. 
 
 
1.1.3 Genetics of Colorectal Cancer 
 
There are known genetic defects which predispose to CRC with known somatic mutations 
that present in sporadic tumours.  These alterations are considered to initiate novel or 
improved function in oncogenes and/or loss of function of tumour suppressor genes, with 
subsequent malignant development.  It is estimated that approximately 15-30% of CRC has 
a significant hereditary component (Lynch and de la Chapelle, 2003), of which 5% have a 
Mendelian cancer syndrome which predisposes to CRC (Rustgi, 2007). The majority of these 
are attributable to hereditary non-polyposis colorectal cancer (HNPCC) and familial 
adenomatous polyposis (FAP), where the lifetime risk of cancer development is 80% by age 
70 in HNPCC and 100% by age 40 in FAP (Fearnhead et al, 2002).  These conditions and other 
less common CRC syndromes with their associated genetic defects are summarised in table 
1.2 below. 
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Syndrome Common Features Gene Defect(s) 
Familial 
Adenomatous 
Polyposis (FAP) 
Multiple adenomatous polyps (>100) and 
carcinomas of the colon and rectum; 
duodenal polyps and carcinomas, fundic 
gland polyps in the stomach, congenital 
hypertrophy of the retinal pigment 
epithelium 
APC (>90%) 
Gardner syndrome 
Same as FAP; also, desmoid tumours and 
mandibular osteomas 
APC 
Turcot’s syndrome 
Polyposis and colorectal cancer with brain 
tumours (medulloblastomas); colorectal 
cancer and brain tumours (glioblastoma) 
APC 
MLH1 
Attenuated 
ademomatous 
polyposis coli 
Fewer than 100 polyps, although marked 
variation in polyp number (from ~5 to 
>1,000) observed in mutation carriers 
within a single family 
APC (predominantly 
5’ mutations) 
Hereditary non-
polyposis 
colorectal cancer 
Colorectal cancer without extensive 
polyposis; other cancers include 
endometrial, ovarian and stomach cancer, 
and occasionally urothelial, hepatobiliary 
and brain tumours 
MSH2 
MLH1 
PMS2 
GTBP, MSH6 
Peutz-Jeghers 
syndrome 
Hamartomatous polyps throughout the GI 
tract; mucocutaneous pigmentation; 
increased risk of GI and non-GI cancers 
LKB1, STK11 (30-
70%) 
Cowden disease 
Multiple hamartomas involving breast, 
thyroid, skin, central nervous system and GI 
tract; increased risk of breast, uterus and 
thyroid cancers; risk of GI cancer unclear 
PTEN (85%) 
Juvenile polyposis 
syndrome 
Multiple hamartomatous / juvenile polyps 
with predominance in colon and stomach; 
variable increase in colorectal and stomach 
cancer risk; facial changes 
DPC4 (15%) 
BMPR1a (25%) 
PTEN (5%) 
MYH-associated 
polyposis 
Multiple adenomatous GI polyps, 
autosomal recessive basis; colon polyps 
often have somatic KRAS mutations 
MYH 
Table 1.2 – Genetics of inherited CRC syndromes.  (Adapted from Fearon, 2011). 
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CRC arises most frequently from dysplastic polyps, and therefore an understanding of 
adenoma to carcinoma transformation is essential.  Most polyps are hyperplastic in nature 
and less than 5mm in diameter, however it is the larger adenomas which harbour malignant 
potential (Jass, 2007).  An adenoma is a benign lesion of glandular epithelium, and has 
prevalence of approximately 25% and 50% by ages 50 and 70 respectively (Rex et al, 1993).  
A small number of polyps will progress to malignancy, often over a period of years to 
decades, with polyp surveillance studies demonstrating that a 1cm polyp has a 10-15% 
chance of becoming malignant within 10 years (Stryker et al, 1987).  Adenoma-carcinoma 
progression was first described as a series of genetic alterations responsible for sporadic 
colorectal cancer (Fearon and Vogelstein, 1990), beginning with mutation in the 
adenomatous polyposis coli (APC) gene, and followed by mutations in KRAS and TP53 genes.  
These mutations are positively selected for during colorectal carcinogenesis and are 
intrinsically involved in DNA repair, cell adhesion and proliferation (Wood et al, 2007). 
1.1.3.1  Adenomatous polyposis coli 
The APC tumour suppressor gene encodes for a protein known to regulate cell-adhesion, 
migration and apoptosis (Fearon and Vogelstein, 1990), and is the genetically defective gene 
in FAP as well as some of the less common inherited cancer syndromes.  The defect is present 
in over 75% of colorectal cancers, and is widely believed to be an early step in sporadic 
carcinogenesis due to its reported presence across the adenoma-carcinoma sequence, 
including microscopic adenomas with a small number of dysplastic glands (Kinzler and 
Vogelstein, 1996). 
The most well understood downstream effect of APC mutation is disruption of the WNT 
pathway.  APC targets β-catenin for proteasomal degradation, and therefore mutation 
results in the nuclear accumulation of β-catenin, increased WNT activity and cellular 
proliferation (Polakis, 2007).  WNT signalling is also significantly implicated in cell migration 
via epithelial-mesenchymal transition. 
1.1.3.2  KRAS / BRAF 
The RAS family of proteins (KRAS, HRAS and NRAS) are G-proteins which predominantly 
undertake the role of molecular switches.  KRAS is a proto-oncogene which, following 
activation through the endothelial growth factor receptor (EGFR) pathway, triggers 
downstream signalling through the PI3K/AKT/MTOR and RAF/MEK/ERK pathways resulting 
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in cellular proliferation (Fearon, 2011).  Up to 40% of colorectal tumours have a mutated 
version of the KRAS gene, most commonly in codon 12, with smaller subsets affecting codon 
13 and rarely codon 61 (Downward, 2003).  The mutation is found in a number of flat colonic 
epithelial lesions without dysplasia, questioning its role in early carcinogenesis (Pretlow and 
Pretlow, 2005), however disruption of mutant KRAS in advanced CRC demonstrates that 
inactivation inhibits tumour growth both in vitro and in animal studies, highlighting its role 
in disease progression (Shirasawa et al, 1993). 
BRAF is a downstream target of KRAS and exhibits its effect through the MEK/ERK pathways.  
BRAF mutation occurs in approximately 5-10% of CRC and appears to be independent of 
KRAS mutation, however mutation in either gene can result in pathway upregulation, and 
activation of relevant downstream transcription factors such as myc (Rajagopalan et al, 
2002). 
1.1.3.3  TP53  
TP53 (p53) is a tumour suppressor gene implicated in a wide range of malignancies, most 
likely due to its significant role as a regulator of cell-cycle checkpoints, genomic stability, 
apoptosis and angiogenesis (Vousden and Prives, 2009).  Under conditions of DNA damage 
resulting from cellular stress, p53 activates DNA repair proteins, arrests growth by holding 
the cell cycle at the G1/S regulation point and initiates apoptosis.  Over 50% of all tumours 
have ineffective p53 (Hollstein et al, 1991), thought to be a combination of loss of 
heterogeneity of one allele of 17p and somatic mutation in the other (Fearon and Vogelstein, 
1990).  This pattern is not observed in most adenomas, highlighting these mutations as 
significant events in the transition from adenoma to carcinoma (Baker et al, 1990). 
1.1.3.4  Mismatch repair and microsatellite instability 
Whilst germline mutations account for a relatively small proportion of tumours they offer a 
unique opportunity to understand the genetic instability which contributes to the 
development of CRC.  Mismatch repair (MMR) genes such as MLH1, MSH2, MSH6 and PMS2, 
are responsible for correcting base mismatches and short insertions or deletions which 
normally occur during DNA replication (Grady and Carethers, 2008).  Where these genes are 
defective, DNA sequences are not faithfully replicated and microsatellites are created; short 
sections of repeating DNA, 1-6 base pairs long. 
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Germ-line mutations in MMR genes are present in only 2-4% of CRC patients, however 15% 
of sporadic CRC exhibit microsatellite instability (MSI).  A key mechanism for this is thought 
to be hypermethylation of the promoter of MLH1, resulting in a loss of function (Aaltonen et 
al, 1993).  Microsatellite unstable tumours exhibit a specific phenotype; they tend to be 
poorly differentiated right colonic tumours with high mucinogen and tumour related 
lymphyocytes and are less likely to metastasise than microsatellite stable tumours (Buecher 
et al, 2013).  These pathological features confer a survival advantage, despite a reported 
resistance to fluorouracil based chemotherapeutic regimens (Ribic et al, 2003).  Tumours 
with MSI can be sub-classified as MSI-low or MSI-high by the presence of fewer or greater 
than 30% unstable loci in a panel of 5-10 points respectively (Boland et al, 1998).  The 
distinction of MSI-high and MSI-low is associated with further variations in tumour 
phenotype and disease characteristics. 
1.1.3.5  Chromosomal instability 
The chromosomal instability (CIN) phenotype is observed in approximately 70%–85% of CRC. 
It is widely accepted that most microsatellite stable tumours follow the CIN mechanism of 
carcinogenesis, however the MSI and CIN phenotypes are not mutually exclusive (Lengauer 
et al, 1997). 
The cause of CIN is not clearly understood, although it is believed to be due to defects in 
genes which regulate formation of the mitotic spindle, and alignment and segregation of 
chromosomes at mitosis (Grady, 2004).  A small number of specific defects have been 
suggested, including alterations in Mad2, BubR1, Bub3 and CENPE proteins as well as loss of 
heterogenicity in chromosome 18q, containing the tumour suppressor genes SMAD2, 
SMAD4, and DCC (Barber et al, 2008).  APC mutation is also thought to play a role but its 
presence in many other chromosomal stable tumour phenotypes suggests that the 
molecular basis for CIN is more heterogenous than the relationship between MMR genes 
and MSI (Alberici and Fodde, 2006). 
1.1.3.6  CpG island methylator phenotype 
DNA methylation is thought to serve the biological function of silencing repetitive elements 
of the genome (Yoder et al, 1997).  The significance of hypermethylation resulting in loss of 
function of MLH1 has already been discussed.  The majority of C-phosphate-G (CpG) sites 
have been lost from the human genome during evolution, however hypermethylation of 
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residual sites, defined as methylation of at least 3 loci from a panel of 5 gene-associated CpG 
islands, results in the silencing of tumour suppressor or other tumour related genes, and 
ultimately carcinogenesis (Carragher et al, 2010).  The CpG island methylator phenotype 
(CIMP) represents a further subset of colorectal cancers with a particular molecular and 
biological profile.  Specifically, these tumours have a higher incidence of concurrent 
mutations in KRAS/BRAF but wild type TP53 and are more frequently proximal tumours with 
mucinous and poorly differentiated histopathological features, most often presenting in 
older female patients (Issa, 2004).  CIMP tumour status has been used to infer potential 
response to irinotecan-based chemotherapy (Shiovitz et al, 2014). 
1.1.3.7  Summary of colorectal cancer genetics 
The majority of colorectal tumours reflect a series of hereditary and somatic mutations in 
key genes such as APC, KRAS, BRAF and TP53.  These mutations are most frequently 
associated with a chromosomal instability phenotype.  The acquisition of these mutations 
frequently occurs in differing orders, although the sequence of events may be relevant to 
tumour development.  A subset of tumours initiaite through inactivation of MMR function, 
which may be through inherited, or less commonly, somatic mutation.  Epigenetic 
inactivation of CpG islands through hypermethylation can alternatively lead to high MSI, with 
cumulative mutations in the APC/KRAS/BRAF/TP53 genes ultimately leading to 
carcinogenesis. 
The understanding of colorectal carcinogenesis has developed significantly since the model 
first proposed by Vogelstein in 1990 and is summarised in figure 1.1. 
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Figure 1.1 – The suggested genetic model for CRC.  (a) A number of hereditary and sporadic 
mutations drive the transformation of normal epithelium to adenomatous lesion and subsequently 
carcinoma.  (b) An inherited or acquired defect in DNA MMR function is the initiator for 
carcinogenesis.  (Taken from Fearon, 2011) 
 
 
1.1.4 Consensus Molecular Subtypes of Colorectal Cancer 
An international expert collaboration recently defined colorectal cancer into four clear 
consensus molecular subtypes (CMS).  The colorectal cancer subtyping consortium (CRCSC) 
was formed to assess the presence or absence of core subtype patterns among existing gene 
expression-based CRC subtyping algorithms.  They characterised the key biological features 
of the core subtypes, integrating other data regarding mutations, copy number, methylation 
status, microRNA, and proteomics, and correlated the subtype assignment with patient 
outcome.  The intention was for the subtypes to have a clear biological interpretation, in 
order to form the basis for future stratification and subtype-based targeted interventions 
(Guinney et al, 2015), and are detailed below. 
CMS1 (MSI immune, 14%) tumours are frequently right sided, diagnosed in females, and 
present with higher histopathological grade.  This subtype is hypermutated, has a low 
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prevalence of somatic copy number alterations (SCNA), and accounts for the majority of MSI 
tumours.  These tumours over-expressed DNA repair proteins and display a high CIMP.  BRAF 
mutations commonly seen in MSI frequently occur in this subtype, and genes associated with 
immune infiltration and activation are increasingly expressed. 
CMS2 (canonical, 37%) tumours are predominantly left sided, and display high CIN 
demonstrated by high SCNA, with more frequent copy number gains in oncogenes and losses 
in tumour suppressor genes than other subtypes.  These tumours display epithelial 
differentiation and strong upregulation of WNT and MYC downstream targets, both of which 
are classically implicated in CRC carcinogenesis.  There is a superior survival after relapse in 
this patient group. 
CMS3 (metabolic, 13%) tumours are characterised by KRAS mutations and the associated 
metabolic deregulation.  These tumours display high CIN but with fewer SCNA, a mixed MSI 
status, and low CIMP. 
CMS4 (mesenchymal, 23%) tumours demonstrate high CIN with high SCNA.  There is clear 
upregulation of genes implicated in epithelial mesenchymal transition and gene signatures 
associated with TGFβ signalling, angiogenesis and stromal infiltration, with over-expression 
of extra-cellular matrix proteins and those associated with stromal invasion, mesenchymal 
activation and complement pathways.  These tumours are diagnosed at a more advanced 
stage, with associated poorer overall and relapse-free survival. 
 
Figure 1.2 – Summary of CMS of CRC according to the CRCSC international collaboration.  (Taken 
from Guinney et al, 2015) 
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The remaining 13% of samples are considered to represent a transition sub-type or intra-
tumour heterogeneity. 
 
1.1.5 NHS Bowel Cancer Screening Program (BCSP) 
The NHS BCSP offers biennial population screening to those aged 60-74, as over 80% of bowel 
cancers occur at and after this age.  Screening with the guaiac faecal occult blood test (FOBT) 
has been demonstrated to reduce CRC mortality in four large population based randomised 
controlled trials, each with more than 10 years follow up (Hewitson et al, 2008).  The UK data 
demonstrated a relative mortality risk of 0.87 (95% CI 0.78-0.97) with a follow up period of 
11.7 years.  People with positive FOBT tests are offered a screening colonoscopy, with earlier 
detection of CRC facilitating the increased use of minimally invasive treatment techniques, 
with subsequent improvement in 30-day post-operative mortality and overall survival. 
The guaiac FOBT is being replaced with the faecal immunohistochemical test (FIT), which has 
been demonstrated to be both more accurate in detecting CRC and advanced adenomas, 
and with improved uptake (Moss et al, 2017).  The FIT eliminates potential dietary 
interference and can measure very low concentrations of human-specific haem in stool from 
bleeding cancers and pre-cancerous lesions.  It only requires one stool sample, whereas three 
are required for the current guaiac FOBT, and also uses a simple and cleaner sampling 
technique with an easy-return postal package.  The uptake with the FIT increased to 63.9% 
in all those at age 60 invited to undertake screening for the first time, compared to 54.4% 
with the guaiac FOBT. 
A one-off flexible sigmoidoscopy is also being rolled out as part of the BCSP under the ‘Bowel 
Scope’ program for those age 55 with the option to opt-in until age 60.  This is based on a 
randomised controlled trial from the UK demonstrating a 23% reduced incidence of CRC, and 
a 31% reduced CRC mortality following a screening flexible sigmoidoscopy, after a median 
follow up of 11 years (Atkin et al, 2010). 
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1.1.6 Diagnosis of Colorectal Cancer 
 
Despite the NHS BCSP, the majority of patients with CRC continue to present 
symptomatically.  Typical symptoms of left sided lesions include alteration in bowel habit, 
rectal bleeding, and tenesmus with rectal lesions, whereas right sided lesions more 
commonly present with anaemia, abdominal pain or mass, and systemic symptoms of 
malignancy such as anorexia or weight loss (Majumdar et al, 1999).  The National Institute 
for Health and Clinical Excellence (NICE) define criteria for urgent assessment under two-
week wait referral guidelines based upon these features (NG12, updated 2017), where 
duration of bowel habit and/or rectal bleeding (in the absence of anal symptoms) for more 
than 6 weeks based on a patient’s age, and abdominal or rectal mass and/or anaemia at any 
age, are considered for straight to test assessment.  Patients over 75 years should be 
reviewed within two weeks in an outpatient clinic to determine appropriate investigation 
potentially based upon co-morbidity (NICE, 2015). 
1.1.6.1 Choice of investigation 
The UK Special Interest Group in Gastrointestinal and Abdominal Radiology (SIGGAR) trials 
provided level I evidence on the choice for whole colon imaging in patients with symptoms 
suggestive of CRC.  The two arms of the trial compared CT colonography (CTC) with double 
contrast barium enema (DCBE) to assess cancer and large polyp detection rate, and 
compared CTC with colonoscopy in assessing the requirement for further colonic assessment 
following CTC.  CTC was superior to DCBE in detecting cancers and large polyps (7.3% vs 5.6% 
p=0.039), and patients randomised to CTC were diagnosed with fewer cancers during the 
three-year follow up (Halligan et al, 2013).  No significant differences were observed in 
detection rate, or sensitivity based on post-test cancer diagnoses during follow up, between 
CTC and colonoscopy.  CTC did generate an increased number of further colonic investigation 
with a relative risk of 3.75 (Atkin et al, 2013), although either CTC or colonoscopy is 
recommended for investigation by the Association of Coloproctology of Great Britain and 
Ireland (ACPGBI) (Cunningham et al, 2017). 
 
1.1.6.2 Colonoscopy 
Colonoscopy allows the visualisation of the entire colonic and rectal mucosa whilst 
facilitating biopsy of any suspicious lesion, and the procedure can be considered therapeutic 
in the context of undertaking polypectomy.  Full assessment of the colon is important given 
14 
 
the incidence of synchronous cancers (2-3%), or significant other benign disease (20%), 
which may influence subsequent management (Langevin and Nivatvongs, 1984).  The 
procedure also facilitates the marking of the most significant distal colonic lesion with a 
tattoo on the anal side (but not in the rectum), particularly for subsequent localisation during 
laparoscopic surgery (Williams et al, 2013). 
 
1.1.6.3 CT Colonography 
This investigation combines the use of oral faecal tagging agents with mechanical rectal 
insufflation with CO2 to produce detailed mucosal images of the colon and rectum.  It can be 
performed following full purgative bowel preparation, although some faecal tagging agents 
(such as Gastrograffin) have a laxative effect and can be used as a combined 
cleansing/tagging agent.  In the context of frail patients where only exclusion of clinically 
relevant malignancy is required, dietary modification with non-laxative faecal tagging may 
be appropriate.  The investigation can also be combined with intravenous contrast to assess 
for the presence of extra-colonic disease (Neri et al, 2013). 
 
1.1.6.4 Diagnosis of colorectal cancer 
Tissue obtained at endoscopy is assessed by histopathological examination.  This involves 
formalin-fixing and paraffin-embedding (FFPE) the tissue, before cut sections are stained 
with haematoxylin and eosin (H&E) and assessed under microscopy.  The histological 
diagnosis of CRC is based on tumour invasion through the muscularis mucosae into the 
submucosa, as depicted in figure 1.3.  The digestive tract can be considered as a continuum 
which, from mouth to anus, is outside the body - biopsies can therefore be taken without 
fear of seeding tumour into adjacent tumour free tissue. 
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Figure 1.3 – Invasive colonic adenocarcinoma stained with H&E, demonstrated by penetration of the 
muscularis mucosa.  Photomicrograph taken at x200 magnification.  (Adapted from Rose and Wu, 
2010) 
Virtually all CRC is adenocarcinoma, with other rare types being mucinous carcinoma (a 
variant of adenocarcinoma with >50% composed of extracellular mucin), signet ring cell 
carcinoma (another variant of adenocarcinoma with >50% signet ring cells), adenosquamous 
carcinoma, primary squamous carcinoma, goblet cell carcinoids and other mixed 
adenocarcinoma-neuroendocrine carcinoma, medullary carcinoma, and undifferentiated 
carcinoma (Hamilton et al, 2010). 
An important element of the histopathological assessment of colorectal adenocarcinoma is 
an interpretation of the degree of differentiation from the morphology of the original tissue.  
This considers features such as nuclear pleomorphism, cellular architecture and mitotic 
count to determine poorly differentiated tumours from moderately or well differentiated 
tumours for prognostic purposes. 
 
1.1.7 Radiological Assessment of Colorectal Cancer 
Radiological assessment of CRC should assess and stage local disease as well as assessing for 
the presence of metastases or synchronous disease.   
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1.1.7.1 Computed tomography 
Computed tomography (CT) is used for colonic tumours to assess the extent of disease 
relative to the bowel wall and local organs, in order to plan anatomical or non-anatomical 
resection, and to determine the requirement for neo-adjuvant or systemic treatment in the 
case of unresectable disease.  It is considered that CT has sensitivities of 86% and 70% on 
meta-analysis for the prediction of T3 disease and lymph node status respectively (Dighe et 
al, 2010), and further reliable prognostic information to separate low from high risk groups 
based on extent of trans-mural spread and local lymph node status can be determined (Smith 
et al, 2007).  This information may well be used in the future to select higher risk patients for 
neo-adjuvant chemotherapy; a question that will be determined by the FOxTROT trial 
(FOxTROT Collaborative Group, 2012), which finished recruiting in 2016.  Modern techniques 
of dual-phase helical scanning have significantly improved lesion characterisation in the liver 
(Scott et al, 2001), and it is used for the detection and characterisation of both hepatic and 
extra-hepatic metastases in all CRC, where it has a sensitivity of 60-90% (Ong and Leen, 
2007).   
1.1.7.2 Magnetic resonance imaging 
Magnetic resonance imaging (MRI) is used in the local staging of rectal cancer, where pre-
operative high-resolution imaging provides information not previously known until the 
surgical specimen had undergone histopathological assessment.  Knowledge of this in 
advance of surgery affords the opportunity to deliver neo-adjuvant therapy in attempt to 
influence outcome.  On T2-weighted images obtained with a 1.5T system with phased array 
coils, information regarding tumour morphology and stage, lymph node status and 
extramural vascular invasion (EMVI) can be obtained (Taylor et al, 2011).  The greatest 
significance of MRI is in the reliable identification of a ‘threatened’ or involved 
circumferential resection margin (CRM), where tumour is within 1mm of (or involving) the 
mesorectal fascia.   This is a very sensitive predictor of a positive CRM following surgery (with 
associated poorer outcome), with a non-threatened CRM on MRI pre-operatively 
demonstrating a 92% specificity for a clear surgical CRM (MERCURY Study Group, 2006).  MRI 
can also determine the higher risk low rectal cancers, defined by a tumour with its lower 
edge at or below the level of origin of the levator muscle on the pelvic side-wall.  Specific 
management issues for this patient group have been identified and addressed by the Low 
Rectal Cancer (LOREC) development programme (Moran et al, 2014). 
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MRI is also used to further assess indeterminate lesions in the liver, where gadolinium 
contrast enhanced imaging is considered the most effective modality for accurate 
characterisation (Kamel and Bluemke, 2003). 
1.1.7.3 Positron emission tomography 
Positron emission tomography (PET) utilises the increased glucose metabolism in tumour 
cells to distinguish them by uptake of the radiotracer 18-fluorodeoxyglucose (FDG).  FDG is 
phosphorylated and becomes metabolically inactive upon uptake and thus accumulates.  
When combined with CT scanning, PET imaging allows for the accurate localisation of small 
disease deposits, for example extra-hepatic abdominal metastases or local disease 
recurrence.  The principle for use of this modality is that metabolic changes in cells can be 
detected, and this precedes any anatomical variance that would be detected on contrast 
enhanced CT imaging (Arulampalam et al, 2004).  The additional information from PET-CT 
imaging has been shown to alter disease management in 29% of patients with colorectal liver 
metastases (Huebner et al, 2000), and prevents futile surgery in those being considered for 
non-anatomical resection (Adams et al, 2013). 
 
1.1.8 Staging of Colorectal Cancer 
The first staging system described was devised for rectal cancer by Dr Cuthbert Dukes in 
1932.  Initially this classification assigned a Dukes’ stage from A-C, where stage A represented 
a malignant invasion into but not through the bowel wall, stage B represented malignant 
growth through the bowel wall, and stage C represented lymph node involvement (Dukes, 
1932).  The system was refined to correlate pathological grade with prognosis (Dukes and 
Bussey, 1958), at which time the subdivision of stages C1 (regional lymph node involvement) 
and C2 (apical node involvement) were made.  Stage D representing distant or metastatic 
disease was later added (Turnbull et al, 1967), and the scoring system was informally applied 
to carcinomas arising in the colon. 
Advancements in both our understanding of disease biology and in radiological techniques, 
have led to the current gold standard staging system of the Union for International Cancer 
Control / American Joint Committee for Cancer (UICC/AJCC) TNM classification.  This 
classification is a disease specific extension of the original TNM system devised by Denoix et 
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al in 1946, whereby the degree of invasion and tumour spread is characterised by a T stage 
referring to the primary tumour, N stage recording the presence and extent of local lymph 
node involvement, and M stage describing the presence or absence of metastatic disease.  
The current version in widespread clinical use is the 7th edition published in 2010 (table 1.3). 
 
TNM Stage Description 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ: intra-mucosal carcinoma 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades through muscularis propria into peri-colorectal tissues 
T4a Tumour invades through visceral peritoneum 
T4b Tumour directly invades or is adherent to adjacent organs or structures 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-3 regional lymph nodes 
N1a Metastasis in 1 regional lymph node 
N1b Metastasis in 2-3 regional lymph nodes 
N1c Tumour deposits in sub-serosa, mesentery, or non-peritonealised pericolic 
or perirectal tissues without regional nodal metastasis 
N2 Metastasis in 4 or more regional lymph nodes 
N2a Metastasis in 4-6 regional lymph nodes 
N2b Metastasis in 7 or more regional lymph nodes 
M0 No distant metastasis by imaging, no evidence  
M1 Distant metastasis 
M1a Metastasis confined to 1 organ or site without peritoneal metastasis 
M1b Metastases in 2 or more organs or sites without peritoneal metastasis 
M1c Metastasis to the peritoneal surface alone or with other site or organ 
metastases 
Table 1.3 – UICC/AJCC TNM staging of CRC, 8th edition (2017).  (Adapted from http:// 
pathologyoutlines.com/topic/colontumourstaging8ed.html) 
 
It is possible to stage a patient’s disease for some parameters at different points in their 
treatment pathway.  Supplementary prefixes to the TNM system have been developed to 
highlight the origin of the information used for staging;  c indicates the stage is given by 
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clinical examination of the patient, p indicates the stage is given by histopathological 
examination of a surgical specimen, y indicates the stage is assessed after chemotherapy 
and/or radiation therapy (i.e. the patient received neoadjuvant treatment), r indicates 
staging of a recurrent tumour following a substantial disease-free period, a indicates staging 
determined at post mortem examination, and u is for staging determined by 
ultrasonography. 
 
Stage Description TNM Stages 
0 No tumour Tis, N0, M0 
I Primary tumour into but not 
through muscularis propria, and 
no metastases 
T1-2, N0, M0 
IIa Primary tumour grown through 
to serosa and peritoneal surface 
but no metastases 
T3, N0, M0 
IIb T4a, N0, M0 
IIc T4b, N0, M0 
IIIa 
Any size of primary tumour with 
lymph node metastases 
T1-2, N1-N1c, M0 or T1, N2a, M0 
IIIb T3-T4a, N1-N1c, M0 or T2-T3, N2a, M0 or 
T1-T2, N2b, M0 
IIIc T4a, N2a, M0 or T3-T4a, N2b, M0 or T4b, 
N1-2, M0 
IVa 
Presence of distant metastatic 
disease 
Any T, Any N, M1a 
IVb Any T, Any N, M1b 
IVc Any T, Any N, M1c 
Table 1.4 - UICC/AJCC stage groupings for CRC, 8th edition (2017).  (Adapted from http:// 
pathologyoutlines.com/topic/colontumourstaging8ed.html) 
There are numerous potential combinations of TNM criteria, which are grouped together 
into stages 0-IV (table 1.4) by UICC/AJCC for the benefit of simplifying treatment decisions 
(Carrato, 2008).  Alternative staging systems have been established to further guide 
treatment or gain prognostic information. The most commonly used of these is the Jass 
classification (figure 1.4), which combines some of the common genetic aberrations 
identified, with a number of macroscopic and microscopic pathological correlates, and 
patient features (Jass, 2007). 
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Figure 1.4 – The Jass classification combines a number of patient, histopathological and genetic 
factors to allocate a patient to a group (1-5).  (Taken from Jass, 2007) 
The Jass classification is often used as a decision-making tool for those patients with Dukes’ 
B (or Stage II) disease.  A study of 183 patients with Dukes’ B disease who were also Jass 
grouped, identified that cancer specific mortality was considerably higher in those with Jass 
group III than in those groups I or II.  The additional prognostic information from Jass 
grouping may facilitate the selection of patients who are most likely to benefit from adjuvant 
chemotherapy (Mander et al, 2006), although the classification highlights the complexity of 
CRC. 
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1.2 The Curative Management of Rectal Cancer 
The rectum is distal to the sigmoid colon, with its upper limit at the termination of the 
sigmoid mesocolon, although the common surgical definition is that the rectum starts at the 
sacral promontory, and generally a rectal cancer is defined as being at or below 15cm from 
the anal verge as measured by rigid sigmoidoscopy (UKCCCR, 1989).   
 
1.2.1 Early Rectal Cancer 
Small tumours contained within polyps are often removed by polypectomy at the time of 
colonoscopy, and rectal tumours may be amenable to local or trans-anal excision (Atallah 
and Albert, 2013) preserving the rectum and its function, and avoiding the morbidity and 
mortality of radical surgery.  Full thickness excision offers accurate pathological assessment, 
and potential cure for many pT1 and pT2 cancers, which can be prior selected by accurate 
staging with MRI and endorectal ultrasound (Ashraf et al, 2012). 
The presence of untreated involved mesorectal lymph nodes is a cause of local disease failure 
following local excision, with 2%, 8% and 23% risks of lymph node involvement for Kikuchi 
sm1, sm2 and sm3 penetration respectively in pT1 tumours (Tytherleigh et al, 2008).  Tumour 
implantation is a potential source for luminal recurrence with depth of invasion, maximum 
tumour diameter and the presence of lympho-vascular invasion (LVI) as independent 
predictors (Bach et al, 2009).  The ACPGBI introduced guidance for the use of local excision 
in early rectal cancer, advising that an acceptable <10% risk of local disease failure can be 
expected in T1 tumours with a maximum diameter of 3cm, and in those that are well or 
moderately differentiated, and without LVI (Williams et al, 2013).  Regular surveillance and 
early detection of local recurrence to facilitate salvage surgery can mitigate the 
consequences (De Graaf et al, 2009). 
Whilst short course pre-operative radiotherapy (SCPRT) before trans-anal excision has shown 
promising results in a retrospective analysis of patients unfit for total mesorectal excision 
(TME) (Smart et al, 2016), pre-operative chemoradiotherapy (CRT) has demonstrated 
unacceptable toxicity in the context of an organ sparing approach (Verseveld et al, 2015).  
The role of radiotherapy and local excision in early rectal cancer remains to be defined in 
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those fit for major resection, with outcomes from the TREC trial awaited and recruitment to 
STAR-TREC (Rombouts et al, 2017) underway.  It can be considered currently in those who 
refuse or are unfit for major resection. 
 
1.2.2 Resectable Rectal Cancer 
Surgical resection remains the mainstay of treatment for rectal cancer, with tumours in the 
middle and lower thirds of the rectum resected using the technique of TME.  This was 
popularised by Professor Bill Heald in 1982, recognising that the lateral, deep or 
circumferential margins were much better predictors of local disease recurrence than the 
distal margin (Heald et al, 1982), and later published (Heald, 1988).  The follow up data 
reported local recurrences of 3-6%, which were significantly reduced from the historical 30% 
(Heald et al, 1998).  Tumours in the upper third of the rectum can be adequately resected 
with a mesorectal transection 5cm beyond the distal margin of the tumour.  It is widely 
accepted that involvement of the CRM predicts local disease recurrence, distant metastasis 
and survival (Nagtegaal and Quirke, 2008). 
The risk of pelvic local recurrence remains the basis for the stratification of rectal cancers in 
considering treatment strategies according to NICE (CG 131, 2011) and is presented in table 
1.5. 
Low and moderate risk groups are considered resectable, whereas the high local recurrence 
risk group is at significant risk of a positive surgical CRM, unless pre-operative downstaging 
can be achieved.  The aims of radiotherapy in the intended curative management of rectal 
cancer are therefore to reduce the risk of local disease recurrence, and to downstage high-
risk tumours to achieve successful surgical resection.  Moderate- and high-risk groups remain 
at significant risk of distant metastases, which overall is the main cause of mortality (Gollins 
et al, 2017). 
23 
 
Risk of pelvic local recurrence 
Characteristics of rectal tumours 
predicted by MRI 
Low (resectable) cT1 or cT2 or cT3a and 
no lymph node involvement 
Moderate (resectable) any cT3b or greater, in which the potential surgical 
margin is not threatened or 
any suspicious lymph node not threatening the 
surgical resection margin or 
the presence of extramural vascular invasion 
High (borderline resectable or unresectable 
i.e. threatened or involved CRM) 
a threatened (<1 mm) or breached resection margin 
or 
low tumours encroaching onto the inter-sphincteric 
plane or with levator involvement 
 
Table 1.5 - Risk assessment for pelvic local recurrence according to MRI findings.  (Adapted from 
NICE, CG131, 2011) 
 
1.2.3 Radiotherapy in Rectal Cancer 
The addition of pre- or post-operative radiotherapy to surgery originally demonstrated a 
reduction of local disease recurrence risk (Colorectal Cancer Collaborative Group, 2001) but 
without an improvement in overall survival where historical radiotherapy techniques (large 
parallel-opposed fields), were associated with non-cancer deaths. 
Epithelium within the small bowel are rapidly dividing, and are therefore prone to the risks 
of radiation, with resultant radiation enteritis.  This feature, in combination with the relative 
mobility of the colon within the abdomen, limits the use of radiotherapy to rectal cancer 
exclusively.  In the context of resectable disease, radiotherapy can be administered either 
pre- or post-operatively.  The main advantage of pre-operative treatment is that pelvic 
anatomy is undisturbed and toxic doses of radiation to the small bowel are reduced.  Post-
operative radiotherapy however allows for potentially better treatment personalisation by 
targeting those patients with adverse pathological features. 
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Pre-operative radiotherapy has been commonly delivered as short or long course treatment, 
consisting of 25Gy in 5 fractions over one week, or 45-50.4Gy in 25-28 fractions over 5 weeks 
respectively.  Short course treatment (SCPRT) is followed by immediate surgery one week 
later, whereas long course treatment (commonly combined with chemotherapy, CRT), is 
followed by a ‘downstaging’ period to allow for maximal response to occur, prior to surgery 
6-12 weeks after CRT completion (Gollins et al, 2017). 
 
1.2.4 Biological Effects of Radiation 
Radiotherapy is administered by an external beam, delivered via a linear accelerator, and 
works by inducing DNA damage, either by direct or indirect ionisation from photons or 
charged particles.  The indirect effects occur as a consequence of radiation interaction with 
intra-cellular water, where free radicals (notably hydroxyl radicals) are formed and interact 
with DNA.  This indirect ionisation comprises the majority of the effect of radiation therapy.  
Cells have mechanisms for repairing both single-stranded and double-stranded DNA damage 
but double-stranded breaks increase the probability that a cell will undergo cell death.  The 
sensitivity of cells to radiotherapy is proportional to their rate of replication, and the 
accumulation of single stranded breaks is exploited by radiotherapy in cancer cells which are 
less well differentiated than normal cells and reproduce more frequently but have a reduced 
ability to repair sub-lethal damage.  This results in the accumulation of single-stranded 
breaks and increases the likelihood of creating stalled replication forks, leading to replication 
fork collapse and the generation of double-stranded breaks, which ultimately leads to cell 
death (Bauer et al, 2015). 
The ability of tumour cells to repair DNA damage from radiotherapy may determine the 
response or resistance to treatment, and base excision repair is the process by which single-
stranded DNA damage repair is undertaken.  This process is initiated by DNA glycosylases 
which recognise and remove damaged or inappropriate bases, forming AP sites, which are 
then cleaved by an AP endonuclease.  The resulting DNA break is then repaired by 
replacement of a single nucleotide in short-patch base excision repair, or by 2-10 nucleotides 
in long-patch base excision repair (Liu et al, 2007).  In humans, the main proteins involved in 
this process are AP endonuclease 1, DNA polymerase β (which catalyses short-patch repair), 
and DNA ligase III along with its cofactor XRCC1 (which catalyse the nick-sealing step in short-
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patch repair) (Carter & Parsons, 2016).  The expression of these proteins has been 
investigated for their potential as biomarkers and therapeutic targets but are not in routine 
clinical use (Vens & Begg, 2010). 
Double-stranded DNA breaks are ultimately the most likely contributor to ionising radiation-
induced cell death.  Whilst these breaks are frequently lethal to a cell, repair either by 
homologous recombination requiring a homologous DNA sequence, or non-homologous end 
joining involving ligation of the DNA ends of a double-stranded break in the absence of a 
homologous sequence, can be attempted (Le Guen et al, 2015). 
 
1.2.5 Radiotherapy in Resectable Rectal Cancer 
The Swedish Rectal Cancer Trial popularised the use of SCPRT, where in n=1168 patients, an 
improved overall survival at five years (58% vs. 48%, p=0.004) and reduced local recurrence 
(11% vs. 27%, p<0.001) was demonstrated in patients undergoing SCPRT then surgery 
compared to surgery alone (Swedish Rectal Cancer Trial, 1997), albeit with non-TME surgery.  
In the context of standardised TME surgery, the Dutch Colorectal Cancer Study Group trial 
compared SCPRT and TME surgery with TME surgery alone in n=1861 patients.  A reduced 
risk of 2.4% vs. 8.2% (p<0.001) was observed in those receiving SCPRT before surgery 
(Kapiteijn et al, 2001).  The UK Medical Research Council CR07/NCIC‐CTG C016 trial, 
compared SCPRT and surgery to surgery with selective post-operative CRT (in those with a 
positive CRM) in n=1350 patients, demonstrating a relative risk reduction of 61% at 3 years 
in n=1350 patients (4.4% vs. 10.6% respectively, p<0.0001), although without an 
improvement in overall survival (Sebag-Montefiore et al, 2009). 
Comparison of pre-operative long course radiotherapy with pre-operative CRT was studied 
in the EORTC 22921 (n = 1011) (Bosset et al, 2006) and FFCD 9203 (n = 733) (Gérard et al, 
2006) trials, where local disease recurrence was significantly reduced (8-9% vs. 17%) with 
the addition of synchronous intravenous 5-fluorouracil (5-FU) to radiotherapy.  The oral 
fluoropyrimidine capecitabine has also been demonstrated to be non-inferior to intravenous 
5-FU in pre-operative CRT regimens for rectal cancer (Hofheinz et al, 2012). 
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A comparison of the efficacy of SCPRT against long course CRT was studied in two 
randomised controlled trials.  The Polish trial (n-316) compared SCPRT against CRT followed 
by TME at 4-6 weeks in patients with palpable (low) rectal cancer (Bujko et al, 2006).  There 
was no difference in the primary end-point of sphincter preservation rate, and despite a 
higher pathological complete response (pCR) observed with CRT, there were no differences 
in local recurrence rate, disease-free or overall survival.  The Trans‐Tasman Radiation 
Oncology Group 01.04 trial (n = 326), made a similar comparison in T3 N0-2 M0 rectal cancers 
(Ngan et al, 2012) but with no difference in rates of 3-year local recurrence, 5-year distant 
metastases or overall survival. 
The optimum timing for long course CRT was determined by the German CAO/ARO/AI0-94 
trial (n=823), where pre- and post-operative treatment in the context of standardised TME 
surgery and adjuvant chemotherapy was compared (Sauer et al, 2003).  Pre-operative CRT 
resulted in a reduced local recurrence rate (6% vs. 12%, p=0.006), and was associated with 
lower acute and late toxicity (12% vs. 24%, p=0.01) but with no difference in distant 
metastases, disease-free or overall survival (Sauer et al, 2012). 
 
1.2.6 High Local Recurrence Risk Rectal Cancer 
SCPRT and long course radiotherapy have both been evaluated in locally advanced disease 
whereby the tumour is threatening or involving the mesorectal fascia.  Prior to routine MRI 
assessment, patients with clinically fixed or tethered tumours underwent surgery with or 
without SCPRT in a prospective randomised trial (Marsh et al, 1994).  A significantly reduced 
local recurrence rate was observed in the SCPRT group (12.8% vs. 37.5%, p<0.0001), although 
there was no difference in survival benefit.  The Second MRC Rectal Cancer trial (n = 279) 
randomised the same category of rectal cancer patients to long course radiotherapy prior to 
surgery or to surgery alone (Medical Research Council Rectal Cancer Working Party, 1996).  
Local recurrence and disease-free survival were improved in the radiotherapy group but 
again with no overall survival benefit. 
The ability of MRI to identify patients with a threatened or involved mesorectal fascia from 
the primary tumour, tumour deposits or EMVI enables the selection of those appropriate for 
downstaging CRT.  In 80 patients with tumour identified within 1mm of the mesorectal fascia 
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on MRI, a positive histological CRM was observed in only 13 (16%) after surgery following 
CRT (Kulkarni et al, 2008).  The presence and depth of EMVI away from the CRM as identified 
using diffusion weighted MRI, have also both been correlated with recurrence risk and 
prognosis (Smith et al, 2008). 
The presence of suspicious lymph nodes on MRI less than 1mm from the mesorectal fascia 
does not itself predict for a positive CRM.  In a study of 396 patients where 31 had this 
finding, none had a positive CRM following resection (Shihab et al, 2010).  The presence of 
tumour in mesorectal lymph nodes at histopathological assessment is associated with a 
higher risk of local disease recurrence independent of a positive CRM however.  In a 
subgroup analysis of patients with stage III disease, the Dutch Colorectal Cancer Study Group 
and UK Medical Research Council CR07/NCIC‐CTG C016 trials demonstrated reductions in 
local recurrence of 19% to 9% (p<0.001) and 15.4% to 7.4% (p<0.001) respectively with 
SCPRT, and with a resultant improvement in 10-year overall survival (50% vs 40%, p=0.032) 
in the Dutch trial. 
MRI remains poor at predicting mesorectal lymph node involvement though, despite 
diffusion weighted sequences and accurate characterisation of involved nodes as those with 
an irregular border and heterogenous signal intensity (Heijnen et al, 2013). 
 
1.2.7 Low Rectal Cancer 
It is widely accepted that low rectal cancers have historically had poorer oncological 
outcome, due in part to the tapering of the mesorectum and compromise of the resection 
margin, with higher risk of tumour perforation at surgery, CRM positivity, local recurrence 
and poorer survival (Nagtegaal et al, 2005).  Whilst an attempt at sphincter preservation can 
be made, this should not be at the expense of oncological clearance, and in the context of 
neoadjuvant treatment and a very low anastomosis, functional outcome and quality of life 
can often be reduced (How et al, 2012).  Involvement of the external sphincter / levator or 
where this margin is threatened requires an abdomino-perineal excision (APE), with curative 
management of these tumours requiring a permanent stoma. 
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Adoption of extra-levator (ELAPE) or ischio-anal approaches in APE to compliment 
conventional or inter-sphincteric approaches, alongside appropriate patient selection based 
upon accurate MRI staging can facilitate optimal personalised management of these cases 
(Holm, 2014).  The use of neoadjuvant CRT can be further refined to optimise sphincter 
function, whilst reducing local recurrence rates with tailored approaches to surgery (Moran 
et al, 2014).  There is no strong evidence however to support the use of CRT for the purposes 
of sphincter salvage (Bujko et al, 2006a), and perineal wound healing (particularly following 
ELAPE) can be problematic (Gollins et al, 2017). 
In patients undergoing low anterior resection there is a risk of poor functional outcome.  Low 
anterior resection syndrome (LARS) includes symptoms of stool urgency, stool clustering, 
evacuation difficulty and incontinence.  The risk of this increases most with tumours <6cm 
from the anal verge and where pre-operative radiotherapy has been delivered, with up to 
60% of these patients experiencing significant symptoms affecting quality of life (Battersby 
et al, 2016). 
 
1.2.8 Pelvic Radiotherapy Toxicity 
Further consequences of pelvic radiotherapy include both short- and long-term toxicities.  
There does not appear to be an increased risk of post-operative mortality or anastomotic 
leak rate (in those undergoing anterior resection) with SCPRT, although a delay to surgery 
beyond 11 days increases mortality, particularly in older patients (van den Broek et al, 2013).  
Perineal wound healing can also be impaired after APE following SCPRT (Sebag-Montefiore 
et al, 2009).  The risk of post-operative mortality and morbidity does not seem to be 
increased by the use of neo-adjuvant CRT (Sauer et al, 2004), although the risk of acute grade 
3 or 4 toxicity is significantly higher with CRT (18.2%) than with SCPRT (3.2%) (Bujko et al, 
2004).  An infrequent incidence of acute lumbosacral plexopathy (gluteal / radicular leg pain) 
has been associated with SCPRT (Marijnen et al, 2002). 
Recognised late toxicities of pelvic radiotherapy include bowel obstruction, bowel / urinary 
/ sexual dysfunction, pelvis and femoral neck fractures and second malignancies (Gilbert et 
al, 2015), although the incidence of these complications appears to be reducing, likely with 
improvements in radiotherapy techniques including reduced irradiated volumes.  Along with 
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the significant risk of LARS as discussed, SCPRT has been observed to increase sexual 
dysfunction particularly in men (Stephens et al, 2010).  No difference in quality of life scores 
relating to sexual function for men or women have been observed between irradiated or 
non-irradiated patients however (Marijnen et al, 2005).  There appears to be no difference 
between SCPRT and CRT in reported bowel or sexual dysfunction (Pietrzak et al, 2007), or 
with long term quality of life (Ngan et al, 2012a). 
The current use of neo-adjuvant radiotherapy is therefore determined by the potential risk 
of local recurrence from an involved or threatened CRM, by the presence of EMVI, which can 
be accurately predicted by pre-operative MRI, or by the presence of suspicious mesorectal 
lymph nodes.  Tumours staged as mrT2-3 N0 have a very low (<3%) risk of local recurrence 
with surgery alone if a good quality TME is performed with a negative CRM (Taylor et al, 
2011).  Determining the presence of involved mesorectal lymph nodes pre-operatively 
remains inaccurate.  In the absence of an involved or threatened CRM, the use of neo-
adjuvant radiotherapy (either SCPRT or CRT) does approximately halve the local recurrence 
risk but the number need to treat is 17-20 (Gollins et al, 2017), with no impact on the risk of 
distant metastases or overall survival and with potentially significant morbidity.  It should 
therefore be undertaken in carefully selected patients after MDT evaluation. 
 
1.2.9 Pharmacology of 5-fluorouracil 
Historically the only available chemotherapeutic agent for the treatment of metastatic and 
advanced colorectal cancer was 5-flourouracil (5-FU), which remains as the cornerstone of 
treatment.  It is an oral pro-drug of 5-FU (capecitabine), that is conventionally used alongside 
radiotherapy (as CRT) in the neo-adjuvant treatment of locally advanced rectal cancer. 
1.2.9.1  5-fluorouracil 
5-fluorouracil (5-FU) is a fluoropyrimidine anti-metabolite.  The drug was designed, 
synthesised and patented in 1957 as an analogue of uracil, a normal component of RNA.  The 
analogue substitutes a hydrogen atom for fluorine at the C5 position and is a specific 
competitive antagonist for uracil.  Its mis-incorporation into RNA and DNA arrests RNA 
synthesis, with resultant cytotoxicity, and therefore halts tumour growth (Longley et al, 
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2003), although an intact MMR system may be required to detect this mis-incorporation (Jo 
and Carethers, 2006).   
As well as being incorporated into macromolecules, 5-FU is converted inside cells into a 
number of active metabolites which disrupt biological function: fluorodeoxyuridine 
monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine 
triphosphate (FUTP).  It is FdUMP which inhibits thymidylate synthetase (TS), a nucleotide 
synthetic enzyme which is thought to be the main target for 5-FU.  TS methylates 
deoxyuridine monophosphate (dUMP) to form thymidine monophosphate (dTMP), 
therefore administration of 5-FU causes a scarcity in dTMP, with rapidly dividing cancerous 
cells undergo cell death via thymineless death (Longley et al, 2003).  It is also thought to 
result in dinucleotide pool imbalances and increased levels of deoxyuridine triphosphate 
(dUTP), both of which can cause DNA damage (Yoshioka et al, 1987). 
 
 
Figure 1.5 – The metabolism of 5-FU and its oral prodrug capecitabine.  (Taken from Walther et al, 
2009) 
5′DFCR, 5′deoxy-5-fluorocytidine; 5-FUR, 5-fluorouridine; DHP, dihydropyrimidinase; FBAL, fluoro-b-
alanine; MTHFR, methylenetetrahydrofolate reductase; RNR, ribonucleotide reductase; UK2, uridine-
cytidine kinase 2. 
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The mechanism of 5-FU activation is by conversion to fluorouridine monophosphate (FUMP) 
by uridine monophosphate synthetase (OPRT).  FUMP is then phosphorylated first to 
fluorouridine diphosphate (FUDP) and then to FUTP.  Alternatively, thymidine phosphorylase 
(TP) can activate 5-FU by catalysing the conversion of 5-FU to fluorodeoxyuridine (FUdR) 
which is then phosphorylated by thymidine kinase (TK) to FdUMP.  FdUMP can be 
phosphorylated to fluorodeoxyuridine diphosphate (FdUDP), and again to FdUTP.  The 
metabolism of 5-FU is summarised in figure 1.5. 
Variation in the enzymes that mediate the incorporation into RNA and DNA, the conversion 
of the oral prodrug capecitabine to 5-FU, or metabolism to inactive breakdown products can 
alter the intracellular 5-FU concentrations and cytotoxicity, leading to altered anti-tumour 
activity or systemic toxicity.  CRC patients with higher tumour levels of TS for example, seem 
to have a poorer overall survival than those with lower expression (Popat et al, 2004). 
The drug is predominantly catabolised by dihydropyrimidine dehydrogenase (DPD), which 
converts 5-FU to dihydrofluorouracil (FUH2), with around 80% of this occurring in the liver 
(Diasio and Harris, 1989).  It is estimated that 0.2% of individuals have a complete DPD 
deficiency - those with a partial or complete DPD deficiency have a significantly increased 
risk of severe or even fatal drug toxicities when treated with fluoropyrimidines (Caudle et al, 
2013). 
Common side-effects of 5-FU based therapy include nausea, vomiting, diarrhoea, mucositis, 
headache, myelosuppression, alopecia and photosensitivity. 
1.2.9.2  Leucovorin 
High intra-cellular concentration of the reduced folate leucovorin (folinic acid), are required 
for optimal binding of FdUMP to TS.  Leucovorin is transported into cells via the reduced 
folate transporter, anabolised and polyglutamated.  This not only increases intra-cellular 
retention of FdUMP but further stabilises the complex formed between FdUMP and TS.  It is 
widely accepted that co-administration of leucovorin with 5-FU, increases 5-FU toxicity both 
in vitro and in vivo (Wright et al, 1989). 
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1.2.9.3  Capecitabine 
An alternative approach to the delivery of 5-FU has originated from the design of oral pro-
drugs which avoid DPD mediated catabolism in the liver.  Capecitabine is an oral 
fluoropyrimidine absorbed via the GI tract and converted in the liver to 5’deoxy-5-
fluorouridine (5’DFUR) by the enzymatic action of carboxylesterase (CES) and cytidine 
deaminase (CDD) (Johnston and Kaye, 2001).  5-dFUR is ultimately converted to 5-FU by 
thymidine phosphorylase (TP) and uridine phosphorylase (UP1).  The higher abundance of 
these enzymes in tumour tissue is thought to account for the more tumour-specific 
conversion of capecitabine to 5-FU (Schüller et al, 2000). 
1.2.9.4 Tegafur 
Another alternative oral 5-FU prodrug is tegafur, although not routinely used in the UK.  It is 
commonly administered with agents such as gimeracil, oteracil or uracil that inhibit the 
action of DPD to increase its bioavailability in tumour cells and therefore toxicity.  It is 
metabolised to 5-FU by cytochrome P450 2A6 (CYP2A6), which is predominantly localised in 
the liver (Chionh et al, 2017). 
 
 
1.2.10 Evaluation of Response to Chemoradiotherapy 
Repeated radiological evaluation of a rectal cancer with MRI and CT after CRT ensures that 
appropriate subsequent treatment is undertaken.  The timing of this further evaluation is 
performed so that the inflammation produced as a consequence of radiotherapy does not 
under-estimate tumour response, and also allows for the ongoing effects of radiotherapy on 
tumour cells undergoing attempted cell division to be realised.  Following early studies 
whereby better clinical tumour response and pathological downstaging was observed with 
surgery at 6 weeks (vs. 2 weeks) following completion of radiotherapy (Francois et al, 1999), 
it has been commonplace to operate 6-8 weeks following CRT. 
Whilst there is evidence to suggest that ongoing radiological downstaging occurs up to 12 
weeks following cessation of treatment (Johnston et al, 2009), the phase 3, multi-centre, 
GRECCAR-6 randomised-controlled trial demonstrated no increase in pathological complete 
response with resection 11 weeks post-CRT (compared to 7 weeks) but with significantly 
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greater morbidity and with a poorer quality mesorectal specimen at the later time (Lefevre 
et al, 2016). 
 
 
1.2.10.1 Radiological response to treatment 
 
The standard evaluation of radiological response to treatment is usually performed in 
accordance with the international consensus guidelines defined in 1994 and referred to as 
the Response Evaluation Criteria in Solid Tumours (RECIST) guidelines (Therasse et al, 2000).  
These were updated to RECIST 1.1 in 2008 (Eisenhauer et al, 2009), where pathological lymph 
nodes were included as target lesions.  In the context of rectal cancer and evaluating 
response to CRT, MRI is the optimal imaging modality for local re-staging.  The challenge for 
radiologists is to distinguish between normal mucosa, oedema, fibrosis and residual tumour, 
to determine the suitability for surgical resection with respect to the CRM, or for appropriate 
selection for non-operative management.  A specific MRI regression grading system is used 
(Battersby et al, 2014) and presented in table 1.6.  The system is based upon established 
histopathological regression grading systems and has been validated as an independent 
predictor of overall- and disease-free survival (Patel et al, 2011). 
 
 
MRI Tumour 
Regression Grade 
Description 
mrTRG1 Complete radiological response (linear scar only) 
mrTRG2 Good response (dense fibrosis, no obvious tumour signal) 
mrTRG3 Moderate response (>50% fibrosis and visible intermediate signal) 
mrTRG4 Slight response (mostly tumour) 
mrTRG5 No response/regrowth of tumour 
 
Table 1.6 – MRI assessment of regression grading in rectal cancer.  (Adapted from Battersby et al, 
2014) 
 
T2 weighted sequences in expert hands can determine residual intermediate intensity signal 
representing tumour from hypointense signal representing fibrosis, although the routine use 
of functional diffusion weighted images (DWI) has confirmed the greater bio-specificity of 
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this signal in the tumour bed (Lambregts et al, 2011).  DWI is considered particularly useful 
for highlighting residual tumour in incomplete responders but has a limited positive-
predictive value in confidently identifying complete responders (Blazic et al, 2017).  Dynamic 
contrast-enhanced MR imaging is another functional MRI sequence, which evaluates tumour 
vessel permeability and blood ﬂow.  Ktrans as a measure of capillary permeability, has so far 
been identified as the most useful potential parameter, with pre-CRT Ktrans signiﬁcantly 
differentiating responders from non-responders (Gollub et al, 2012). 
The evaluation of the mrTRG system to define treatment stratification to according to 
response is proposed as a phase III study in the TRIGGER trial (Battersby et al, 2017).  The 
assessment of safety of non-operative management in those patients achieving mrTRG 1 or 
2, and the evaluation of systemic therapy after CRT (and prior to resection) in those patients 
with mrTRG 3-5 is planned. 
 
1.2.10.2 Pathological response to treatment 
The current definitive assessment of response to CRT is made upon histopathological 
assessment following surgical resection. 
The earliest histopathological tumour regression grade (TRG) system originated from 
correlation of pathological response with outcome in oesophageal cancer (Mandard et al, 
1994).  In this system, TRG was quantified as one of five grades; TRG1 (complete regression) 
showed an absence of residual cancer with fibrosis extending through the oesophageal wall, 
TRG 2 was characterised by the presence of rare residual cancer cells scattered through the 
fibrosis, TRG 3 was characterised by an increase in the number of residual cancer cells but 
fibrosis still predominated, TRG 4 showed residual cancer outgrowing fibrosis, and TRG 5 was 
characterised by an absence of regressive changes.  On univariate analysis, tumour size, 
lymph node status, TRG and oesophageal wall involvement correlated with disease free 
survival, however after multivariate analysis only TRG (at this point dichotomised as 1-3 vs. 
4-5) remained a significant predictor of disease free survival. 
A specific grading system was subsequently published for the regression of rectal tumours 
after neoadjuvant CRT (Dworak et al, 1997), including assessment of tumour mass, fibrotic 
change, irradiation vasculopathy and peri-tumour inflammatory reaction.  The system 
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graded regression from TRG 0-4, as demonstrated in figure 1.6, and was later demonstrated 
to have prognostic value in predicting outcomes in rectal cancer (Losi et al, 2006). 
 
Figure 1.6 - The tumour regression grading system proposed by Dworak et al (1997).  TRG4 – no 
tumour cells, only fibrotic mass (total regression); TRG3 – very few (difficult to find microscopically) 
tumour cells in fibrotic tissue with or without mucous substance; TRG2 – dominant fibrotic changes 
with few tumour cells or groups (easy to find); TRG1 – dominant tumour mass with obvious fibrosis 
and/or vasculopathy; TRG0 – no regression.  (Adapted from Santos et al, 2014).  Areas of fibrosis and 
tumour are depicted in the figure. 
The Royal College of Pathologists have more recently produced a minimum dataset for 
reporting in CRC, where a 4-tier system based on the classification by Ryan et al (2005) is 
now endorsed.  The system classifies tumour regression as: TRG 4 - no viable tumour cells 
(fibrosis or mucus lakes only), TRG 3 - single cells or scattered small groups of cancer cells, 
TRG 2 - residual cancer outgrown by fibrosis, and TRG 1 - minimal or no regression (extensive 
residual tumour).  This system has also been accepted as the best methodology in the 7th 
edition of the TNM staging system and has been adopted by the currently recruiting 
FOxTROT trial (FOxTROT Collaborative Group, 2012). 
Any tumour regression grading system needs to be cross-validated for its predictive and 
prognostic value and reproducibility in both clinical and research settings.  At the current 
time there is no system that accounts for the presence of (or response in) nodal disease, 
which has been demonstrated to be as significant a prognostic factor as regression grading 
following CRT (Huebner et al, 2012). 
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1.2.11 Complete Response to Chemoradiotherapy 
1.2.11.1 Pathological complete response 
The reported incidence of pathological complete response (pCR) following CRT varies 
dependent on study populations, disease staging and neoadjuvant CRT regimens.  pCR 
detection is also dependent upon pathological assessment which is currently non-
standardised.  These factors potentially account for the variability in the reported rates and 
makes the interpretation of studies more difficult.  An overall pCR rate of 13.5% was 
identified in a review of phase II and III studies, where a single fluoropyrimidine based radio-
sensitiser was used (Hartley et al, 2005).  Equally of significance is that approximately 50% of 
patients receiving CRT will achieve a minimal or no response to treatment or will develop 
disease progression.  Even a near-complete response does not produce a statistically 
significant prognostic benefit compared to those with a minimal or no response (Bujko et al, 
2010). 
There is a clear oncological benefit for patients achieving a pCR.  In a meta-analysis of long-
term outcomes involving 3363 patients in 16 studies (of which 1263 (37.6%) had achieved a 
pCR), local recurrence rate, and overall- and disease-free survival was evaluated between 
those with a pCR against those without, with a mean follow-up of 55.5 (40-87) months 
(Martin et al, 2012).  The mean local recurrence rate was significantly lower (0.7%) in patients 
with a pCR (odds ratio (OR) 0.25, p=0.002), as well as the rate of distant failure (8.7%, OR 
0.23, p<0.001).  The 5-year overall survival in patients with a pCR was 90.2%, with a 5-year 
disease-free survival of 87.0%, significantly better than those without (OR 3.28, p=0.001 and 
4.33, p<0.001 respectively). 
In pursuit of increasing the rate of pCR following CRT and potential associated favourable 
outcome, several studies have examined the role of novel chemotherapy regimens prior to 
CRT or as radio-sensitisation.  The EXPERT (Chau et al, 2006) and Spanish GCR-3 (Fernández-
Martos et al, 2010) studies utilised capecitabine and oxaliplatin (CAPOX) as chemotherapy 
prior to CRT and observed pCR rates of 20% and 14% respectively.  The CONTRE trial utilised 
longer cycles of CAPOX in 39 patients and observed a pCR rate of 33%, however also observed 
greater rates of grade 3/4 toxicities (Perez et al, 2017).  The French ACCORD 12 trial (n=598) 
examined intensified radiotherapy with the addition of oxaliplatin to capecitabine against 
standard CRT but found no difference in pCR rate or disease-free or overall survival at 3 years 
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(Gerard et al, 2012).  The addition of irinotecan to capecitabine with radiotherapy at 45Gy 
yielded a promising pCR rate of 22% in 110 patients in a phase II trial (Gollins et al, 2011) but 
was not powered to detect survival outcomes.  This regimen is being further assessed in the 
ongoing UK phase III ARISTOTLE trial, in MRI‐defined unresectable or borderline resectable 
rectal cancer. 
A dose-response relationship has been demonstrated for tumour regression after CRT with 
higher than normal radiation doses between 50.4 and 70Gy and incorporating brachytherapy 
(Appelt et al, 2013), although the effect on toxicity was not assessed.  It may be that this 
technique has greatest potential benefit for those with distal lesions with a desire to achieve 
sphincter preservation. 
In a Danish study utilising 60Gy in 30 fractions to the tumour, 50Gy in 30 fractions to elective 
lymph node volumes and 5Gy endorectal brachytherapy boost, with concomitant oral 
tegafur-uracil, 40 of 51 patients with T2/3 N0-1 low rectal cancer were considered to have 
achieved a clinical complete response (cCR) and managed without surgery (Appelt et al, 
2015).  Follow up data regarding functional outcome at 2 years was only reported for 16 
(40%) of these patients however. 
Intensity-modulated radiation therapy (IMRT) is being used increasingly over traditional 3D 
conformal treatment due to the perceived benefit of delivering higher radiation doses to the 
tumour whilst minimising delivery to surrounding tissues.  Its use is technically challenging 
and costly however.  In a retrospective study of 7386 patients in the United States 
undergoing CRT between 2006 and 2013, adjusted multivariable regression modelling was 
used to isolate the impact of IMRT (n=3330) against 3D conformal treatment (n=4056).  A 
higher risk of a positive margin was identified in the IMRT group (OR 1.57, p < 0.001) and 
with no difference in pathological downstaging (OR 0.89, p = 0.051) but with no difference in 
overall survival at 8 years (64% vs. 64 %, OR 1.06, p = 0.47) (Sun et al, 2017).  In a recent 
phase II trial with 20 patients where IMRT was used with capecitabine for radio-sensitisation 
in stage II / III rectal cancer, 7 patients (35%) were determined to have achieved a pCR and 
with only 1 patient experiencing grade III radiation proctitis (Tey et al, 2017). 
A summary of these trials is presented in table 1.7 below. 
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Study Design Tumour 
Characteristics 
Neoadjuvant 
Treatment 
pCR 
Rate 
Limitations 
Chau et al, 
2006 
EXPERT 
Observational 
study 
n=77 
CRM threatened CAPOX prior to 
CRT 
20% n=4 deaths 
during 
neoadjuvant 
chemotherapy 
Fernandez-
Martos et 
al, 2010 
GCR-3 
Phase II 
randomised 
trial 
n=108 
CRM threatened A: CAPOX with 
CRT and adjuvant 
CAPOX vs. B: 
CAPOX then CRT 
14% in 
each arm 
Increased rate 
of grade 3/4 
toxicities in 
arm A 
Perez et al, 
2017 
CONTRE 
Observational 
study 
n=39 
Stage II / III CAPOX then CRT 33% n=3 did not 
complete 
CAPOX 
Gerard et 
al, 2012 
ACCORD 
12 
Phase II 
randomised 
trial 
n=598 
T3-4 Nx M0 
resectable cancer 
A: CRT (45Gy) vs. 
B: Intensified CRT 
(50Gy) with 
CAPOX 
13.9% vs. 
19.2%, 
p=0.09 
No significant 
difference in 
overall or 
disease-free 
survival after 3 
years between 
groups 
Gollins et 
al, 2012 
Phase II trial 
n=110 
CRM threatened 
or involved 
CRT with 
capecitabine and 
irinotecan 
22% Not powered 
to detect 
survival 
outcomes 
Appelt et 
al, 2015 
Observational 
study 
n=51 
T2-3 N0-1 low 
cancer 
60Gy to tumour, 
50Gy to lymph 
nodes, 5Gy 
brachytherapy 
boost 
Clinical 
complete 
response 
in 78% 
Local 
recurrence in 
16%, with 
functional 
outcome at 2 
years only 
reported in 
40% 
Sun et al, 
2017 
Retrospective 
study 
n=7386 
Stage II / III A: Intensity 
modulated vs. B: 
3D conformal 
radiotherapy 
11% vs. 
13%, 
p=0.012 
No difference 
in overall 
survival at 8 
years 
Tey et al, 
2017 
Phase II trial 
n=22 
Stage II / III Intensity 
modulated 
radiotherapy with 
capecitabine 
35% Limited 
sample size 
and dropout 
n=3  
 
Table 1.7 – Summary of selected trials investigating novel neoadjuvant CRT regimens and the 
associated pCR rate. 
 
 
 
 
 
39 
 
1.2.11.2 Clinical complete response 
The identification of a pCR following surgical resection has naturally raised the possibility 
that selected patients may not benefit from surgery after CRT.  In particular, the avoidance 
of the morbidity and mortality associated with a pelvic operation / anastomosis, as well as 
the avoidance of a permanent stoma in those that would otherwise require APE, is an 
attractive potential.  Accurate identification of those with a cCR and correlation of this with 
a pCR would be necessary to potentially manage patients non-operatively following CRT.   
A standardised definition of cCR was proposed by Professor Habr-Gama, incorporating 
assessment at or after 8 weeks following completion of CRT, with the requirement for a 
normal digital rectal examination (DRE), normal MRI imaging and a normal endoscopic 
mucosal appearance (Habr-Gama et al, 2010).  The mucosa in these cases should be intact, 
with only superficial whitening and the presence of telangectasia.  Any residual ulceration, 
nodularity or irregularity should raise concern of an incomplete response.  The addition of 
DWI with MRI increases the sensitivity of detection of pCR (Lambregts et al, 2011), with 
distinction of fibrosis from residual tumour. 
A retrospective assessment of the correlation of mucosal response with histopathological 
findings following CRT and proctectomy was undertaken in 238 consecutive patients (Smith 
et al, 2014).  61 patients (26%) were categorised with a pCR but 45 (74%) of these were 
determined to have a residual mucosal abnormality (ulceration / nodularity).  The remaining 
16 patients with a pCR had no residual mucosal abnormality but 6/22 patients overall with a 
mucosal cCR still had residual disease, rendering the finding of mucosal cCR in isolation 
poorly sensitive (26%) but highly specific (97%). 
A prospective study combining assessment modalities was undertaken in 50 patients, of 
whom 17 (34%) were determined to have achieved a complete response (Maas et al, 2015).  
Areas under receiver operator characteristics curves were 0.88 (0.78-1.00) for clinical 
assessment (comprising DRE, endoscopy +/- biopsy) and 0.79 (0.66-0.92) for MRI imaging 
with DWI.  Combining all modalities resulted in a 98% probability of predicting a complete 
response, and negative likelihood ratio conversely indicated a 15% chance of a complete 
response even when combined modality assessment had predicted residual tumour.  These 
statistics would suggest that combined modality assessment is a potentially safe and 
accurate method for selecting patients with a cCR for a watch and wait approach with 
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frequent surveillance, although no data from randomised-controlled trials exists (Glynne‐
Jones & Hughes, 2012). 
The initial data to advocate a watch and wait approach in cases of suspected cCR following 
CRT for resectable distal rectal cancer originated from Brazil (Habr-Gama et al, 1998), where 
30 patients (of 36/118 (31%) defined as achieving cCR) were managed non-operatively with 
no reported disease recurrence in the median 36-month follow-up.  This approach was 
considered non-inferior to surgical resection on long-term follow-up for those patients 
downstaged to stage 0 disease (those determined to have achieved a cCR and managed with 
watch and wait (n=71), and those achieving a pCR after surgical resection (n=22)) in a further 
cohort of 265 distal rectal cancer patients (Habr-Gama et al, 2004).  Five-year overall and 
disease-free survivals were 100% vs 88% and 92% vs 83% for patients managed by watch and 
wait compared against those with a pCR after resection respectively. 
More recent data from Habr-Gama’s group report a cCR rate of 68% following CRT for distal 
rectal cancer, with half of those in the study (35/70) avoiding surgery in the 12-month follow 
up period and considered to have maintained a long-term response (Habr-Gama et al, 2013).  
These studies include patients with earlier stage disease than those normally considered for 
CRT in the UK, and in distal (palpable) rectal cancers.  The translation of these results into 
potentially more advanced mid- and upper-rectal cancers (and with a greater likelihood of 
nodal disease) remains uncertain. 
The UK experience of 129 patients from the North West considered to have achieved a cCR 
following CRT was reported in a propensity score-matched cohort analysis (OnCoRe).  During 
the median 33-month follow-up period, 44 (34%) of those patients managed by watch and 
wait developed local regrowth, and 36/41 patients (88%) of those with non-metastatic 
recurrence underwent salvage surgery.  There was no difference in non-regrowth disease 
free or overall survival at 3 years comparing those in the watch and wait group with those 
undergoing initial surgical resection (non-cCR), indicating oncological safety, but a 
significantly better colostomy free survival at 3 years (74% vs 47%, p<0.0001) was observed 
in those managed by watch and wait (Renehan et al, 2015). 
A potential alternative to radical resection in the presence of a near-cCR following CRT, is for 
trans-anal excision of small (<3cm) residual ulcers in those with an objective clinical response 
(Creavin et al, 2017).  The aim of organ preservation in this context is to deliver equivalent 
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oncological outcome, with reduced surgical risk and improved functional outcome, and 
consequent improved quality of life.  In this observational study of 785 rectal cancer patients, 
60/362 (16.5%) receiving CRT were managed with an organ preservation strategy.  10 of 
these patients were managed entirely by a watch and wait approach; 50 patients underwent 
trans-anal excision of the scar/ulcer (with a desired 1cm margin), with a further 15 of these 
50 patients requiring salvage TME surgery due to adverse histological findings.  There was no 
significant difference in overall survival (85.6% vs 93.3%, p=0.414) or disease-free survival 
(78.3% vs 80%, p=0.846) comparing those undergoing radical surgery (n=317) against those 
managed with an organ preservation strategy (active surveillance and local excision, n=45).  
48/302 patients (15.9%) were observed to have achieved a pCR after initial resection, with 
local recurrence occurring in 4 (9%) of those managed with organ preservation. 
In cases of an apparent cCR, a risk of lymph node metastases remains.  In one study, 17% of 
patients with a pCR in the primary tumour (ypT0) following resection were identified to have 
lymph node metastases (Hughes et al, 2006).  These patients would be at higher risk of local 
or distant failure in the context of a watch and wait or local excision approach. 
The phase III prospective randomised-controlled GRECCAR 2 trial was powered to evaluate 
outcome comparing local excision or TME following CRT in T2/3 low rectal cancer.  At 2-year 
follow up and with analysis on an intention to treat basis, there was no difference in survival, 
local recurrence or significant after effects (considered as colostomy rate or the incidence of 
faecal incontinence or sexual dysfunction), however morbidity (48% vs 22%, p=0.001) and 
severe after effects (62% vs 29%, p<0.001) were significantly increased in the sub-group 
requiring TME after local excision (Rullier et al, 2017). 
A summary of the trials evaluating cCR and the reported outcomes is presented in table 1.8 
below. 
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Study Design Tumour 
Characteristics 
Neoadjuvant 
Treatment 
cCR Rate Comments 
Habr-
Gama et 
al, 1998 
Observational 
study 
n=118 
Low and 
resectable 
50.4Gy 
radiotherapy 
with 
leucovorin / 
5FU 
31% Includes n=6 patients 
with pCR identified 
post-resection 
Habr-
Gama et 
al, 2004 
Observational 
study 
n=265 
Low and 
resectable 
50.4Gy 
radiotherapy 
with 
leucovorin / 
5FU 
26.8% No difference in 
survival with cCR 
compared to ypT0N0 
post-resection 
Habr-
Gama et 
al, 2013 
Observational 
study 
n=70 
T2-4, N0-2 low 
cancer 
54Gy 
radiotherapy 
with 
leucovorin / 
5FU 
68% (initial) Sustained complete 
response (57%) at 12 
months, limited 
follow up 
Renehan 
et al, 
2015 
OnCoRe 
Propensity-
score matched 
cohort 
analysis 
n=259 (+98 
cCR) 
CRM 
threatened 
45Gy 
radiotherapy 
with 5FU 
12% No difference in 3-
year overall survival 
with cCR compared 
to resection.  
Improved colostomy-
free survival with cCR 
managed by watch 
and wait. 
Creavin 
et al, 
2017 
Observational 
study 
n=362 
≥T3, N0-2 50-54Gy 
radiotherapy 
with 5FU 
16.5% 
managed 
with organ 
preservation 
strategy 
Trans-anal excision in 
n=50.  Salvage TME 
in 30% of these.  
Tumour regrowth in 
9% who had organ 
preservation. 
Rullier et 
al, 2017 
GRECCAR 
2 
Randomised 
open-label 
phase III trial 
n=186 
T2-3 low cancer 
<4cm 
50Gy 
radiotherapy 
with CAPOX 
n=148 with 
good 
response 
and residual 
tumour 
randomised 
to local 
excision or 
TME 
No difference in 
survival or significant 
after-effects 
between groups on 
intention to treat 
analysis.  Increased 
morbidity and after-
effects in n=26 (35%) 
requiring TME after 
local excision. 
 
Table 1.8 – Summary of selected trials evaluating cCR and subsequent outcome with rectal-
preservation strategies. 
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1.3 Biomarkers of Response to Chemoradiotherapy in Rectal Cancer 
 
The current pCR rate with CRT remains low, with some patients experiencing disease 
progression despite treatment, and there are currently no biomarkers in routine clinical use 
to reliably predict response or guide decision making regarding the use of CRT (Ryan et al, 
2016).  The ability to predict response would positively select those patients who will derive 
benefit, whilst sparing others the morbidity associated with CRT and a potential delay in the 
local and systemic management of their disease.  The necessity for further research in this 
area has recently been highlighted by the ACPGBI, who have advocated the need for reliably 
predicting the response of rectal cancer to CRT, and for novel strategies for improving the 
sensitivity of rectal cancer to radiation therapy (Tiernan et al, 2014). 
Historical studies of the sensitivity of rectal cancer to CRT have been based around the core 
of sensitivity to 5-FU based protocols and have focussed on individual or a few markers based 
on immunohistochemical (IHC) expression.  The profiling of rectal cancer sensitivity to CRT 
has been facilitated by the evolution of high-throughput analyses to produce expression 
profiles or signatures, particularly at genomic level, and the developing knowledge of 
involved pathways has further refined the focus of potential biomarkers.  In the clinical 
setting 5-FU is being complimented by other chemotherapeutic agents such as oxaliplatin 
and irinotecan, and modern studies need to reflect this change in practice. 
 
1.3.1 Gene Expression Analysis 
Gantt et al (2014) correlated mRNA profiling of pre-treatment rectal adenocarcinoma 
biopsies with TRG at resection in 33 patients, subsequent to standard 5-FU based CRT.  They 
derived 812-gene and 183-gene differentially expressed signatures (at p<0.05 and p<0.01 
respectively) that separated ‘non-responders’ from ‘responders’.  Sensitivity and specificity 
in a small verification set was 100% for the 812-gene signature but sensitivity dropped to 
33% with the 183-gene signature.  Ingenuity Pathway Analysis (IPA) software was used to 
derive significant biological functions and canonical pathways associated with 666 of the 812 
genes (78 genes with indeterminable fold change, and a further 68 unmapped genes were 
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eliminated from this analysis).  The ‘DNA double-strand break repair by homologous 
recombination’ pathway was considered to contain amongst the highest ratio of significantly 
differentially expressed genes but the authors acknowledged their small sample size, and the 
intrinsic limitations of multiple testing / false positives associated with the evaluation of tens 
of thousands of genes with microarray analysis – none of their candidate genes passed a 
Bonferroni correction. 
Watanabe et al (2014) constructed a predictive model comprising a 4-gene signature derived 
from microarray analysis of 46 pre-CRT biopsy samples.  Twenty-four probes were identified 
as differentially expressed between responders and non-responders (t test with false 
discovery rate p<0.046, fold change >2.0).  Eighteen genes (representing 22 probes) were 
identifiable, and significantly validation of the microarray data was performed on parallel 
samples by quantitative RT-PCR, with good correlation.  Predictive modelling utilising ≤4 out 
of the 18 genes found the highest accuracy (89.1%) with LRRIQ3, FRMD3, SAMD5 and TMC7, 
and further validation was performed in an independent sample (n=16) with a predictive 
accuracy of 81.3%. 
None of these 4 genes (LRRIQ3, FRMD3, SAMD5 and TMC7) has been previously associated 
with rectal cancer, although one of the other 18 differentially expressed genes (REG4) was 
identified as significantly over-expressed by Kobunai et al (2011) in relatively radio-resistant 
CRC cell lines.  Up-regulation of REG4 in the radio-sensitive cell lines HCT116 and Colo320 
produced a significantly increased survival fraction on clonogenic assay following irradiation, 
and significantly inhibited radiation-induced DNA fragmentation.  REG4 expression in a 
limited validatory clinical sample (n=22) was also significantly 8.3 times higher in ‘non-
responders’ to pre-operative radiotherapy. 
Whilst REG4 may play a role in radiotherapy resistance, an in vitro gene expression signature 
for sensitivity to CRT was derived from 12 CRC cell lines by Spitzner et al (2010).  In this study, 
treatment response to 3µM 5-FU and 2Gy radiation was observed by clonogenic assay and 
correlated with pre-treatment gene expression profiles of the cell lines.  2770 genes were 
correlated with sensitivity to CRT at a significance level of Q<0.05.  IPA software determined 
canonical pathways to include RAS-MAPK, with DOK3 as an upstream regulator of RAS 
signalling and deregulation conferring resistance; insulin signalling, where insulin binding 
activates PI3K-AKT; and Wnt/β-catenin signalling.  These pathways will be further 
considered.   
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When compared with other microarray gene expression studies (Ghadimi et al, 2005; Kim et 
al, 2007; Rimkus et al, 2008; Brettingham-Moore et al, 2011; Nishioka et al, 2011; Watanabe 
et al, 2006), there does not appear to be concordance of candidate genetic markers for 
response to CRT, as different gene expression signatures are reported between studies.  This 
may be likely to be due to genetic differences between populations but is also confounded 
by variations in sample collection and preparation, by a lack of conformity to one particular 
CRT regimen, a varying definition of ‘responder’ and ‘non-responder’, and with the intrinsic 
limitations of multiple testing / false positives associated with the evaluation of tens of 
thousands of genes with microarray analysis.  Gene expression analysis however offers the 
identification of a wide range of potential markers of sensitivity/resistance to CRT, as well as 
potential therapeutic targets but requires wider validation in larger samples and across 
populations. 
A more focussed approach was adopted by Sebio et al (2014), with analysis of 
polymorphisms in EGFR (whose activation by radiation induces cell proliferation / radio-
resistance) and its ligands, DNA repair genes and TS.  Genomic DNA was extracted from blood 
samples in 84 patients undergoing capecitabine-based CRT.  A pCR was observed in 17 
patients (20.2%).  Correlation with the studied polymorphisms demonstrated significant 
association with pCR following multivariate analysis for rs11615 in the ERCC1 gene (DNA 
repair), and rs11942466 in the AREG gene region (EGFR ligand), which may have implications 
for biological therapy with cetuximab. 
A summary of the discussed gene expression studies investigating the association with 
response to CRT is presented in table 1.9 below. 
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Study Design Evaluation Outcome Comments 
Gant et al, 
2014 
mRNA 
profiling in 
n=33 pre-CRT 
biopsies 
Correlation with 
TRG 
812-gene signature separating 
responders and non-
responders, highest ratio of 
differentially expressed genes 
implicated in ‘DNA double-
strand break repair by 
homologous recombination’ 
Small sample 
size, limitations 
of multiple 
testing / false 
positives with 
microarray 
analysis 
Watanabe 
et al, 2014 
Microarray 
analysis in 
n=46 pre-CRT 
biopsies, 
predictive 
modelling 
Differential 
expression 
between 
responders and 
non-responders 
18 genes identifiable, 
validated with parallel 
quantitative RT-PCR, 
predictive modelling utilising 
≤4 genes demonstrated 
highest accuracy (89.1%) with 
LRRIQ3, FRMD3, SAMD5 and 
TMC7 
Small sample 
size, limitations 
of microarray 
analysis 
Kobunai et 
al, 2011 
Microarray 
analysis in n=8 
CRC cell lines 
pre-irradiation 
Differential 
expression 
between radio-
sensitive and 
radio-resistant 
REG4 expression 12-fold 
higher in radio-resistant cells, 
increased surviving fraction 
on clonogenic assay post-
irradiation with REG4 up-
regulation in (radio-sensitive) 
HCT116 and Colo320 cell lines 
REG4 
expression x8.3 
higher in non-
responders to 
CRT in a 
validatory 
clinical dataset 
(n=22) 
Spitzner et 
al, 2010 
Microarray 
analysis in 
n=12 CRC cell 
lines pre-CRT 
Correlation of 
gene expression 
profile with 
sensitivity to 
CRT 
2770 genes correlated with 
sensitivity to CRT at a 
significance level of Q<0.05, 
IPA software determined 
canonical pathways to include 
RAS-MAPK and insulin 
signalling 
In vitro data, 
limitations of 
microarray 
analysis 
Sebio et al, 
2014 
Genomic DNA 
extracted 
from blood 
samples in 
n=84 patients 
pre-CRT 
Correlation of 
polymorphisms 
in EGFR, TS and 
DNA repair 
genes with pCR 
Significant association with 
pCR following multivariate 
analysis for rs11615 in the 
ERCC1 gene (DNA repair), and 
rs11942466 in the AREG gene 
region (EGFR ligand) 
Liquid biopsy, 
stage II and III 
disease 
 
Table 1.9 – Summary of gene expression studies investigating response to CRT in rectal cancer. 
 
 
 
1.3.2 miRNA Profiling 
MicroRNAs (miRNAs) are small non-coding RNAs with regulatory function at a post-
transcriptional level.  Each miRNA can regulate the expression of hundreds of target genes, 
and many proteins involved in signalling pathways in CRC have been identified to be 
modulated by miRNAs (Calin and Croce, 2006).  miR-143 is downregulated in CRC, normally 
functioning as a tumour suppressor through inhibition of the KRAS oncogene.  miR-145 is 
equally a tumour suppressor and downregulated in CRC, with its action in regulating insulin-
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receptor substrate-1 (IRS-1) and control of cell growth and proliferation.  miR-21 is 
conversely upregulated in CRC, and demonstrates inhibition of the tumour suppressor gene 
PTEN, which has a significant role in the regulation of the PI3-K pathway (Slaby et al, 2007).  
Drebber et al (2011) characterised the expression of these miRNAs pre- and post-CRT in 40 
patients, identifying significant changes in expression of miR-143 and miR-145 following CRT 
but non-significant changes in the association with tumour regression or in predictive pre-
treatment levels. 
miR-21 in its mature form (miR-21-5p) was the most sensitive and specific miRNA (78% and 
86% respectively) predicting pCR and cCR from fresh frozen, pre-treatment biopsies (n=43), 
out of 4 differentially expressed miRNAs in the study by Lopes-Ramos et al (2014).  Further 
analysis of putative target genes identified using TargetScan software, found a significant 
negative correlation with the SATB1 gene alone but not others including PTEN.  SATB1 has 
been associated with a poorer prognosis in rectal cancer (Meng et al, 2012).  The group 
established the inverse relationship between miR-21-5p and SATB1 mRNA expression, by 
manipulating miR-21-5p expression in HCT116 and SW480 colorectal cancer cells.  
Clonogenic assay following exposure to CRT (5µM 5-FU and GammaCell 3000 irradiation) 
resulted in significantly increased radio-sensitivity with increased miR-21-5p expression, and 
significantly decreased radio-sensitivity with inhibition of miR-21-5p.   
Scarpati et al (2011) evaluated miRNA expression in pre-treatment fresh frozen biopsies, 
comparing complete responders (n=9) against all others (n=29).  Standard neoadjuvant CRT 
in this study also included oxaliplatin.  53 differentially expressed miRNAs were further 
analysed and 14 with the highest-fold change were selected for RT-PCR analysis.  Their data 
revealed two miRNAs (622 and 630) with 100% sensitivity and specificity for pCR in the study, 
alongside a panel that could be validated further in a larger cohort.  Bioinformatic prediction 
of the evaluated miRNAs in the study targeted EGFR pathways, IGFR pathways and DNA 
repair pathways, with miR-630 specifically being considered to invoke tumour inability to 
repair DNA damage induced by combined radiotherapy and oxaliplatin. 
Another small study of miRNA expression in pre-CRT specimens (n=12) by Kheirelsied et al 
(2013) used FFPE tissue, identifying a different miRNA signature of complete vs incomplete 
response (miR-16, miR-590-5p and miR-153) to neoadjuvant CRT.  Svoboda et al (2012) 
identified another different panel of 8 significantly differentially expressed miRNAs from 
fresh frozen pre-treatment biopsies, separating responders (TRG1/2) from non-responders 
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(TRG3/4).  Putative pathways for this panel of miRNAs related to TS inhibition, highlighting 
the significance of 5-FU sensitivity to treatment outcomes. 
An in vitro expression signature of miRNAs in 12 colorectal cancer cell lines, was studied by 
Salendo et al (2013), following on from their work establishing a cell line-based model of CRT 
sensitivity, where gene expression level of the miRNAs correlated significantly with 
sensitivity.  Significant putative pathways in this model involved MAPK, Wnt signalling 
pathways and cell cycle genes.  The functional significance of selected significant miRNAs was 
confirmed in vitro in SW480 and SW837 cell lines, with miRNA-mimic transfections 
conferring either radio-sensitivity (miR-320a, miR-132 and let7g) or radio-resistance (miR-
224) to irradiation or CRT but not 5-FU in isolation.  The clinical significance of these miRNAs 
was assessed in 128 pre-CRT biopsies but no significant correlation with TRG was found.  A 
significant association with disease free survival was seen with high expression of let-7g, 
which could be further prospectively investigated for its value as a prognostic marker. 
Overall, a number of miRNAs have been identified in different studies as potential predictors 
of response to neoadjuvant CRT, or as having prognostic value, and a summary of these 
studies is presented in table 1.10 below.  The functional relevance of single miRNA does not 
currently seem to offer a robust therapeutic target but further understanding their 
interactions and pathways can only help to understand their role.  It may be that an 
expression profile of miRNAs is able to predict response, and that this can be established 
with further validation. 
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Study Design Evaluation Outcome Comments 
Drebber et 
al, 2011 
FFPE 
biopsies pre- 
and post-
CRT, n=40 
Expression 
of miR-21, -
143 and -
145 
Significant up-regulation of miR-143 
and -145 post-CRT 
Non-significant 
association with 
TRG 
Lopes-
Ramos et 
al, 2014 
Fresh frozen 
biopsies pre-
CRT, n=43 
miRNA 
expression 
profiling 
n=4 differentially expressed miRNAs 
between complete and incomplete 
responders, miR-21 most sensitive 
and specific (78% and 88% 
respectively) 
In vitro validation 
of manipulation of 
miR-21 expression 
correlating with 
radio-sensitivity 
Scarpati et 
al, 2011 
Fresh frozen 
biopsies pre-
CRT, n=38 
miRNA 
expression 
profiling 
n=53 differentially expressed miRNAs 
between pCR and others, miR-622 
and -630 demonstrated 100% 
sensitivity and specificity for pCR 
Standard CRT 
included oxaliplatin 
Kheirelsied 
et al, 2013 
FFPE 
biopsies pre-
CRT, n=12 
miRNA 
expression 
profiling 
miRNA signature for complete 
response (miR-16, miR-590-5p and 
miR-153) 
Limited sample size 
Svoboda et 
al, 2012 
FFPE 
biopsies pre-
CRT, n=8 
miRNA 
expression 
profiling 
n=8 differentially expressed miRNAs 
between responders and non-
responders, putative pathways for 
this panel related to TS inhibition 
Limited sample size 
Salendo et 
al, 2013 
In vitro 
evaluation 
of n=12 CRC 
cell lines 
miRNA 
expression 
profiling 
n=36 miRNAs correlated with 
sensitivity to CRT, miRNA-mimic 
transfections in SW480 and SW837 
CRC cells conferred radio-sensitivity 
(miR-320a, miR-132 and let7g) or 
radio-resistance (miR-224) 
No correlation with 
TRG for these 
miRNAs in n=128 
clinical pre-CRT 
biopsies 
 
Table 1.10 – Summary of studies investigating miRNA expression and correlation to response to CRT 
in rectal cancer 
 
1.3.3 Protein Biomarkers 
The literature contains numerous IHC-based studies of individual or a few markers, with 
conclusions from previous comprehensive reviews (Grade et al, 2012; Kuremsky et al, 2009; 
Kapur, 2011; Aklilu and Eng, 2011; Torino et al, 2013) being that these studies provide 
conflicting evidence for many markers, without universal acceptance of any one marker 
individually or in combination.   The most significantly studied markers include p53, p21, p27, 
Ki-67, Bax, Bcl-2, XIAP, survivin, VEGF, HIF-1α, EGFR, TS, and TCF4.  The review by Kuremsky 
et al (2009) concluded that of the six markers cited more than five times (p53, EGFR, TS, Ki-
67, p21, and Bax/Bcl-2), EGFR and TS held promise as predictive biomarkers particularly with 
focus on genetic polymorphisms, and further investigation of p21 and Bax was justified.  
These markers correlate strongly with cell pathways previously identified by gene expression 
studies, including apoptosis and WNT pathway signalling. 
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1.3.3.1 Apoptosis 
Survivin and XIAP are members of the inhibitors of apoptosis (IAP) protein family.  High 
survivin expression has been associated with reduced apoptosis in pre-treatment biopsies of 
rectal cancer patients, and conferred an increased risk of local disease recurrence (26% vs. 
6%, p=0.05) in the study by Rödel et al (2005).  In the study by Kim et al (2011) where 
imunohistochemical staining on tissue microarray (TMA) of seven markers (Cox-2, TS, VEGF, 
EGFR, Ki-67, p21 and survivin) from a pre-CRT biopsy, was correlated with Dworak tumour 
regression grading in a cohort of 54 patients, only survivin expression was significantly 
related to tumour downstaging, with higher expression observed with a poorer response. 
Expression of XIAP was demonstrated to be the only significantly differentially expressed 
apoptotic protein in a tumour:normal mucosa ratio in biopsies of 38 rectal cancer patients 
(Moussata et al, 2012).  In vitro analayis of XIAP expression in a radio-resistant CRC cell line 
(SW480) increased following irradiation, with subsequent siRNA knockdown of the protein 
conferring significantly increased radio-sensitivity on the basis of clonogenic assay and 
apoptotic index.  Hehlgans et al (2013) further demonstrated that single or double targeting 
of survivin and XIAP with siRNA in 4 CRC cell lines grown in 3D culture (as a potentially closer 
model of in vivo behaviour) conferred significantly increased radio-sensitivity, and that 
double knockdown of these proteins significantly decreased phosphorylation of the markers 
FAK Y397 and Akt1 S473, which are associated with cellular survival, deregulated migration 
and cancer invasion. 
A therapeutic model of the action of the smac mimetic JP-1201, as an inhibitor of IAPs was 
developed by Huerta et al (2010).  In HT-29 CRC cells, significantly increased radio-sensitivity 
was observed following irradiation on clonogenic assay with JP-1201 pre-incubation, which 
was translated into an immunodeficient mouse xenograft model, where a 46% reduction in 
tumour load was observed in an irradiation + JP-1201 group against irradiation alone (and 
with no reduction against JP-1201 treatment in isolation).  The mechanism of action for 
increased radio-sensitivity with JP-1201 was proposed to be evidenced by a marked 
reduction in XIAP expression in pre-treated cells following irradiation associated with more 
double-stranded DNA breaks. 
Further studies in HCT116 cells and xenografts undertaken by Huerta et al (2013) 
demonstrated a radio-sensitive phenotype in DNA-PKcs, p21, and Bax deficient cell lines, and 
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a radioresistant phenotype in a p53 deficient cell line.  In vivo work demonstrated Bax 
deficiency resulted in increased tumour necrosis and decreased microvessel density, with 
complementary in vitro data demonstrating decreased levels of VEGF.  siRNA inhibition of 
apoptosis inducing factor (AIF) in Bax deficient HCT116 cells conferred a significant survival 
advantage following ionising radiation compared with AIF inhibition in wild type controls, 
implicating AIF in the radio-sensitivity of Bax deficient cells. 
The effect of Bax was evaluated in a clinical dataset by Fucini et al (2012).  IHC Bax positivity 
on FFPE pre-CRT biopsies was significantly associated with downstaging in a group of 34 
patients (p=0.001) but not p53, Bcl-2 or Bcl-xl. 
1.3.3.2 WNT pathway 
Epithelial mesenchymal transition (EMT) as a marker of response to neoadjuvant CRT was 
evaluated by Bhangu et al (2014).  The process represents the conversion of epithelial cells 
into motile mesenchymal cells under the major influence of transforming growth factor-β1, 
and is seen mainly at the invasive edge of the tumour.  Nuclear β-catenin accumulation 
occurs following downregulation of E-cadherin, with activation of downstream EMT 
pathways (Kalluri and Weinberg, 2009).  The study was performed as a proof-of-principle, 
using FFPE resection specimens, and equally representing post-CRT tissue.  Reduced E-
cadherin expression, nucleic β-catenin expression and tumour budding were significantly 
associated with EMVI, and miRNA 200c loss (as an upstream regulator of EMT) in addition to 
the other markers were strongly associated with non-response to CRT, defined by Mandard 
tumour regression grade 3-5.   
Wang et al (2013) corroborate the association of nuclear β-catenin overexpression with 
radio-resistance.  68 patients (57.6%) who exhibited radio-resistance, as defined by Dworak 
TRG 0-2 had high nuclear β-catenin expression, compared with 3 radio-sensitive cases 
(16.7%) with low nuclear expression.  It is not clear in the paper that the evaluated tissue is 
a pre-treatment biopsy in isolation.  Equally treatment was with SCPRT and not CRT, 
therefore β-catenin may reflect radio-sensitivity not sensitivity to CRT. 
The expression of β-catenin was also demonstrated to be influenced by lincRNA-p21 by 
Wang et al (2014).  LincRNAs have been shown to be novel regulators of transcription and 
post-transcriptional translation, and are regulated by p53 (Huarte et al, 2010).  Reduced 
lincRNA-p21 expression in CRC cells was associated with elevated β-catenin expression, and 
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its expression was induced by irradiation.  Overexpression of lincRNA-p21 in SW1116 cells 
increased their radio-sensitivity by inducing apoptosis.  In 30 clinical samples its expression 
was elevated in rectal adenocarcinoma compared to normal adjacent mucosa.  Whilst the 
authors propose lincRNA-p21 as a novel therapeutic target, it would certainly seem 
appropriate to further target Wnt/β-catenin signalling. 
 
1.3.4 Conclusions and Future Direction 
A wide range of potential markers for sensitivity to CRT have been evaluated, however there 
remains no current universal acceptance for either a single biomarker or panel of 
biomarkers, in predicting outcome to neoadjuvant CRT in locally advanced rectal cancer.  
Variations in tissue collection and processing, different stratifications of pathological 
response, varying interpretations of ‘responder’ vs. ‘non-responder’, the divergent 
chemotherapy and radiotherapy regimens employed even within 5-FU based therapy, as well 
as more novel radio-sensitisers used in addition/combination, have muddied the waters in 
the search for predictive markers, whilst simultaneously broadening the scope for further 
research and redefining targets. 
The future direction for further work encompasses further genome wide expression 
analyses, further focussed SNP analysis of key genetic markers, and further validation of key 
or novel protein biomarkers, in wider and co-ordinated studies, to establish markers for the 
range of potential CRT regimens, either within and/or across populations.  This would lead 
to the personalisation of CRT regimens, and/or the selection of patients most appropriate 
for CRT, with hopefully improved cancer specific outcomes, whilst limiting off target effects, 
morbidity and improving functional outcome. 
Modification of treatment response is equally a therapeutic goal and following the validation 
of robust prognostic markers at the genetic or post-transcriptional level, novel therapies may 
emerge.  The growing development of organ preserving surgical techniques in rectal cancer 
mean that radiotherapy will have an even greater role to play in the future, and therefore 
further improvement in the efficacy and prediction of response is critical in the ongoing 
management of rectal cancer. 
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1.4 Acid Ceramidase 
 
1.4.1 Precipitating Research 
The research underpinning the experimental work presented in this thesis was performed at 
The University of Liverpool as one aspect of PhD studies undertaken by Mr Paul Sutton.  A 
novel temporal proteomic profiling in patients receiving CRT for locally advanced rectal 
cancer was performed, in attempt to identify differentially expressed proteins that may be 
implicated in CRT response.  Cancer tissue was obtained at the time of diagnosis before CRT, 
at the completion of CRT, and after the downstaging period at the time of surgical resection, 
then subjected to mass spectrometry analysis (with isobaric tagging for relative and absolute 
quantification) to determine protein expression.  Differential protein expression between 
the respective samples was assessed to identify temporal changes with CRT and during 
subsequent downstaging, and a comparison of protein expression between patients 
dichotomised to have responded or not to CRT was performed from the potentially 
predictive pre-CRT samples.  This data has been deposited to the ProteomeXchange 
Consortium via the PRIDE (Vizcaíno et al, 2016) partner repository with the dataset identifier 
PXD008436. 
The abundance of contributing peptide ions for 18 proteins were significantly different 
between pre- and post-CRT samples, of which 16 were upregulated and 2 downregulated.  
There were 19 upregulated and 10 downregulated proteins when comparing pre-CRT and 
resection samples, and 9 upregulated and 30 downregulated between post-CRT and 
resection samples.  When comparing tumours between those patients subsequently 
dichotomised as relative responders or non-responders to CRT, the abundance of 
contributing peptide ions for 8 proteins were significantly different, 5 of which were 
upregulated in responders and 3 downregulated.  Tables detailing these results are included 
in appendix A. 
Those proteins identified as statistically significantly different were subjected to analysis with 
IPA (Redwood City, USA).  The ceramide degradation pathway was identified as the most 
significantly downregulated pathway in those tumours responding to CRT (p=9.92E-04) 
based on the significantly lower abundance of contributing peptide ions for acid ceramidase 
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(AC) (log fold change -1.526, p=1.17E-02).  AC was also significantly differentially expressed 
in the tumours between the point of CRT completion and at the time of surgical resection, 
with downregulation (log fold change -1.568, p=1.35E-02) during this downstaging period. 
 
1.4.2 Biology and Pathophysiology of Acid Ceramidase 
AC is a hydrolase important in the regulation of sphingolipids – a group of biomolecules 
known to be responsible for structural components of biological membranes (particularly 
ceramide) but with increasing evidence to implicate them as bioactive molecules involved in 
the modulation of cell growth, differentiation, cell migration and apoptosis.   
 
 
Figure 1.7 – Sphingolipid metabolism.  (Taken from Arana et al, 2010) 
 
 
Ceramide is produced by degradation of sphingomyelin by sphingomyelinase (SMase), by de 
novo synthesis through the action of serine palmitoyltransferase and dihydroceramide 
synthase and is generated through metabolism of more complex sphingolipids.  It is 
metabolised to ceramide-1-phosphate by ceramide kinase, or to glucosylceramide by 
glucosylceramide synthase.  Ceramide can be degraded by ceramidases to form sphingosine 
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(SPH), which can then be phosphorylated to sphingosine-1-phosphate (S1P) by sphingosine 
kinase (SK).  SPH can be produced from S1P under the action of phosphatases, and ceramide 
generated from SPH under the action of ceramide synthase. 
SPH, ceramide and S1P are the main bioactive molecules, with ceramide and S1P exerting 
opposing influences on the cell – ceramide has been demonstrated to mediate cell cycle 
arrest and apoptosis in response to cell stress, and S1P demonstrated to promote cell survival 
and proliferation (Garcia-Barros et al, 2014).  The regulation of these molecules is controlled 
by enzymes such as AC, and sphingolipid metabolism is depicted in figure 1.7 above. 
 
The degradation of ceramide to SPH occurs by hydrolysis and is catalysed by ceramidases.  
These are characterised by the pH required for their optimal activity (acid, neutral or 
alkaline).   
AC is a lysosomal cysteine amidase that catalyses the breakdown of ceramide into SPH and 
free fatty acid.  It was first discovered in rat brain homogenates and was further 
characterised and purified from human urine in 1995 (Bernado et al, 1995).  AC has a 
molecular weight of 53-55kDa depending on the degree of glycosylation and is composed of 
α and β sub-units which are 13 and 40kDa in weight respectively.  The sub-units are joined 
by a disulphide bond, with glycosylation only occurring on the β sub-unit.  AC is synthesised 
as a pro-enzyme, undergoing autoproteolytic cleavage into its constituent sub-units post-
translationally within lysosomes, and has an optimal enzymatic pH range of 4-5 (He et al, 
2003). 
The ASAH1 gene is located on chromosome 8 and encodes for AC (Li et al, 1999).  Mis-sense 
mutations in this gene have been associated with an extremely rare autosomal recessive 
condition called Farber’s disease / lipogranulomatosis.  This is a lysosomal storage disease, 
characterised by ceramidase deficiency and resulting in ceramide accumulation in tissues.  
Symptoms usually present within the first few weeks of life, with impaired mental ability and 
dysphagia.  Other symptoms include arthritis, lymphadenopathy, contractures, hoarseness 
and xanthomas, and hepatic, cardiac and renal impairment can occur.  Most children with 
the condition usually die as a consequence of respiratory disease by the age of 2 (Farber, 
1952).  More recently another mutation in the ASAH1 gene has been associated with spinal 
muscular atrophy associated with progressive myoclonic epilepsy, characterised by damage 
to lower motor neurons.  The reduced expression of AC in this condition (but not <10% as in 
Farber disease) is thought to allow for near-normalised ceramide levels but results in a later 
onset phenotype restricted to the central nervous system (Zhou et al, 2012). 
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1.4.3 Acid Ceramidase in Apoptosis 
 
Apoptosis refers to an inducible and pre-programmed cell pathway resulting in the activation 
of calcium- and magnesium-dependent endonucleases that fragment nuclear chromatin.  
The involvement of ceramide in apoptosis was demonstrated by the induction of apoptosis 
with exogenously added ceramide to bovine aortic endothelial cells.  In addition, radiation 
induced sphingomyelin hydrolysis and apoptosis, that had been blocked by protein kinase C 
activation, was reversed with the addition of ceramide (Haimovitz-Friedman et al, 1994).   
The mechanism of ceramide-induced apoptosis has been considered to be both via the 
extrinsic pathway as a consequence of enhanced signalling from pro-apoptotic membrane 
molecules such as CD95 (Miyaji et al, 2005), or via the intrinsic pathway by the formation of 
trans-membrane mitochondrial channels that allow the release of apoptosis inducing 
proteins such as caspase-3 and cytochrome c (Siskind et al, 2002).  Ceramide has also been 
associated with reduced telomerase activity and with the acceleration of telomere 
shortening, thus increasing the likelihood of cell senescence or apoptosis once the telomere 
reaches a critical length (Ogretmen et al, 2001). 
It is proposed that many cancer cells are able to resist apoptosis as a consequence of limiting 
ceramide generation, or by its rapid removal (Truman et al, 2014).  One such mechanism is 
via the de-acetylation of ceramide by AC to SPH, which is then modified by a SK to S1P.  S1P 
has been demonstrated to initiate the pro-survival PI3K/AKT signalling pathway, thus 
opposing the effect of ceramide, with the balance between ceramide and S1P determining 
cell fate (Bonnaud et al, 2010).  Co-expression of Akt2 and ASAH1 genes has been 
demonstrated to significantly induce cell invasion and resistance to apoptosis, with siRNA 
inhibition of both genes, as well as combined pharmacological inhibition, more potent than 
inhibiting each individually in inhibiting cell viability, proliferation and invasion (Berndt et al, 
2013). 
S1P has also been revealed to promote invasiveness in glioblastoma by upregulation of the 
urokinase plasminogen activator and its receptor, and the pro-invasive molecule cysteine-
rich angiogenic protein 61 (Young et al, 2009).  In the rat HTC hepatoma cell line, ceramide 
accumulation itself did not appear to induce apoptosis in response to tumour necrosis factor-
α and cycloheximide therapy but by the lysosomal conversion to SPH by AC which causes 
lysosomal membrane permeability, with siRNA inhibition of AC interestingly preventing 
apoptosis induced by the therapy (Ullio et al, 2012). 
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AC is therefore centrally placed in the pathway of sphingolipid metabolism and may well 
have a key role in the fate of cells in response to stresses that induce ceramide.  Over-
expression seemingly catalyses the breakdown of ceramide and drives the cell away from 
apoptosis towards survival, with reduced expression or inhibition resulting in ceramide 
accumulation and apoptosis. 
 
 
1.4.4 Acid Ceramidase in Malignancy 
 
A summary of the studies implicating AC in numerous malignancies is presented in table 1.11 
below with subsequent further detailed appraisal. 
 
Study Malignancy Evaluation Outcome Comments 
Roh et al, 
2016 
Head and 
neck cancer 
AC expression, effect 
of genetic and 
pharmacological 
manipulation 
AC over-expression in 4 of 6 primary 
tumours and 6 of 9 cell lines, increased 
cell sensitivity to cisplatin with AC 
inhibition 
Increased ceramide 
and apoptotic protein 
levels with AC 
inhibition 
Korbelik et 
al, 2016 
Head and 
neck cancer 
Effect of AC inhibition 
with LCL521 in SCCVII 
cells 
Reduced cell survivability after 
photodynamic therapy 
 
Elojeimy et 
al, 2007 
Head and 
neck cancer 
Effect of manipulation 
of AC expression in 
SCC-1 cells 
Increased resistance to Fas-induced 
apoptosis with over-expression of AC, and 
increased sensitivity with down-regulation 
AC inhibition with 
LCL204 sensitises to 
Fas-induced apoptosis 
Realini et 
al, 2016 
Melanoma AC expression, effect 
of AC inhibition with 
ARN14988 in 
proliferative 
melanoma cells 
Melanocytes and melanoma cell lines 
over-express AC relative to non-
melanoma skin cancer cells, synergistic 
action of AC inhibition with 5-FU to 
increase cytotoxicity 
AC inhibition increases 
ceramide and 
decreases S1P levels 
Bedia et al, 
2011 
Melanoma Effect of manipulation 
of AC expression in 
A375 cells 
Over-expression and down-regulation 
conferred resistance and sensitivity to 
dacarbazine respectively 
 
Tan et al, 
2016 
Acute 
myeloid 
leukaemia 
AC expression, effect 
of AC inhibition with 
LCL204 in mouse 
models 
Primary AML cells highly express AC, 
LCL204 treatment increases survival in 
C57BL/6 mice engrafted with C1498 
leukaemia cells and reduces disease 
burden in NSG mice engrafted with 
primary human AML cells 
Increased expression 
of anti-apoptotic Mcl-
1 with AC inhibition 
Hu et al, 
2011 
Acute 
myeloid 
leukaemia 
AC expression relative 
to IRF8 expression in 
myeloid cells 
IRF8 expression lost in AML, restoration of 
IRF8 reduces AC expression, increases 
ceramide levels and increases sensitivity 
to FasL-induced apoptosis 
AC expression 
significantly increased 
in cells derived from 
IRF8 deficient mice 
Ramírez de 
Molina et 
al, 2012 
Non-small 
cell lung 
cancer 
Response in primary 
cell culture to ChoKα 
inhibitors and 
associated AC 
expression 
Raised AC expression in cells with 
acquired resistance to ChoKα inhibition 
Anti-proliferative 
effect of ChoKα 
inhibition enhanced 
with synergistic 
inhibition of AC  
Flowers et 
al, 2012 
Breast 
cancer 
Effect of AC inhibition 
with DM102 on the 
apoptosis inducing 
effects of C6-ceramide 
in three cell lines 
AC inhibition synergistically produced a 
significant reduction in viability in all cell 
lines 
AC expression related 
to HER2 status 
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Hanker et 
al, 2013 
Ovarian 
cancer 
IHC expression of AC 
in n=112 cancers 
Low expression correlated with poorer 
cancer specific survival 
Contrary to other data 
Morales et 
al, 2007 
Hepatoma In vitro and in vivo 
study, effect of AC 
inhibition on 
daunorubicin 
treatment 
Inhibition of AC with genetic (siRNA) or 
pharmacological (N-oleoylethanolamine) 
means sensitised human (HepG2) and 
mouse (Hepa1c17) hepatoma cell lines to 
treatment, in vivo AC inhibition with 
siRNA reduced growth in liver tumour 
xenografts of HepG2 cells 
Cell death preceded 
by structural 
mitochondrial 
changes, stimulation 
of reactive oxygen 
species generation 
and cytochrome c and 
caspase-3 activation. 
Mahdy et 
al, 2009 
Prostate 
cancer 
Effect of AC 
manipulation on 
sensitivity to radiation 
in PPC-1 cells 
Down-regulation of AC with siRNA and 
inhibition with LCL385 confers radio-
sensitivity 
Up-regulation of AC 
decreased sensitivity 
to radiation and 
created cross-
resistance to 
chemotherapy 
Cheng et al, 
2013 
Prostate 
cancer 
AC expression post-
irradiation in PPC-1 
cells and IHC 
expression in human 
prostate cancer 
Up-regulation of AC post-irradiation, over-
expression in surviving clones associated 
with increased radio-resistance, higher AC 
expression after radiotherapy failure 
(than in irradiation-naïve cancer, intra-
epithelial neoplasia or benign tissue) 
Inhibition with LCL521 
in a xenograft model 
produced radio-
sensitisation and 
prevented relapse 
Camacho et 
al, 2013 
Prostate 
cancer 
IHC AC expression in 
n=33 prostate cancers 
and PC-3 cell line 
Higher AC expression with more advanced 
disease stage, higher expression in 
tumourigenic PC-3/Mc clone than non-
metastatic PC-3/S clone 
siRNA inhibition of AC 
in PC-3/Mc clone 
resulted in ceramide 
accumulation and 
reduced viability 
Holman et 
al, 2008 
Prostate 
cancer 
Effect of AC inhibition 
with LCL204 in DU 145 
cells 
Increased ceramide, decreased 
sphingosine, caspase activation and 
increased apoptosis with inhibition 
Degradation of AC by 
LCL204 was cathepsin-
dependent  
Gouazé-
Andersson 
et al, 2011 
Prostate 
cancer 
In vitro evaluation of 
AC inhibition in PC-3 
and DU 145 cell lines 
Synergistic cell toxicity with ceramide 
generation (fenretidine) and AC inhibition 
with DM102 (but not N-
oleoylethanolamine) 
Toxicity with 
fenretidine/DM102 
treatment persisted 
despite blocking 
ceramide generation 
Turner et 
al, 2011 
Prostate 
cancer  
In vitro evaluation of 
PPC1 and DU 145 cells 
over-expressing AC 
Increased lysosomal density, high 
expression of lysosomal stabilising protein 
KIF5B, increased levels of autophagy 
Possible mechanism of 
resistance to ceramide 
accumulation 
 
Table 1.11 – Summary of studies implicating AC in malignancy and response to treatment 
 
 
1.4.4.1 Head and neck cancer 
AC over-expression has been observed in squamous cell head and neck cancer (HNC) in four 
out of six primary tumours and six out of nine HNC cell lines in a study by Roh et al (2016) 
and was correlated with resistance to cisplatin chemotherapy in the cell lines.  
Pharmacological (with N-oleoyl-ethanolamine) and genetic (with small hairpin RNA) 
inhibition of AC in the cell lines significantly increased their sensitivity to cisplatin, with 
increased ceramide production and activation of pro-apoptotic proteins.  In another study of 
squamous cell cancer cells, the inhibition of AC with the small molecule inhibitor LCL521 
significantly reduced the survivability of SCCVII cells on the basis of clonogenic assay after 
photodynamic therapy (Korbelik et al, 2016), with AC activity inhibition and increases in 
ceramide levels also having been observed after photodynamic therapy in isolation 
(Separovic et al, 2013).  Over-expression of AC in the SCC-1 cancer cell line increased 
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resistance to Fas-induced apoptosis, with down-regulation inducing sensitivity.  The AC 
inhibitor LCL204 was also demonstrated in this study to sensitise HNC cell lines to Fas-
induced apoptosis in both in vitro and in a xenograft model in vivo (Elojeimy et al, 2007). 
 
1.4.4.2 Melanoma 
Melanocytes and proliferative melanoma cell lines have been demonstrated to over-express 
AC relative to other skin cells and non-melanoma skin cancer cells (Realini et al, 2016).  
Application of the AC inhibitor ARN14988 acted synergistically with 5-FU to increase 
cytotoxicity in the proliferative melanoma cell line in this study, with increased ceramide 
levels and reduced S1P levels noted.  This may have positive implications for 5-FU based CRT 
in rectal cancer.  In the context of the clinical management of metastatic melanoma, where 
dacarbazine is a chemotherapeutic option, targeting of AC may improve sensitivity to 
therapy.  This was demonstrated by over-expression and down-regulation of AC in human 
A375 melanoma cells in vitro conferring resistance and sensitivity respectively to dacarbazine 
(Bedia et al, 2011). 
 
1.4.4.3 Myeloid leukaemia 
A comprehensive experimental assessment of the role of AC in acute myeloid leukaemia 
(AML) was undertaken by Tan et al (2016).  Primary AML cells were observed to highly 
express AC, with AC over-expression increasing the expression of the anti-apoptotic Mcl-1, 
and reduced Mcl-1 expression observed with the synthetic AC inhibitor LCL204.  LCL204 
treatment significantly increased the overall survival of C57BL/6 mice engrafted with C1498 
leukaemia cells and significantly decreased disease burden in NSG mice engrafted with 
primary human AML cells, implicating AC as an independent therapeutic target.  IFN 
regulatory factor 8 (IRF8) is a key transcription factor for myeloid cell differentiation, with 
expression frequently lost in haematopoeitic cells in myeloid leukaemia.  Hu et al (2011) 
identified AC as a general transcription target of IRF8, with expression of IRF8 regulated by 
promoter DNA methylation.  In myeloid cells, restoration of IRF8 expression supressed AC 
and resulted in ceramide accumulation and increased sensitivity to FasL-induced apoptosis.  
In cells derived from IRF8-deficient mice AC was dramatically increased, with AC inhibition 
or the application of exogenous ceramide sensitising cells to FasL-induced apoptosis, 
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suggesting a mechanism for a pathway of resistance to Fas-mediated apoptosis and disease 
progression. 
 
1.4.4.4 Non-small cell lung cancer 
In non-small cell lung cancer cells with acquired resistance to the pro-apoptotic effect of 
choline kinase α (ChoKα) inhibitors, raised levels of AC have been demonstrated compared 
to non-resistant cells.  The anti-proliferative effect of ChoKα therapy is enhanced with the 
synergistic inhibition of AC in primary cell culture, suggesting a model for combination 
therapy (Ramírez de Molina et al, 2012). 
 
1.4.4.5 Breast cancer 
High genetic expression of ASAH1 has also been observed to correlate with a better 
prognosis in invasive breast cancer, and with a reduced incidence of recurrence in pre-
invasive DCIS (Sänger et al, 2015), although how this correlates with a functional post-
translational expression of AC is not identified.   
In three breast cancer cell lines, Flowers et al (2012) assessed the effect of AC inhibition (with 
DM102) on the apoptosis inducing effects of C6-ceramide.  As single agents, C6-ceramide 
and DM102 were only moderately cytotoxic but co-administration produced a reduction in 
viability in all cell lines.  This was considered to be synergistic in MDA-MB-231 and MCF-7 
cells but antagonistic in BT-474 cells.  Correlations of AC expression and sensitivity to C6-
ceramide/DM102 were independent of oestrogen receptor status or molecular subtypes but 
AC expression was related to HER2 status.  This potentially suggests a prognostic relevance 
of AC tumour expression and the sensitivity of certain breast cancer subtypes to ceramide-
targeted therapy and warrants further investigation. 
 
1.4.4.6 Ovarian cancer 
On IHC analysis on n=112 ovarian cancer tumour samples, low AC expression was correlated 
with a poorer cancer specific survival (Hanker et al, 2013), although this is contradictory to 
the centrally described outcomes of sphingolipid metabolism as discussed.  It may be that 
AC expression and function is not ubiquitous across all tumours, that its expression is 
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implicated in response to selected therapies, or that it is involved in alternative pathways in 
certain tumours, and further investigation in these cancers is required. 
 
1.4.4.7 Hepatoma 
AC is activated by the chemotherapeutic daunorubicin in human (HepG2) and mouse 
(Hepa1c17) hepatoma cell lines as well as in primary cells from murine liver tumours but not 
in cultured mouse hepatocytes.  Inhibition of AC by siRNA or pharmacological means 
sensitised the cell lines to daunorubicin-induced cell death, preceded by structural 
mitochondrial changes, stimulation of reactive oxygen species generation and cytochrome c 
and caspase-3 activation.  In vivo AC inhibition with siRNA also reduced growth in liver 
tumour xenografts of HepG2 cells and also enhanced daunorubicin therapy, offering a 
potential therapeutic target in the management of liver cancers (Morales et al, 2007). 
 
1.4.4.8 Prostate cancer 
The depth of literature implicating AC in tumour proliferation and resistance to treatment in 
greatest in relation to prostate cancer.  Importantly, the study from Mahdy et al (2009) has 
convincingly demonstrated that downregulation of the corresponding gene for AC with 
siRNA in a prostate cancer cell line confers radio-sensitivity.  This in vitro study in PPC-1 cells 
assessed radiation response by clonogenic and cytotoxic assays, demonstrating that up-
regulation of AC decreased sensitivity to radiation and created cross-resistance to 
chemotherapy, with the small molecule AC inhibitor LCL385 also sufficient to sensitize PPC-
1 cells to radiation.   
In addition, the cell line is observed to preferentially upregulate AC in response to irradiation, 
with over-expression of AC in clones that survived an irradiation course and that were further 
associated with increased radio-resistance and proliferation (Cheng et al, 2013).  This was 
validated with IHC analysis of human prostate cancer tissues where higher levels of AC were 
observed after radiotherapy failure than in irradiation-naïve cancer, intra-epithelial 
neoplasia or benign tissue.  In addition to AC inhibition in an animal xenograft model 
producing radio-sensitisation, it also prevented relapse. 
Higher IHC expression of AC in primary prostate cancers is associated with more advanced 
disease stage, and in a model derived from PC-3 prostate cancer cells, the highly 
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tumourigenic, metastatic and chemo-resistant PC-3/Mc clone expressed higher levels of AC 
than the non-metastatic PC-3/S clone, with stable knockdown of ASAH1 in PC-3/Mc cells 
resulting in an accumulation of ceramide, reduced clonogenic potential and inhibition of 
tumourigenesis and lung metastases (Camacho et al, 2013).  The DU 145 prostate cancer cell 
line has also been demonstrated to be sensitive to the effect of AC inhibition following 
treatment with LCL204, with raised ceramide and decreased sphingosine levels, caspase 
activation and ultimately apoptosis observed (Holman et al, 2008).  In this study, the 
degradation of AC by LCL204 was cathepsin-dependent. 
The PC-3 and DU 145 prostate cancer cell lines are considered to be hormone-refractory.  In 
a study by Gouazé-Andersson et al (2011), combination therapy in these cell lines with the 
ceramide-generating chemotherapeutic fenretinide and the synthetic AC inhibitor DM102 
significantly decreased cell viability in a synergistic manner, with single-agent treatment 
being only weakly cytotoxic.  An alternative known AC inhibitor N-oleoylethanolamine did 
not produce a synergistic effect with fenretinide in the cells and blocking ceramide 
generation (with either vitamin E or myriocin) did not prevent cytotoxicity from combined 
fenretinide/DM102 treatment, suggesting alternative metabolic pathways in this context. 
Turner et al (2011) demonstrated that the PPC1 and DU 145 prostate cancer cell lines over-
expressing AC relative to controls have increased lysosomal density, high expression of the 
lysosomal stabilising protein KIF5B and increased levels of autophagy, complimenting the 
enhanced stress-resistance inherent to the cells, and to potentially explain the ability of the 
prostate cancer cells to respond to ceramide accumulation following irradiation. 
 
 
1.4.5 Summary Statement and Further Research 
The above data support the findings of lower levels of AC in those rectal tumours responding 
to CRT, with differential expression from pre-CRT biopsies suggesting the potential for its 
evaluation as an up-front predictive biomarker of response.  Further evaluation in a larger 
patient cohort, and validation in vitro data is clearly required. 
Carmofur, in common to the widely used radio-sensitiser capecitabine, is an oral 5-FU 
analogue that has been used in the US and Japan in the adjuvant setting for colorectal cancer.  
In addition to its presumed primary mode of action as a TS inhibitor, it has also independently 
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been shown to potently inhibit AC in the human tumour derived cell lines SW403 (colorectal) 
and LNCaP (prostate), a property not shared by 5-FU or capecitabine (Realini et al, 2013).  In 
light of both this and the proteomic profiling data, further investigation is required to 
compare the radio-sensitisation of capecitabine (TS inhibition) and carmofur (TS and AC 
inhibition). 
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1.5 Predicting and Modifying Response to Chemoradiotherapy in Rectal Cancer 
 
 
It is clear from the literature that the current response to CRT in rectal cancer is poorly 
understood and that its efficacy needs to be improved.  AC has been identified as a potential 
novel biomarker and therapeutic target but needs further validation.  The aim of this thesis 
is therefore to attempt to provide this further validation with assessment in a wider clinical 
dataset, and by performing an in vitro evaluation of the effect of AC inhibition on radio-
sensitivity in a CRC cell line. 
 
 
1.5.1 Research Questions 
The specific questions to be answered by this thesis are therefore: 
• Does AC expression predict response to CRT in clinical rectal cancer samples in a 
larger patient cohort? 
• Does the inhibition of AC in a CRC derived cell line increase radio-sensitivity? 
• Does inhibition of AC increase radio-sensitivity when compared to standard 5-FU 
radio-sensitisation? 
 
1.5.2 Hypotheses 
These questions can be used to formulate a number of testable hypotheses to be 
investigated: 
• Differential expression of AC is present in rectal cancer and/or normal colon 
• Expression of AC in rectal cancer and/or normal colonic tissue can predict response 
to neoadjuvant CRT, and/or is a biomarker of response to treatment 
• Expression of AC can be inhibited by siRNA transfection in the HCT116 CRC cell line, 
subsequently inhibiting protein activity 
• AC activity +/- expression can be inhibited by the chemotherapeutic carmofur in the 
HCT116 CRC cell line 
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• HCT116 cell radio-sensitivity can be increased by the pharmacological inhibition of 
AC activity using the chemotherapeutic carmofur 
• HCT116 cell radio-sensitivity can be increased by the genetic suppression of AC 
expression (and subsequent activity) using siRNA transfection 
• Any increase in cell radio-sensitivity based on inhibition of AC is independent of the  
presence of 5-FU 
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Chapter 2 
 
Validation of Acid Ceramidase as a Potential Predictive and/or 
Prognostic Biomarker of Response to Chemoradiotherapy in Rectal 
Cancer 
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2.1 Introduction 
 
 
2.1.1 Background 
 
In the late 1990s, TMA technology revolutionised the investigation of potential prognostic 
and predictive biomarkers (Kallioniemi et al, 2001).  A TMA involves the transfer of small 
tissue cores, typically 0.6 mm in diameter, from FFPE tissues into an empty paraffin block, 
and this repeated transfer of tissue cores leads to the construction of a “tissue-archive” that 
can contain hundreds of tissue samples.  TMAs can be used to study tissue morphology, 
expression of proteins or genes and chromosomal aberrations using different stains, IHC and 
in-situ hybridization (Voduc et al, 2008).  The combination of TMAs and clinically annotated 
samples represents an elegant and cost-effective approach to study panels of biomarkers 
under identical experimental conditions and to develop prognostic or predictive models of 
patient outcomes (Horvath et al, 2001). 
It was considered that the optimal strategy for investigation of AC expression on TMA, would 
include assessment of normal colon and cancer site samples, at both the point of diagnosis 
prior to CRT and from the resection specimen after treatment.  This would mimic the tissue 
dataset obtained from the original proteomic profiling as closely as possible in terms of 
providing a temporal assessment of AC expression with treatment, as well as obtaining 
information from normal colon in addition as a comparison.  Assessment of tissue from a 
diagnostic biopsy would provide information regarding the potential of AC as a predictive 
biomarker of response to CRT.  Comparing normal and malignant tissue both before and after 
treatment may also yield prognostic information, or demonstrate where further studies 
would be needed to evaluate a potential mechanism of action.  
Given that this proposed TMA study was to be performed retrospectively, it was not possible 
to determine the tissue collected, as it would be reliant on retrieving archived FFPE tissue 
blocks.  The diagnostic biopsy specimens were considered to potentially harbour some 
normal colonic tissue within, although this was not considered to be a reliable source, as the 
endoscopic target biopsied is overwhelmingly likely to have been macroscopically abnormal.  
Even if normal tissue were to have been present, it was considered highly unlikely to be 
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present in sufficient volume to have technically been viable to be used to construct a 
meaningful TMA.  The best hope for normal tissue was therefore considered to originate 
from the resection specimen, albeit with limitations. 
 
 
2.1.2 Hypotheses 
 
• Differential expression of AC is present in rectal cancer, and/or normal colon 
• Expression of AC in rectal cancer and/or normal colonic tissue can predict response 
to neoadjuvant CRT, and/or is a biomarker of response to treatment 
 
 
2.1.3 Aims and Study Design 
 
• Identification of ≥100 rectal cancer cases whereby surgical resection of the primary 
tumour had been performed following completion of neoadjuvant CRT 
• Assessment of TRG in these cases 
• TMA construction comprising 
o Tissue from the diagnostic biopsy specimen 
o Normal epithelium from the resection specimen 
o Cancer site tissue from the resection specimen 
• Optimisation of IHC staining of TMAs for AC 
• Assessment of TMA IHC staining for AC and correlation with TRG 
• Correlation of clinical and pathological data with IHC staining and TRG 
 
 
 
 
 
69 
 
2.2 Methods 
 
 
2.2.1 Ethical Approval 
 
The study was performed under existing NHS Research Ethics Committee and Research and 
Development approval (12/NW/0011).  111 consecutive patients were identified from 
histopathological records at The Countess of Chester Hospital NHS Foundation Trust to have 
undergone surgical resection of a primary rectal cancer at the hospital between January 2007 
and July 2015, and having prior completed a course of neoadjuvant CRT.  In six of the 
identified cases, the diagnostic biopsy specimen had been obtained and was located at Mid 
Cheshire Hospitals NHS Foundation Trust.  A materials transfer agreement was sought and 
agreed to facilitate acquisition of these samples. 
 
 
2.2.2 Assessment of Tumour Regression Grading 
 
H&E stained slides for the identified cases were reviewed by consultant histopathologist (Dr 
Michael Wall (MW), FRCPath) to confirm the diagnosis of adenocarcinoma, and slides from 
the resection specimen were assessed to allocate a TRG.  The four-tier system recommended 
by The Royal College of Pathologists, and like that described by Ryan et al (2005) was used 
(https://www.rcpath.org/resourceLibrary/dataset-for-colorectal-cancer-histopathology-
reports--3rd-edition-.html). 
• TRG 4: no viable tumour cells (fibrosis or mucus lakes only) 
• TRG 3: single cells or scattered small groups of cancer cells 
• TRG 2: residual cancer outgrown by fibrosis 
• TRG 1: minimal or no regression (extensive residual tumour) 
The practicable application of this system was considered to comprise; a) complete 
responders (TRG 4) vs. others, b) relative responders (TRG 4&3) vs relative non-responders 
(TRG 2&1), and c) non-responders (TRG 1) vs. others.  This is in accordance with the 
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correlation of complete response and near-complete response with outcome, as described 
by Hermanek et al (2013). 
 
 
2.2.3 Tissue Microarray Construction 
 
Three sets of TMAs were constructed comprising; a) malignant tissue from the diagnostic 
biopsy specimen (n=106), b) ‘normal’ colonic epithelium obtained from the colonic end of 
the resection specimen outside the radiation field (n=111), and c) tissue from the cancer site, 
specifically targeting residual malignant cells where present, or areas of fibrosis consistent 
with radiotherapy exposure in those with a pCR (n=111).  The technique for TMA 
construction was as described by Kononen et al (1998).  H&E slides were reviewed by a 
consultant histopathologist (MW) and the best representative slide for each tissue group was 
marked (circled) by permanent marker to identify the area to target for obtaining donor 
cores.  The corresponding FFPE tissue blocks were retrieved from storage.  A visual 
comparison between the marked slides and donor blocks was made by overlying the marked 
slide on the tissue block, and the targeted area was subsequently marked on the donor block. 
TMAs were constructed using a tissue microarrayer (Beecher Instruments Inc., Wisconsin, 
USA), with 0.6mm cores retrieved from donor blocks, and transferred into the recipient 
master paraffin blocks.   Triplicate cores were randomised across three TMAs for each tissue 
type, with cores of kidney, lung, ovary, and thyroid tissue equally randomised into each TMA 
as controls.  Randomisation was performed using the sequence generator facility available 
at https://www.random.org/sequences/.  TMAs were incubated at 37°C overnight, then 
placed on ice prior to 5µm sections being cut on a rocking microtome.  Sections were then 
placed onto coated glass slides, which were further incubated at 37°C prior to performing 
IHC staining. 
H&E staining was undertaken with the initial TMA sections, which were examined to assess 
for adequate tissue coverage.  In cases where at least one representative core of the targeted 
tissue wasn’t observed, further TMAs were constructed to attempt to encompass as many 
of the cases as possible.  This resulted in a further two TMAs being constructed for the normal 
colon blocks – triplicate cores from 29 cases randomised into one block, with further 
triplicate cores randomised into a subsequent block for 8 cases where the targeted tissue 
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had still not been represented.  A single additional TMA was constructed for 42 of the cancer 
site blocks, where a single 2mm core from each donor block was randomised into the further 
recipient block, to allow for a slightly wider margin of error with these blocks to achieve the 
specifically targeted tissue.  There was insufficient tissue in the diagnostic biopsy specimen 
blocks to consider it worthwhile attempting to obtain further cores if the initial cores had 
not yielded adequate tissue on sectioning.  A subsequent TMA was constructed comprising 
the diagnostic biopsy blocks (n=6) that originated from Mid Cheshire Hospitals NHS 
Foundation Trust (Crewe), as these were acquired later.  The tissue blocks for n=5 diagnostic 
biopsy samples were unable to be located. 
The key for the respective TMAs is detailed in table 2.1 below. 
 
Tissue 
Microarray 
Tissue 
Type 
Description 
A 
Diagnostic 
Biopsy 
Single core from all diagnostic biopsy blocks retrieved from 
Chester n=100 
B As A 
C As A & B 
D 
Triplicate cores from diagnostic biopsy blocks retrieved from 
Crewe n=6 
E 
Cancer 
Site 
Single core from all cancer site blocks n=111 
F As E 
G As E & F 
H 
Single 2mm core from cancer site blocks not adequately 
represented on initial H&E examination of E, F & G n=42 
I 
Normal 
Colon 
Single core from all normal colon blocks n=111 
J As I 
K As I & J 
L 
Triplicate cores from normal colon blocks not adequately 
represented on initial H&E examination of I, J & K n=29 
M 
Triplicate cores from normal colon blocks not adequately 
represented on initial H&E examination of L (or I, J & K) n=8 
Table 2.1 – A description of the tissue cores incorporated into the constructed TMAs. 
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2.2.4 Immunohistochemical Staining 
 
Sections were de-waxed and antigen retrieval performed using the PT Link (Dako UK Ltd, Ely, 
UK), with slides placed in EnVisionTM FLEX target retrieval solution pH 9 (K8004, Dako) diluted 
to the manufacturer’s instruction and at 65°C, heated to 96°C for 20 minutes, then returning 
to 65°C prior to the slides being washed in EnVisionTM FLEX wash buffer (K8007, Dako) diluted 
to the manufacturer’s specification for 10 minutes.  The tissues sections were ringed at the 
edge of the slides with a hydrophobic pen to prevent stain run-off.  After blocking for 5 
minutes at room temperature with 100µL EnVisionTM FLEX peroxidase blocking reagent 
(S2023, Dako), further washing was performed prior to application of 100µL of the primary 
antibody at the required concentration in EnVisionTM FLEX antibody diluent (K8006, Dako).  
Negative controls consisted of antibody diluent only and a mouse IgG1 isotype control 
(ab91353, Abcam, Cambridge, UK) to assess for background staining.  The primary antibody 
was incubated at room temperature for 30 minutes, before being washed, and the slides 
then further incubated with 100µL of an appropriate linker (mouse or rabbit, K8002 and 
K8009 respectively, Dako) for 15 minutes at room temperature.   
The slides were then washed again prior to use of the EnVision detection system (K4065, 
Dako) incorporating incubation with 100µL horseradish-peroxidase (HRP) conjugated 
secondary antibody solution (against rabbit and mouse immunoglobulins) applied for 20 
minutes at room temperature, before being developed with fresh diaminobenzidine 
tetrahydrochloride (DAB) solution (made according to manufacturer’s instruction) which was 
again incubated for 20 minutes at room temperature. 
Further washing was performed, before the slides were dipped in distilled water prior to 
counter-staining with haematoxylin for 1 minute.  Excess haematoxylin was removed in a 
running water bath until clear, the slides were then dipped momentarily in acid alcohol 
before being dipped in ammonia water for 30 seconds.  The slides were placed back in a 
running water bath for one minute, before being dehydrated through an ethanol series in a 
fume hood.  This involved vigorous agitation for 10 seconds in x5 industrial methylated spirits 
and x2 xylene baths.  A coverslip was then applied to each slide using DPX mountant (Sigma-
Aldrich, Dorset, UK). 
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2.2.5 Acid Ceramidase Antibody Optimisation for Immunohistochemistry 
 
Antibody optimisation for IHC analysis of AC was undertaken subsequent to initial attempts 
to optimise a primary antibody for use in Western blotting, as described in chapter 3.  A 
different primary antibody to those used in Western blotting was demonstrated to identify 
AC on IHC on Protein Atlas (www.proteinatlas.org) – a rabbit polyclonal anti-ASAH1 antibody 
(HPA005468, Sigma-Aldrich).  Given the initial difficulties in achieving antibody specificity for 
Western blotting, it was considered appropriate that this antibody should be attempted to 
be optimised for IHC, alongside the others used in Western blotting, to provide verification 
of antibody specificity for the IHC work, and in attempt to provide cross validation between 
IHC and Western blotting.  The anti-ASAH1 antibodies already assessed in Western blotting 
were a rabbit monoclonal (ab174828, Abcam), a rabbit polyclonal (ab74469, Abcam), and a 
mouse monoclonal (BD612302, BD Transduction Laboratories). 
Protein Atlas identified kidney and lung as positive control tissues for AC expression, 
therefore these were sourced from The Liverpool Tissue Bank and sections cut.  Each 
antibody was assessed at the upper and lower concentrations as recommended by 
manufacturer datasheets – 1/50 and 1/100 for ab174828, 1/400 and 1/1000 for ab74469, 
and 1/200 and 1/500 for HPA005468.  Whilst BD612302 had only a recommendation for its 
use in Western blotting from the manufacturer’s datasheet, it had been the only antibody 
observed to demonstrate specificity for AC on Western blotting, therefore was assessed for 
use in IHC.  Extrapolating data observed with all antibodies on Western blotting, this mouse 
monoclonal antibody was initially assessed for IHC at concentrations of 1/100 and 1/250.  
IHC staining of the tissue sections was performed, incorporating negative control reactions 
using antibody diluent only and a mouse IgG1 isotype control, as described in section 2.2.4. 
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Figure 2.1 – Light microscope images of kidney sections stained for AC on IHC to facilitate antibody 
selection and optimisation.  Images taken at x400 magnification.  The brown staining in the images 
represents antibody binding and oxidation of DAB by HRP.  The four images demonstrate the 
optimal results for the four anti-ASAH1 antibodies initially assessed; A) HPA005468 (Sigma-Aldrich) 
at 1/500, B) BD612302 (BD Transduction Laboratories) at 1/250, C) ab174828 (Abcam) at 1/100, and 
D) ab74469 (Abcam) at 1/1000. 
 
Stained slides were reviewed by a consultant histopathologist (MW), where non-specific 
binding, as well as binding to a structural component of the cell wall was observed with 
ab174828 and ab74469, as can be seen in images C and D in figure 2.1.  Appropriate granular 
cytosolic staining of the renal epithelium was observed with both HPA005468 and BD612302, 
which also matched the staining pattern represented on Protein Atlas.  The staining pattern 
was equivalent to that observed in kidney across the four antibodies in the lung sections.  
ab174828 and ab74469 were therefore considered inappropriate to pursue for further 
optimisation due to their inappropriate and non-specific binding. 
Further optimisation was subsequently performed with HPA005468 and BD612302 on 
normal colon and malignant rectal cancer tissue sections, to determine the optimal 
conditions with which to perform IHC staining of the TMAs.  These optimisation slides and 
corresponding positive and negative controls were again reviewed by a consultant 
histopathologist (MW), who confirmed the appropriateness of the staining and advised that 
the optimum antibody to be used was BD612302 at a concentration of 1/500, and without 
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the use of a mouse linker.  Images of the pertinent slides assessed in this process are 
demonstrated in figure 2.2 below. 
 
 
Figure 2.2 – Images of sections taken from kidney, normal colon, and rectal cancer (post-CRT) 
specimens, for AC antibody optimisation.  The sections in the left column have been stained for AC 
using BD612302 mouse monoclonal antibody at a concentration of 1/500, with corresponding 
sections in the right column stained as a negative control.  Images taken at x200 magnification, with 
the bar in each image representing 100μm.  
 
Upon determination of the optimal IHC conditions for AC staining with BD612302, sections 
of the TMAs were cut and stained using the previously described methodology.  All TMAs 
assessed for AC expression were stained simultaneously, alongside their respective negative 
controls.  This staining was undertaken using the Dako Autostainer (Dako, Colorado, USA) to 
facilitate optimal control over the application and timing of reagent incubation on the slides. 
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2.2.6 Immunohistochemical Staining Analysis 
 
Stained sections of the TMAs were assessed under light microscopy and semi-quantitative 
analysis for each tissue core using a simplified H-score (Allred) undertaken.  The system 
applies a score to the percentage of positive staining cells (0-5) added to a score for the 
intensity of that positivity (0-3), giving a total score of 0, 2, 3, 4, 5, 6, 7 or 8 (Mohsin et al, 
2004).  The breakdown of scoring for the percentage of positive staining cells is defined as 
0% = 0, <1% = 1, 1-10% = 2, 10-33% = 3, 33-66% = 4, and >66% = 5, with the intensity score 
defined as none = 0, weak = 1, intermediate = 2, strong = 3. 
The images in figure 2.3 below demonstrate differential staining for AC and are depicted to 
demonstrate the H-score as was applied at each end of the scale. 
 
    
Figure 2.3 – Images of individual cores from one TMA section originating from diagnostic biopsy 
specimens, taken under light microscopy at x200 magnification – the sections had undergone IHC 
staining for AC using BD612302 primary antibody at a concentration of 1/500.  Differential epithelial 
staining is observed between the two images.  ‘Background’ staining can also be observed at a 
comparable intensity and distribution in non-epithelial cells in both images, representing uptake by 
plasma cells and macrophages and potential stromal cells.  Strong staining in the vast majority of 
epithelial cells in the left-hand image (H score = 5 + 3 = 8) is observed in a case where a poor 
response to CRT was assigned to the resection specimen (TRG 1).  The right-hand image 
demonstrates no epithelial staining (H score = 0 + 0 = 0) in a case where a subsequent pCR was 
observed (TRG 4). 
 
An epithelial score and a stromal score was assigned individually for each tissue type where 
both tissue subsets were present.  The scores for each tissue subset and type (i.e. epithelium 
and stroma in diagnostic biopsy, normal colon, and cancer site) were dichotomised about 
the median score for that group to determine relatively high versus relatively low expression 
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of AC for the purposes of statistical analysis.  Scoring was undertaken by consultant 
histopathologist (MW) and I individually, with differences resolved by consensus in order to 
reduce intra-observer error. 
 
 
2.2.7 Clinical and Pathological Data 
 
The TMAs were complimented by the collection of a clinical dataset, in order to glean 
prognostic information that could be analysed against the IHC findings.  Data was gathered 
from computerised patient records at The Countess of Chester NHS Foundation Trust.  
Information regarding gender, age, radiological staging (pre- and post-neoadjuvant 
treatment), tumour site (low, mid or high rectum), operation undertaken and timing, 
histopathological findings (ypTNM staging, EMVI, CRM positivity, KRAS status), adjuvant 
treatment, and stoma rates were collected, as were follow up data to investigate overall- 
and disease-free survival.   
 
 
2.2.8 Statistical Analysis 
 
Statistical analysis was undertaken using SPSS® Statistics version 22 (IBM®, New York, USA).  
Interpretation of the IHC staining of the TMAs was performed by dichotomising the scores 
for each tissue group about the median value to distinguish between relatively low and 
relatively high expression.  This categorical data was analysed against TRG groupings using 
the Pearson chi-square test.  Correlation of AC expression with the incidence of locally 
recurrent and metastatic disease, was performed using Fisher’s exact test as the expected 
counts were lower.  Kaplan-Meier analysis was used to correlate TRG with survival. 
 
 
 
78 
 
2.3 Results 
 
The median age at diagnosis for the patients in the study was 66 (33-86).  There were 82 
males (74%) and 29 females (26%).  The clinical and pathological data pertaining to these 
patients is demonstrated in appendix B. 
 
2.3.1 Assessment of Tumour Regression Grading 
 
 
Figure 2.4 – Pie chart demonstrating the groupings of the cases identified, according to the four tier 
(Ryan) TRG system as recommended by The Royal College of Pathologists. 
 
22/111 (19.9%) of the assessed cases were grouped as TRG 4 (no viable tumour cells, fibrosis 
or mucus lakes only), and therefore were considered to have achieved a pCR.  When 
combined with the 15 cases (13.5%) that were assessed as TRG 3 (single cells or scattered 
small groups of cancer cells), 37/111 (33.3%) of cases overall are considered to represent 
relative responders (TRG 4&3) to neoadjuvant CRT.  The greatest number of cases (55/111, 
representing 49.5%) were assigned as TRG 2 (residual cancer outgrown by fibrosis), with the 
remaining 19/111 (17.1%) of cases demonstrating TRG 1 (minimal or no regression, extensive 
residual tumour). 
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2.3.2 Diagnostic Biopsy Tissue Microarrays 
 
 
Figure 2.5 – Pie chart demonstrating the number of tissue cores originating from the diagnostic 
biopsy specimens considered as adequate and scored for AC expression, subsequent to TMA 
construction, sectioning and IHC staining. 
 
As demonstrated in figure 2.5 106/111 (95.5%) of the tissue blocks for the diagnostic biopsy 
specimens for the identified cases were retrieved from archived storage and incorporated 
into the TMAs.  Four of the tissue blocks were located in other hospitals, from  where it was 
not possible to retreive them in a timely manner, and the last tissue block was not present 
in its designated location in storage, and was unable to be found. 
Subsequent to TMA construction, sectioning and IHC staining, 86 of the 106 cases (81.1%) 
demonstrated at least one adequate tissue core that was assessed for AC expression in both 
epithelium and stroma.  Only 11 cases (10.4%) yielded all three cores that were considered 
adequate for staining assessment, and a total number of 149/318 (46.9%) of the originally 
transferred cores from the diagnostic biopsy specimens were represented in the final 
analysis. 
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Figure 2.6 - Images of three sections from TMA A (representing cores from diagnostic biopsy 
specimens) having been stained for H&E, AC (using BD 612302 at a concentration of 1/500), and 
with mouse IgG as a negative control. 
 
The whole slide sections of TMA A depicted in figure 2.6 are indicative of the coverage 
achieved with cores from the diagnostic biopsy specimens, both within and between 
sections, having been stained as described in section 2.2.4.  The H&E slide was stained and 
assessed individually initially to ascertain coverage.  Variablility in the brown DAB staining 
for AC expression can be observed, compared with an absence of staining with the mouse 
IgG negative control across the whole slide. 
 
 
81 
 
 
Figure 2.7 - Images of selected diagnostic biopsy TMA cores.  The cores were both observed from 
one section of TMA A, having been stained for AC (A&C), with the corresponding cores (B&D) from 
another section exposed to a mouse IgG isotype as a negative control.  The rectangular bar in each 
image represents 50µm. 
 
The core marked A in figure 2.7 demonstrates higher epithelial (H-score = 5+3 = 8) and 
stromal (H-score = 5+2 = 7) expression of AC, in a case where a minimal response to CRT (TRG 
2) was assigned to the resection specimen.  Lower epithelial (H-score = 1+1 = 2) and stromal 
expression (H-score = 0+0 = 0) of AC is demonstrated in the core marked C, in a case where 
a subsequent pCR (TRG 4) was observed.  No inappropriate staining is observed in the 
negative control cores, and the intensity of the background H&E staining is comparable 
across the cores. 
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Table 2.2 – H scores observed upon assessment of epithelial AC expression in diagnostic biopsy 
tissue.  The crude H score is presented for each tissue core adequately present on TMAs A, B, C & D, 
in association with the calculated mean H score for each patient. 
Patient A B C Mean Patient A B C Mean
1 5 6 4 5.0 57 6 6.0
2 8 7 7.5 58 4 4.0
3 5 5.0 59 8 7 7.5
4 0 0.0 60 3 7 5.0
5 7 7.0 61 4 6 5.0
6 3 0 1.5 62 7 7.0
7 63 7 0 3.5
8 64 0 7 3.5
9 65 6 6.0
10 2 3 2.5 66 0 0.0
11 0 0 0.0 67 5 5 5 5.0
12 6 7 6.5 68 7 2 4.5
13 69 2 6 4.0
14 70 4 6 5.0
15 0 0.0 71 0 4 2.0
16 72 6 6.0
17 0 0 0.0 73 8 8 8.0
18 74 0 0.0
19 75 0 0.0
20 76 5 5 5.0
21 8 8.0 77
22 2 4 3.0 78 5 5 5 5.0
23 0 0.0 79 0 0.0
24 80
25 0 0.0 81 7 7.0
26 82
27 0 0.0 83 4 4.0
28 8 7 8 7.7 84 7 6 6.5
29 0 5 6 3.7 85 4 4.0
30 7 4 5.5 86 4 4.0
31 7 7.0 87 2 3 0 1.7
32 88
33 0 4 2.0 89
34 0 7 3.5 90 8 8 8.0
35 3 3.0 91
36 4 5 4.5 92
37 7 7.0 93 4 3 3.5
38 94 8 6 7.0
39 2 7 4.5 95 7 7.0
40 7 6 6.5 96 3 6 4.5
41 7 7.0 97 4 4.0
42 8 5 7 6.7 98 7 4 5.5
43 3 3 3 3.0 99
44 100
45 7 4 5.5 101 6 4 5.0
46 3 7 5.0 102 7 0 3.5
47 7 7.0 103
48 7 7.0 104 8 7 7.5
49 7 6 6.5 105 5 5.0
50 2 3 4 3.0 106 6 6 7 6.3
51 4 7 5.5 107 7 7.0
52 3 0 1.5 108 0 5 2.5
53 0 0.0 109 5 5.0
54 0 4 7 3.7 110 5 5.0
55 111 3 3 3.0
56 0 2 1.0
Diagnostic Biopsy TMAs - Epithelial Acid Ceramidase Immunohistochemical Scoring
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Table 2.3 – H scores observed upon assessment of stromal AC expression in diagnostic biopsy tissue.  
The crude H score is presented for each tissue core adequately present on TMAs A, B, C & D, in 
association with the calculated mean H score for each patient. 
Patient A B C Mean Patient A B C Mean
1 3 3 0 2.0 57 8 8.0
2 4 4.0 58 4 4.0
3 5 5.0 59 7 7.0
4 3 3.0 60 4 6 5.0
5 2 2.0 61 7 7 7.0
6 2 2.0 62 2 2.0
7 63 5 5.0
8 64 4 6 5.0
9 65 5 5.0
10 0 5 2.5 66 0 0.0
11 5 2 3.5 67 5 6 5.5
12 6 7 6.5 68 5 6 5.5
13 69 7 6 6.5
14 70 6 5 5.5
15 0 0.0 71 5 4 4.5
16 72 4 4.0
17 2 2 2.0 73 7 7 7.0
18 74 5 5.0
19 75 4 4.0
20 76 5 6 5.5
21 3 3.0 77
22 7 7 7.0 78 4 7 4 5.0
23 0 0.0 79 5 5.0
24 80
25 3 3.0 81 2 2.0
26 82
27 7 7.0 83 0 0.0
28 7 5 7 6.3 84 6 6 6.0
29 5 6 6 5.7 85 5 5.0
30 6 4 5.0 86 0 0.0
31 7 7.0 87 0 4 6 3.3
32 88
33 0 6 3.0 89
34 5 8 6.5 90 0 7 3.5
35 0 0.0 91
36 6 6 6.0 92
37 6 6.0 93 7 6 6.5
38 94 7 6 6.5
39 3 3.0 95 4 4.0
40 5 5 5.0 96 7 7 7.0
41 7 7.0 97 5 5.0
42 8 6 7 7.0 98 7 7 7.0
43 5 4 0 3.0 99
44 100
45 5 5 5.0 101 8 7 7.5
46 2 5 3.5 102 7 6 6.5
47 4 4.0 103
48 7 7.0 104 8 7 7.5
49 7 2 4.5 105 6 6.0
50 4 7 0 3.7 106 2 6 2 3.3
51 5 7 6.0 107 8 8.0
52 4 4 4.0 108 2 3 2.5
53 6 6.0 109 5 5.0
54 4 6 2 4.0 110 7 7.0
55 111 4 5 4.5
56 4 7 5.5
D D
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The median H-score for AC staining in diagnostic biopsy epithelium was 5.0.  There were no 
statistically significant correlations between a relatively high or low AC expression with either 
a pCR, a relative response or a poor response to neoadjuvant CRT (p=0.695, p=0.699, and 
p=0.375 respectively). 
The median H-score for AC staining in stromal cells in diagnostic biopsy specimens was also 
5.0, and there were again no statistically significant correlations between AC expression with 
TRG by groupings (p=0.472 and p=0.764 for pCR and relative response respectively).  Eleven 
of the nineteen patients categorised as having a poor response to neoadjuvant CRT (TRG 1) 
had tissue represented on analysis of the diagnostic biopsy TMAs - 9/11 of these cases 
demonstrated a relatively high stromal AC expression but this did not quite reach statistical 
significance (p=0.075). 
There were no statistically significant correlations between AC expression in either epithelial 
or stromal tissue from the diagnostic biopsy and the risk of recurrent disease, metastatic 
disease or overall survival. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
85 
 
2.3.3 Cancer Site Tissue Microarrays 
 
 
Figure 2.8 – Pie chart demonstrating the number of tissue cores originating from the cancer site 
specimens considered as adequate and scored for AC expression, subsequent to TMA construction, 
sectioning and IHC staining. 
 
An appropriate tissue block representing the cancer site was retrieved for all 111/111 of the 
identified cases (100%), as demonstrated in figure 2.8.  After TMA construction, sectioning 
and IHC staining, 105 of these cases (94.6%) produced at least one core that was considered 
adequate to assess for AC staining in the stroma.  207/333 (62.2%) of the originally 
transferred cores were represented in the final analysis.  22 of the resection specimens had 
been observed to demonstrate a pCR, and therefore were devoid of malignant epithelium – 
68 of the 89 potential cases (76.4%) where malignant cancer site epithelium was possible to 
have been demonstrated in the finally sectioned TMAs, were considered to have yielded at 
least one adequate core that was analysed. 
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Figure 2.9 - Images of three sections from TMA E (representing cores from the cancer site from 
resection specimens) having been stained for H&E, AC (using BD 612302 at a concentration of 
1/500), and with mouse IgG as a negative control. 
  
The whole slide sections of TMA E depicted in figure 2.9 are indicative of the coverage 
achieved with the cancer site cores from the resection specimens, both within and between 
sections, having been stained as described in section 2.2.4.  The H&E slide was stained and 
assessed individually initially to ascertain coverage.  Variablility in the brown DAB staining 
for AC expression can be observed, compared with an absence of staining with the mouse 
IgG negative control across the whole slide. 
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Figure 2.10 - Images of selected cancer site TMA cores from the resection specimens.  The cores 
were both observed from the same section of TMA E, having been stained for AC (A&C), with the 
corresponding cores (B&D) from another section exposed to a mouse IgG isotype as a negative 
control.  The rectangular bar in each image represents 50µm.  
 
The core marked A in figure 2.10 demonstrates higher epithelial (H-score = 5+3 = 8) and 
stromal (H-score = 5+2 = 7) expression of AC, in a case where a poor response to CRT (TRG 
1) was observed.  Lower epithelial (H-score = 0+0 = 0) but higher stromal expression (H-score 
= 3+2 = 5) of AC is demonstrated in the core marked C in a case with a minimal response to 
CRT (TRG 2).  No inappropriate staining is observed in the negative control cores, and the 
intensity of the background H&E staining is comparable across the cores. 
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Table 2.4 - H scores observed upon assessment of epithelial AC expression in post-CRT cancer site 
tissue.  The crude H score is presented for each tissue core adequately present on TMAs E, F, G & H, 
in association with the calculated mean H score for each patient. 
Patient E F G H Mean Patient E F G H Mean
1 8 8.0 57 4 5 4.5
2 58
3 59 6 4 5.0
4 6 6 6.0 60
5 5 5.0 61 5 5.0
6 62
7 5 0 2.5 63 5 6 5.5
8 7 7.0 64 7 7.0
9 8 4 6.0 65 6 6 6.0
10 66 4 0 2.0
11 7 2 4.5 67 7 7.0
12 68
13 69 0 0 0.0
14 70 4 3 3.5
15 6 6.0 71
16 5 6 5.5 72
17 8 0 6 4.7 73
18 5 5.0 74
19 4 4.0 75 5 5.0
20 5 4 4.5 76 5 3 4.0
21 77 4 0 4 2.7
22 5 5.0 78 6 6.0
23 5 0 2.5 79 7 8 6 7.0
24 80
25 6 5 6 5.7 81
26 82 6 6.0
27 7 8 7.5 83
28 84 5 4 4.5
29 2 6 4.0 85
30 86
31 7 7.0 87
32 7 7.0 88 8 7 7.5
33 89 7 6 6.5
34 90
35 91 7 8 7 7.3
36 92 5 6 5.5
37 93 0 0.0
38 6 6.0 94 8 7 7.5
39 5 7 7 6.3 95 5 7 6 6.0
40 96 5 6 6 5.7
41 7 8 7.5 97 4 4.0
42 98
43 99 6 2 4.0
44 6 6 6.0 100 4 6 5.0
45 101 6 4 5 5.0
46 0 2 1.0 102 4 5 4.5
47 7 7.0 103
48 6 7 6.5 104 6 6.0
49 3 3.0 105 6 7 6.5
50 106 0 2 1.0
51 0 3 0 1.0 107 7 6 6.5
52 5 7 6.0 108
53 109 0 0.0
54 8 8.0 110 5 5.0
55 0 0 3 1.0 111 3 3 3.0
56 0 3 1.5
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89 
 
 
Table 2.5 – H scores observed upon assessment of stromal AC expression in post-CRT cancer site 
tissue.  The crude H score is presented for each tissue core adequately present on TMAs E, F, G & H, 
in association with the calculated mean H score for each patient. 
Patient E F G H Mean Patient E F G H Mean
1 6 3 4.5 57 5 6 5.5
2 2 0 5 2.3 58 0 0.0
3 7 0 3.5 59 5 5 5.0
4 2 5 3.5 60 2 2.0
5 4 5 6 5.0 61 2 6 4.0
6 0 0.0 62
7 4 5 4.5 63 4 6 5.0
8 6 6 5 5.7 64 7 7 7.0
9 2 4 0 0 1.5 65 6 5 5.5
10 0 4 2.0 66 6 5 5.5
11 3 6 4.5 67 5 5.0
12 68 4 4.0
13 6 6.0 69 4 7 5.5
14 5 5.0 70 6 6 6.0
15 4 4.0 71 4 0 2.0
16 2 0 1.0 72 5 2 3.5
17 7 2 2 3.7 73
18 3 2 2 2.3 74 3 3.0
19 0 0.0 75 4 4.0
20 2 3 2.5 76 4 0 2.0
21 5 5.0 77 6 3 3 4.0
22 3 3 3.0 78 2 7 4.5
23 7 7 7.0 79 4 4 4.0
24 4 4 4.0 80 4 0 4 2.7
25 7 3 7 5.7 81 3 4 3.5
26 3 3.0 82 2 2.0
27 4 7 7 6.0 83 7 6 6.5
28 2 3 2.5 84 8 5 6.5
29 2 5 3.5 85 0 2 1.0
30 5 5.0 86 4 4.0
31 4 0 2.0 87 3 3.0
32 4 5 4.5 88 7 2 4.5
33 2 2.0 89 6 6.0
34 90
35 2 3 2.5 91 5 2 6 4.3
36 3 3.0 92 6 6.0
37 0 0.0 93 6 6.0
38 6 2 4.0 94 7 7 7.0
39 4 2 5 6 4.3 95 3 3 8 4.7
40 4 5 4.5 96 6 3 6 5.0
41 5 6 6 5.7 97 2 2.0
42 6 7 0 7 5.0 98 4 4.0
43 2 2 2.0 99 4 3 5 4.0
44 3 3.0 100 6 6 6.0
45 3 0 1.5 101 3 4 3.5
46 2 2 4 2.7 102 5 4 4.5
47 5 4 6 5.0 103 7 3 5.0
48 3 5 4.0 104 6 6 7 6.3
49 5 5.0 105 4 4 4.0
50 6 6.0 106 4 8 6.0
51 6 5 5.5 107 6 4 5.0
52 3 0 2 1.7 108 8 8.0
53 109 0 0.0
54 0 0.0 110 5 3 4.0
55 7 3 7 5.7 111 2 2 2.0
56 6 2 4.0
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The median H-score for AC expression in malignant epithelium at the cancer site was 5.5.  
There was no statistically significant correlation between AC expression with either a relative 
response or a poor response to neoadjuvant CRT (p=0.506 and p=0.487 respectively). 
The median H-score for AC expression in stromal cells at the cancer site was 4.0.  18/22 of 
the patients where a pCR was observed had a relatively low stromal expression of AC 
(p=0.003).  A relatively low stromal expression was also statistically significantly correlated 
with relative responders (TRG 4&3) to neoadjuvant CRT (p=0.048).  Conversely 13/18 of the 
assessed tissue samples where a poor response to treatment had been observed (TRG 1), 
had a relatively high stromal expression of AC (p=0.017). 
The incidence of local recurrence varied significantly according to relative expression of AC 
at the cancer site in both stroma and epithelium.  Across all cases where a stromal expression 
of AC was observed, 6/49 patients with a relatively high expression developed local 
recurrence, compared to 1/56 with a relatively low expression (p=0.038).  In the context of 
an absence of a pCR, local recurrence occurred in 5/35 patients with a relatively high 
epithelial expression of AC, compared to 0/33 with a relatively low expression (p=0.031).  
There was no correlation between cancer site expression of AC in either epithelium or stroma 
with metastatic disease or survival. 
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2.3.4 Normal Colon Tissue Microarrays 
 
 
Figure 2.11 - Pie chart demonstrating the number of tissue cores originating from the normal colon 
specimens considered as adequate and scored for AC expression, subsequent to TMA construction, 
sectioning and IHC staining. 
 
A tissue block demonstrating normal colonic epithelium was identified and retrieved for all 
111/111 cases (100%).  The subsequently constructed TMAs yielded the greatest number of 
adequate cores that were assessed for IHC staining for AC - 221/333 (66.4%), representing 
107/111 (96.4%) of the overall cases.  It was considered (by MW) that most of these cores 
were devoid of stromal tissue, and therefore only an epithelial score of AC expression was 
assigned. 
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Figure 2.12 - Images of three sections from TMA I (representing cores from normal colon from 
resection specimens), having been stained for H&E, AC (using BD 612302 at a concentration of 
1/500), and with mouse IgG as a negative control. 
 
The whole slide sections of TMA I depicted in figure 2.12 are indicative of the coverage 
achieved with the cores of normal colon from the resection specimens, both within and 
between sections, having been stained as described in section 2.2.4.  The H&E slide was 
stained and assessed individually initially to ascertain coverage.  Variablility in the brown DAB 
staining for AC expression can be observed, compared with an absence of staining with the 
mouse IgG negative control across the whole slide. 
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Figure 2.13 - Images of selected TMA cores of normal colon from the resection specimens.  The 
cores were observed from the same section of TMA I, having been stained for AC (A&C), with the 
corresponding cores (B&D) from another section exposed to a mouse IgG isotype as a negative 
control.  The rectangular bar in each image represents 50µm.  
 
The core marked A in figure 2.13 demonstrates higher epithelial expression of AC (H-score = 
5+3 = 8) in a case where a poor response to CRT (TRG 1) was assigned to the resection 
specimen.  Lower epithelial expression of AC is observed in the core marked C (H-score = 2+1 
= 3), in a case where a good response to CRT (TRG 3) was assigned to the resection specimen.  
No inappropriate staining is observed in the negative control cores, and the intensity of the 
background H&E staining is comparable across the cores. 
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Table 2.6 - H scores observed upon assessment of epithelial AC expression in normal colon tissue.  
The crude H score is presented for each tissue core adequately present on TMAs I, J, K, L & M, in 
association with the calculated mean H score for each patient. 
 
Patient I J K Mean Patient I J K Mean
1 7 7.0 57 7 7 7.0
2 7 6 6 6.3 58 7 6 6.5
3 4 7 5.5 59 6 7 6.5
4 6 6.0 60 7 7 7.0
5 6 6 6.0 61 6 6.0
6 7 7 7 7.0 62 6 7 7 6.7
7 7 6 6.5 63 6 6.0
8 7 6 6.5 64 3 3.0
9 5 7 7 6.3 65 7 7.0
10 7 6 7 6 6.5 66 5 5 5.0
11 8 6 7.0 67 7 6 6.5
12 6 6.0 68 8 8.0
13 7 7 7.0 69 6 5 6 5.7
14 5 6 7 6.0 70 7 7.0
15 6 6.0 71 7 7 7 7.0
16 6 6 5 5.7 72 6 6 6.0
17 6 6.0 73 7 7.0
18 7 6 6.5 74 8 7 6 7.0
19 6 6 7 6.3 75 6 7 6.5
20 6 7 6 7 6.5 76 7 7 7.0
21 5 5.0 77
22 5 7 6.0 78 7 6 7 7 7 6.8
23 6 6 6.0 79 5 6 5.5
24 6 6.0 80 7 7 7 7.0
25 7 7 7 7.0 81 8 8.0
26 6 6 6 6.0 82 7 7.0
27 6 6.0 83 7 7 7.0
28 8 8 8 8.0 84 5 7 6 7 8 6.6
29 6 6 6.0 85 5 6 7 6.0
30 6 7 6 7 6.5 86 7 7 7.0
31 5 4 4.5 87 5 6 5.5
32 88 6 6 6.0
33 7 7.0 89 8 8.0
34 6 6.0 90 7 8 7.5
35 7 6 4 5.7 91 8 7 7.5
36 5 6 5.5 92 7 7 7.0
37 7 8 6 7.0 93 7 6 6.5
38 7 7 7 7.0 94 8 7 7 7.3
39 6 6.0 95 7 7.0
40 6 6.0 96 7 7 7 7 7.0
41 7 7 6 6.7 97 8 8.0
42 6 5 5 5.3 98 6 6.0
43 3 3.0 99
44 8 8 8.0 100 8 8 7 7.7
45 7 7 7 7.0 101 7 7 7.0
46 7 7 7.0 102 7 8 7 7.3
47 6 6.0 103 7 6 6.5
48 6 5 6 5.7 104 8 7 8 7.7
49 7 7 7.0 105 7 7 7 7.0
50 6 6.0 106 6 8 7 7.0
51 6 6 6.0 107
52 5 7 6 6.0 108 6 6 6 6.0
53 6 6 6.0 109 8 7 7 7.3
54 7 7.0 110 7 7.0
55 7 7 7.0 111 7 7 7.0
56 7 7 7.0
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The median H-score for AC expression in normal colonic epithelium obtained from the 
resection specimen was 6.5.  There was no correlation between AC expression and either a 
pCR or a relative response to treatment (p=0.816 and p=0.196 respectively).  14/19 of the 
assessed tissue cores from patients where a poor response to treatment (TRG 1) had been 
observed, were found to have a relatively high expression of AC (p=0.012). 
There was no correlation between epithelial AC expression in this tissue with the risk of local 
recurrence or metastatic disease but there was significant correlation between expression 
and survival.  The estimated mean survival in those with a relatively high expression (n=51) 
was 89.7 months (95% CI 80.7 - 98.8), which was significantly longer (p=0.013, Mantel-Cox) 
than those with a relatively low expression (n=56), where estimated mean survival was 71.9 
months (95% CI 61.5 - 82.3). 
 
 
2.3.5 Quality Assessment of Tissue Microarray Staining 
 
 
Figure 2.14 - Images of cores of the positive control tissue (kidney and lung) randomised into each 
TMA constructed (A-M).  The cores demonstrate IHC staining for AC and have been observed from 
the identical sections as those used to score for AC expression in the tissues of interest. 
 
All the present positive control tissue cores as depicted in figure 2.14, achieved the maximal 
H score of 5+3 = 8 for epithelial staining upon assessment.  Cores of kidney tissue were not 
present for assessment from TMAs B, C & D, and cores of lung tissue were not present for 
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assessment from TMAs L & M.  At least one positive control tissue core was present and 
assessed for each TMA and represents the best comparison of staining across all TMAs. 
 
 
2.3.6 Patient Survival Analysis 
 
Figure 2.15 - Kaplan-Meier curves demonstrating post-operative survival in months in the patient 
cohort in this study (n=111), comparing those patients where a pCR (TRG 4, green line n=22) had 
been observed, against those patients without a pCR (TRG 3/2/1, blue line, n=89). 
 
The estimated mean post-operative survival in this patient cohort where a pCR had been 
observed (n=22) was 99.6 months (95% CI 91.1 – 108.0), as depicted in figure 2.15.  This was 
significantly better when compared to non-pCR patients (n=89), where the estimated mean 
survival was 74.5 months (95% CI 66.2 – 82.8, p=0.015, Mantel Cox). 
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Figure 2.16 - Kaplan-Meier curves demonstrating post-operative survival in months in the patient 
cohort in this study (n=111), comparing those patients considered to be relative responders to 
neoadjuvant CRT (TRG 4/3, green line n=37), against those patients considered to be relative non-
responders (TRG 2/1, blue line, n=74). 
 
The estimated mean post-operative survival in these patients defined to be relative 
responders to neoadjuvant CRT (TRG 4/3, n=37) was 87.3 months (95% CI 75.5 – 99.2).  This 
is not statistically significantly better (p=0.182, Mantel Cox) when compared against the 
group defined to be relative non-responders (TRG 2/1, n=74), where the estimated mean 
survival was 76.0 months (95% CI 67.2 – 84.9). 
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Figure 2.17 - Kaplan-Meier curves demonstrating post-operative survival in months in the patient 
cohort in this study (n=111), comparing patients between the specific TRG group assigned to their 
resection specimen.  TRG 4 (pCR, n=22) is depicted by the purple curve, TRG 3 (n=15) by beige, TRG 2 
(n=55) by green, and TRG 1 (minimal or no regression, n=19) by blue. 
 
The estimated mean post-operative survival in months (with associated 95% CI) for the 
patients in this study according to their specific TRG was; TRG 4 – 99.6 (91.1 – 108.0), TRG 3 
– 68.4 (49.9 – 87.0), TRG 2 79.4 (69.4 – 89.3), TRG 1 – 44.5 (35.6 – 53.4).  Complimentary to 
the comparison in figure 2.15 where survival with a pCR was significantly better than with all 
other responses combined, it was also demonstrated (as depicted in figure 2.17) to be 
significantly better when compared to all other responses individually (p=0.010, p=0.040, 
and p=0.005 for TRG 4 against TRG 3, 2, and 1 respectively).  Interestingly the estimated 
mean post-operative survival for what would be considered a poorer TRG 2 response was 
longer than for a TRG 3 response (79.4 vs. 68.4 months), although this was not statistically 
significant (p=0.447), and equally there were no statistically significant differences between 
any of the non-TRG 4 groups. 
 
 
 
 
99 
 
2.4 Discussion 
 
 
2.4.1 Summary of Aims 
 
The aims for the work presented in this chapter were to initially identify rectal cancer 
resection cases that had completed neoadjuvant CRT, and to assess these cases for 
histological regression grading.  TMAs were to be constructed comprising diagnostic biopsy 
and resection specimen tissue (including normal colon) from these cases, and subsequently 
stained for AC expression.  Correlation of AC expression with TRG and clinical outcome data 
was planned in attempt to provide further validation of AC as a predictive and/or prognostic 
marker in the response of rectal cancer to CRT. 
 
 
2.4.2 Summary of Results 
 
2.4.2.1 Tissue microarray staining for acid ceramidase 
Differential staining of the TMAs for AC was observed across all tissue types (diagnostic 
biopsy, cancer site, and normal colon) as depicted by the images in figures 2.7, 2.10 and 2.13.  
86-107 of the 111 cases were successfully represented in the TMAs (depending on the tissue 
component). 
In stromal tissue at the cancer site from the resection specimen, a relatively low expression 
of AC was associated with both a pCR (TRG 4, p=0.003) and with relative responders to CRT 
(TRG 4&3, p=0.048), whereas a relatively high expression of AC was associated with a poor 
response to CRT (TRG 1) (p=0.017). 
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Tissue 
Microarray 
Cellular 
Subset 
Cases 
Represented 
Median 
H Score 
TRG Comparison 
p 
Value 
(χ2) 
Diagnostic 
Biopsy 
Epithelium 86/106 5.0 
pCR vs Others 0.695 
Relative Response 0.699 
Others vs Non-
response 
0.375 
Stroma 86/106 5.0 
pCR vs Others 0.472 
Relative Response 0.764 
Others vs Non-
response 
0.075 
Cancer Site 
Epithelium 68/89 5.5 
pCR vs Others N/A 
Relative Response 0.506 
Others vs Non-
response 
0.487 
Stroma 105/111 4.0 
pCR vs Others 0.003 
Relative Response 0.048 
Others vs Non-
response 
0.017 
Normal 
Colon 
Epithelium 107/111 6.5 
pCR vs Others 0.816 
Relative Response 0.196 
Others vs Non-
response 
0.012 
 
Table 2.7 – TMA IHC scoring of AC expression.  Each tissue assessed (diagnostic biopsy, resection 
specimen cancer site or normal colon) and subset (epithelium or stroma) was analysed by 
correlating lower/higher IHC scoring for AC (dichotomised about the median score) against the 
respective TRG group (compared as pCR (TRG 4) vs. others (TRG 3-1), relative responders (TRG 4&3) 
vs. relative non-responders (TRG 2&1), and non-responders (TRG 1) vs. others (TRG 4-2)) using χ2. 
 
A relatively high epithelial expression of AC in normal colon from the resection specimen was 
also associated with a poor response to CRT (p=0.012).  There were no statistically significant 
results from the diagnostic biopsy samples, although 9/11 cores representing patients with 
a poor response to treatment (TRG 1) had a relatively high stromal expression of AC 
(p=0.075). 
The median stromal H score was lower in post-CRT tissue at the cancer site compared with 
pre-CRT diagnostic biopsy tissue (4.0 vs 5.0).  Whilst the median epithelial H score in these 
‘malignant’ tissues subsequent to CRT was higher (5.5 vs 5.0), it is biased by the absence of 
a score in those with a pCR (and therefore an absence of malignant epithelium).  The median 
H score in normal colon epithelium from the post-CRT resection specimen was higher (6.5) 
than at the cancer site either pre- or post-treatment. 
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2.4.2.2 Acid ceramidase expression and outcome 
Higher AC expression in both epithelium and stroma from the cancer site post-CRT was 
associated with local recurrence (p=0.031 and p=0.038 respectively). 
A relatively high epithelial expression of AC in normal colon from the resection specimen was 
independently, and conversely, significantly correlated with improved survival (p=0.001). 
Table 2.8 below summarises the correlation of AC expression with the incidence of local 
recurrence, distant metastases and survival during the follow-up period.  The data pertaining 
to the clinical and pathological data presented in this chapter is included as appendix B. 
 
Tissue 
Relative 
Acid 
Ceramidase 
Expression 
Local Recurrence Metastases Death 
n= p value n= p value n= p value 
Diagnostic 
Biopsy 
Epithelium 
Lower n=42 1 
0.518 
17 
0.061 
11 
0.263 
Higher n=44 2 10 8 
Diagnostic 
Biopsy Stroma 
Lower n=37 0 
0.180 
12 
0.520 
8 
0.570 
Higher n=49 3 15 11 
Cancer Site 
Epithelium 
Lower n=33 0 
0.031 
11 
0.376 
7 
0.338 
Higher n=35 5 14 10 
Cancer Site 
Stroma 
Lower n=56 1 
0.038 
17 
0.180 
11 
0.200 
Higher n=49 6 20 14 
Normal Colon 
Epithelium 
Lower n=56 3 
0.615 
21 
0.403 
22 
0.001 
Higher n=51 3 17 6 
 
Table 2.8 – Correlation of TMA staining for AC with the incidence of local recurrence, metastases and 
death during the follow-up period in the study, using Fisher’s exact test. 
 
 
2.4.3 Strengths and Limitations 
 
The diagnostic biopsy tissue blocks did not afford sufficient normal epithelial tissue (pre-
neoadjuvant CRT) to be assessed for AC expression.  The best tissue to be considered as 
normal was equally from the post-neoadjuvant CRT resection specimen.  Although this was 
targeted to a tissue block of proximal normal colon that would ordinarily be outside the 
radiotherapy field, irradiation naïve tissue was not guaranteed, and equally this tissue will 
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have been exposed to systemic chemotherapy.  The effect of this is uncertain, although the 
point at which this tissue is obtained at surgical resection is subsequent to a period of 
downstaging following cessation of treatment - this is usually at least six weeks, and 
therefore the tissue may or may not reflect normal pre-CRT tissue.  These normal colon 
samples specifically targeted the epithelium (to mimic an endoscopic biopsy), and were 
therefore devoid of stromal tissue.   
There was clearly no malignant epithelial tissue present at the tumour site in the resection 
specimens where a pCR had been observed, which makes inter-group comparisons (to assess 
any change in AC expression with neoadjuvant CRT) in epithelium difficult. 
A pragmatic approach was required in performing assessment of the tissue cores.  It was 
technically challenging to obtain cores from the biopsy specimens, given the volume of tissue 
remaining in the retrieved tissue blocks, and as reflected by the number of cores considered 
appropriate to score for AC staining on final assessment in this group.  Equally achieving 
malignant epithelium in the TMA sections from the tumour site in the resection specimen 
blocks was technically difficult in cases of a near complete response – whilst malignant cells 
were identifiable in the original H&E stained section, localising this area on the tissue block 
in order to obtain a tissue core was not exact, and equally was not guaranteed to comprise 
malignant cells at a deeper level after the TMA had been cut-in and further sections 
obtained.  In addition, in cases of mucinous adenocarcinoma, there were scanty epithelial 
cells present in the cores.  This meant that whilst it would have been optimal to only consider 
a tissue core as appropriate if a minimum number of cells of interest were present, it was 
not practicable, and an IHC score was assigned at the discretion of the observing consultant 
histopathologist (MW) and I. 
The number of stained TMA cores assessed could be interpreted as low, and a limitation of 
the study.  Triplicate cores for every sample were not present for final analysis, primarily due 
to the absence of cores from the TMA sections or due to insufficient or non-targeted tissue 
in the observed cores.  The nature of the tissue blocks used in the study contributed to this 
being an inherent risk but was impacted upon from technical considerations of TMA 
construction.  Whilst this is a recognised limitation, the statistical power of assessment of 
hundreds of cores overall provides some amelioration of this risk (Parker et al, 2002).  The 
desired material may be present in further sections taken from the TMA in some cores but 
with a risk that other cores would not be present upon deeper sectioning.   
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Staining of each TMA equally was only performed on a single section due to financial 
considerations.  Despite this, the study has observed significant differences in AC expression 
with TRG response, and as such has achieved its initial aim of providing some evidence to 
validate the original proteomic findings.  This justifies further investigation of the role of AC 
in the response to neoadjuvant CRT. 
The semi-quantitative scoring system used for analysis of AC expression on the TMAs was a 
simplified version of an H-score.  An alternative version that allows for a slightly more 
detailed assessment of staining, accounts for the exact percentage of cells staining at the 
previously described staining intensity (0-3).  The score is thus calculated as H = ((% at 0)*0) 
+ ((% at 1+)*1) + ((% at 2+)*2) + ((% at 3+)*3 (McClelland et al, 1990), producing a continuous 
variable that ranges from 0 to 300.  For the purposes of our analysis whereby we were 
seeking to dichotomise the scores about the median for each tissue type analysed (to 
differentiate between relatively low and high expression for statistical analysis), it was 
considered that the simplified version was sufficient, along with the consideration of 
logistical and time constraints in performing a more complex assessment.  This is also 
supported by the literature where simplified scoring systems have correlated highly with the 
more rigorous H-score (Detre et al, 1995) for oestrogen receptor status in breast cancer, 
although validation of any IHC scoring system for AC has not been undertaken. 
A major drawback with TMA construction lies in the approximation of desired tissue spots 
for transfer into the TMA.  The manual alignment of the annotated region from an H&E slide 
to the donating block is not always exact.  Next generation TMA technology based on digital 
imaging and automated processes would have potentially ameliorated this drawback (Zlobec 
et al, 2013) but was not logistically or financially an option for this study. 
Tumour heterogeneity is also a recognised factor with implications for the interpretation of 
biomarker studies such as this (Rehemtulla, 2012), although the impact of this is potentially 
lessened by the attempt in this study to obtain triplicate cores from each tissue sample.  
Validation of triplicate cores correlating with IHC expression of a whole tissue section for 
p53, MLH1 and MSH2 in CRC has been demonstrated (Jourdan et al, 2003).  Equally both 
TMA and whole tissue section expression has been correlated with survival (Nocito et al, 
2001) in prostate cancer but such studies are limited and may be both tumour and/or protein 
specific (Khouja et al, 2010), and AC in rectal cancer has not previously been validated.  It is 
also established that CRC displays high intra-tumour heterogeneity in comparison with other 
cancers (Punt et al, 2017). The concern with regards to tumour heterogeneity is equally 
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pertinent for the assessment of post-neoadjuvant CRT specimens, as the surviving tumour 
cells may not accurately reflect the original tumour.  Information gleaned from this tissue is 
indicative of the response to treatment, and a potential change in the tissue phenotype, as 
opposed to offering predictive information regarding response to treatment itself. 
The original work upon which this thesis is based utilised tissue obtained pre- and post-CRT, 
and subsequently at the time of surgical resection.  No differentiation was possible between 
epithelium, stroma, muscularis etc. within each sample due to the nature of the processing 
of the samples.  In this study, tissue was targeted for incorporation into TMAs based upon 
the presence and density of malignant epithelial cells (where appropriate), primarily to 
guarantee that the tissue being assessed was truly from the cancer site.  There is therefore 
inherent bias between the studies, which makes direct comparison difficult.  Further 
evidence to suggest that AC is implicated in the response to of rectal cancer to neoadjuvant 
CRT has been demonstrated however. 
The correlation of reduced AC expression in epithelial cells with an enhanced response to 
CRT is potentially straightforward to understand as a mechanism.  Whilst the results 
presented only potentially demonstrate a trend towards this observation, the impact of a 
low level or down-regulation of AC in tumour cells in response to the cellular insult, may 
result in a reduction of ceramide cleavage and its subsequent accumulation (Arana et al, 
2010), with ceramide then exerting its influence in mediating cell cycle arrest and apoptosis 
(Garcia-Barros et al, 2014). 
Evaluation of apoptosis as the main predictive mechanism associated with AC activity in the 
tumours post-CRT could have been undertaken with assessment of IHC staining for the 
activator caspases -3 and -7, mediated predominantly through mitochondrial dysfunction 
(Green and Kroemer, 2004).  Assessment of active caspase-3 as the main executioner of 
apoptosis has been evaluated in a variety of FFPE tissues (Gown and Willingham, 2002), 
although caspase-7 can be activated independent of the mitochondrial pathway (Davidson 
et al, 2005), and could be assessed for IHC expression independently.  The cleavage of poly-
ADP-ribose-polymerase (PARP), which detects and signals DNA strand breaks, is considered 
indicative of functional caspase activation (Koh et al, 2005), although IHC evaluation whilst 
possible has been observed to be challenging (Horvath et al, 2015).  The significance of 
evaluation of these markers at the point of assessment 6 weeks following cessation of CRT 
would need to be determined however.  
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An explanation of the impact of the observed lower AC expression in stromal cells with a 
significantly improved response to CRT, can potentially be explained by literature evidence 
for tumour-stromal interaction and signalling between cells. 
The stroma (or tumour micro-environment) is considered to play an essential role in both 
the development of malignancy and in the resistance to treatment.  This environment, 
composed of extracellular matrix, fibroblasts, endothelial cells, and cells of the immune 
system regulates the behaviour of tumour cells and co-evolves (Werb and Lu, 2015).  Cancer 
cells have been demonstrated to activate and recruit carcinoma-associated fibroblasts, 
which are able to both stimulate cell growth and invasion, as well as inflammation and 
angiogenesis but may also be tumour inhibiting (Kalluri and Zeisberg, 2006).  This process is 
considered to be under the regulation of TGFβ signalling, which itself is primarily activated 
by integrins secreted from both tumour and stromal cells.  In normal tissues TGFβ suppresses 
epithelial cell division but tumour cells can develop escape mechanisms to become resistant 
to TGFβ growth suppression.  In addition, TGFβ drives EMT, increasing the potential for 
metastasis (Khan and Marshall, 2016). 
This signalling process may be mediated through ceramide-based lipid rafts, as micro-
domains of regions of the cellular membrane, demonstrated to regulate vesicular traffic, cell 
polarity, and cell signalling pathways (Bieberich, 2018).  They have been found in almost all 
existing experimental cancer models, including CRC, and play key regulatory roles in cell 
migration, metastasis, cell survival and tumour progression (Jahn et al, 2011).  Altered AC 
expression may therefore have central implications for the regulation of ceramide and key 
regulatory inter-cellular signalling between stroma and tumour in response to CRT in rectal 
cancer. 
Information as to the exact neoadjuvant CRT treatment protocols for both chemotherapeutic 
agents used and the radiation doses delivered was not obtained for these patients.  It was 
inferred from the clinical records that a patient had completed the course of treatment by 
the nature of the request for re-staging imaging, the fact that re-staging imaging had been 
undertaken, or the request for histopathological assessment citing long course treatment 
with consistent findings in the resection specimen.  5-FU based therapy, as either intra-
venous infusion or oral capecitabine was, and remains, the only chemotherapeutic radio-
sensitiser in clinical use in the hospital however. 
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2.4.4. Conclusion 
 
In relation to the hypotheses set at the outset of the chapter: 
 
• Differential expression of AC is present in rectal cancer, and/or normal colon - 
PROVEN 
We have observed differential expression of AC in rectal cancer both pre- and post-CRT in 
epithelial and stromal tissue, and in epithelial tissue from normal colon.   
 
• Expression of AC in rectal cancer and/or normal colonic tissue can predict response 
to neoadjuvant CRT, and/or is a biomarker of response to treatment - PARTIALLY 
PROVEN 
Significant differences in expression of AC that separate responders and non-responders to 
neoadjuvant CRT have been observed in stromal tissue from post-treatment resection 
specimens, and in normal colonic epithelium.  These findings validate the original proteomic 
profiling in implicating AC in the response of rectal cancer to CRT and justifies further 
investigation. 
Statistically significant results were not observed in this study from a potentially predictive 
diagnostic biopsy but there was a trend towards higher stromal expression from these 
samples being associated with no response to treatment (TRG 1) - the study may simply be 
under-powered to detect such an association in this sub-group. 
The results in this study overall implicate AC expression in tumour stroma in the response of 
rectal cancer to neoadjuvant CRT.  Whilst lower median H scores were observed in cancer 
site tumour stroma when compared to pre-treatment diagnostic biopsies, it is not possible 
to infer if is a lower or decreasing expression that determines response, or if a lower 
expression is a consequence of response.  Higher AC expression in the cancer site post-CRT 
in both epithelium and stroma was significantly correlated with local disease recurrence 
(p=0.031 and p=0.038 respectively).  In the context of the epithelial score, this is exclusively 
in those without pCR.  Correlations of AC expression and survival further implicate a role for 
AC in the response of rectal cancer to CRT and further assessment of AC expression in 
response to radiotherapy in vitro is required. 
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Chapter 3 
 
Manipulation of Acid Ceramidase Expression and Activity in the 
HCT116 Colorectal Cancer Cell Line 
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3.1 Introduction 
 
 
3.1.1 Background 
 
The effect of variable AC expression upon sensitivity to radiotherapy in rectal cancer, was 
proposed to be further assessed in vitro.  It was considered that the sensitivity to irradiation 
of a CRC cell line should be assessed, both before and following manipulation of AC 
expression / activity.  This manipulation was planned to consist of genetic and 
pharmacological approaches, in order to both optimise experimental laboratory conditions 
(with genetic manipulation), and to assess a potentially more immediately translational 
model of AC dependent radio-sensitivity (with pharmacological inhibition).  It was therefore 
necessary to quantify and optimise the manipulation of AC expression and activity in a CRC 
cell line.   
 
3.1.1.1 HCT116 colorectal cancer cell line 
The HCT116 CRC cell line is commonly utilised for the in vitro modelling of radio-sensitivity 
in rectal cancer (Schilling et al, 2013; Halacli et al, 2013; Adeberg et al, 2014), owing to both 
its lineage but also the use of clonogenic assay as an outcome measure and the 
characteristics of the cells in colonies, which are densely packed and easily visualised.  The 
cell line exists in p53 wild type (p53+/+) and deficient (p53-/-) forms.  An original concept 
was to compare the radio-sensitivity of the two cell lines in an AC dependent model, although 
in the context of the other work proposed for this thesis, and with the duplication of the 
required optimisation, it was considered impracticable.  Thus, it was determined to perform 
further experimental modelling with a single cell line - the wild type p53+/+ cell line was 
available from the Department of Pharmacology, University of Liverpool, and was selected 
as cell culture protocols were established. 
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3.1.1.2 Small interfering RNA 
Small interfering RNA (siRNA) was first described in 1999 (Hamilton and Baulcombe), since 
which time its experimental use for simple and rapid gene silencing, including in cell lines, 
has become widely adopted.  It interferes with the expression of specific genes with 
complimentary nucleotide sequences, and functions by causing mRNA to be broken down 
after transcription (Agrawal et al, 2003).  The negatively charged siRNA can be delivered into 
cells by use of a cationic lipid, forming liposomes which overcome the negative electrostatic 
repulsion of the cell membrane (Dalby et al, 2004). 
Whilst the therapeutic potential of siRNA is beginning to be evaluated in gene-therapy in the 
clinical trial setting, many barriers to its widespread use remain.  Intracellular delivery of 
siRNAs in vivo is impeded by their size and negative charge.  Whilst they are too large to cross 
cell membranes, siRNAs are small enough to be filtered by the kidney, and are rapidly 
excreted unless conjugated to other molecules or incorporated into complexes.  Unintended 
on-target effects in non-redundant functions of the target gene can occur in the targeted 
tissue, or unwanted effects can occur in non-targeted tissue.   Sequence specific off-target 
effects are rare but innate immune inactivation and toxicity of delivery vehicles are common 
(Wittrup and Lieberman, 2015). 
 
3.1.1.3 Chemotherapeutic inhibition of acid ceramidase activity 
The chemotherapeutic carmofur (as an orally available 5-FU prodrug) was found to be a 
potent inhibitor of AC activity, whereas 5-FU itself was not (Realini et al, 2013).  Carmofur is 
also known to have been used in the clinical setting in the adjuvant treatment of colorectal 
and breast cancers (Watanabe et al, 2006), although neoadjuvant CRT for rectal cancer in 
the UK currently utilises the mainstream oral 5-FU prodrug capecitabine for radio-
sensitisation. 
Clearly the finding of carmofur potently inhibiting AC has a potential translational benefit, 
given the confirmation of differential expression of AC separating responders and non-
responders to CRT in rectal cancer.  Investigating the response to neoadjuvant CRT in rectal 
cancer comparing radio-sensitisation with capecitabine against carmofur, could potentially 
be a logical clinical trial. 
It was therefore proposed to assess the effect of inhibition of AC with carmofur in vitro, 
alongside siRNA inhibition.  Quantification of mRNA and protein expression would be 
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determinable using reverse-transcription polymerase chain reaction (RT-PCR) and Western 
blotting respectively.  Assessment of AC activity would provide the key functional significance 
of any expressional changes. 
 
3.1.1.4 Acid ceramidase activity assay 
Historical assessment of AC activity has traditionally been performed using: i) enzymatic 
based activity assays, classically with radiolabelled substrates; ii) loading tests, consisting of 
the addition of exogenous radiolabelled sphingolipids on cultured cells and the study of their 
metabolism; and iii) determination of accumulated ceramide.  The main drawbacks of these 
methods include the lack of commercially available radiolabelled compounds, the laborious 
processes required in the separation and identification of reaction products, and the need 
for specific instruments, which has restricted assessment of AC activity to very few expert 
laboratories (Bedia et al, 2010). 
The Bedia et al. group have developed a fluorometric procedure to determine AC activity 
using a synthetic ceramide analogue carrying a 2-oxo-2H-chromen-7-yloxy moiety in the CH3-
terminal part of the sphingoid chain (Bedia et al, 2007).  The structure of this substrate 
enabled the release of umbelliferone after hydrolysis by AC, periodate oxidation of the 
resulting aminodiol, and further β-elimination of the aldehyde oxidation product, resulting 
in a simple assay that could be performed in a 96-well plate format.  The specificity of the 
substrate towards lysosomal AC was further refined by manipulation of the fatty acid chain 
length, revealing the Rbm14-12 substrate (figure 3.1), possessing a 12-carbon fatty acid 
chain, as highly specific (Bedia et al, 2010). 
 
 
Figure 3.1 – General chemical structure of the Rbm14 compound, where n=10 for Rbm14-12.  (Taken 
from Bedia et al, 2010) 
 
The AC activity assay was deemed central to the experimental work in the thesis, to provide 
the quantifiable functional link between siRNA transfection and small molecule inhibition.  It 
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is equally the functional significance of AC activity, as opposed to expression, that we were 
seeking to evaluate as the key determinant of potentially translational research. 
 
 
3.1.2 Hypotheses 
 
• Expression of AC can be inhibited by siRNA transfection in the HCT116 CRC cell line, 
subsequently inhibiting protein activity 
• AC activity +/- expression can be inhibited by the chemotherapeutic carmofur in the 
HCT116 CRC cell line 
 
 
3.1.3 Aims and Study Design 
 
• Perform siRNA transfection targeting AC in the HCT116 CRC cell line, assessing 
subsequent genomic expression, and proteomic expression and activity 
• Perform dosing of the HCT116 cells with carmofur, assessing subsequent proteomic 
expression and activity 
• Genomic expression of AC to be quantified by mRNA expression using RT-PCR 
• Proteomic expression of AC to be quantified by Western blotting 
• AC activity to be quantified by direct activity assay 
• Establish the optimal conditions for inhibition of AC in the HCT116 CRC cell line with 
siRNA and carmofur, establishing maximal activity inhibition whilst minimising off-
target effects 
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3.2 Methods 
 
 
3.2.1 Culture of the HCT116 Colorectal Cancer Cell Line 
 
The HCT116 cell line is an immortal, epithelial-like CRC derived cell line, originating from a 
male human colon cancer.  The cells are commonly utilised for in vitro radiotherapy 
modelling, and were provided as a kind gift from The Department of Molecular and Clinical 
Pharmacology at The University of Liverpool. 
Cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma-Aldrich), 10% 
foetal bovine serum (Gibco Life Technologies, Cheshire, UK) and 1% penicillin/streptomycin 
(Sigma-Aldrich), in 75cm2 Nunc™ (Thermo Fisher Scientific, Cheshire, UK) cell culture flasks, 
and were incubated at 37°C and 5% CO2. 
 
 
Figure 3.2 – Morphology of the HCT116 CRC cells in culture.  Light microscopy images taken at x200 
magnification.  The image on the left demonstrates adherent cells 1 day after sub-culture, whereas 
the image on the right demonstrates the cells at 80-90% confluence 3 days after sub-culture. 
 
The morphology and confluence of the cells (figure 3.2) was observed every 1-2 days, and 
upon establishing 80-90% confluence every 3-4 days, cells were sub-cultured as follows in an 
Airstream® biological safety cabinet (ESCO, Barnsley, UK).  The existing culture medium was 
removed, and the cells were washed in 5mL DMEM at 37°C to remove all traces of serum 
containing trypsin inhibitor.  5mL of 0.25% trypsin-EDTA solution at 37°C (Sigma-Aldrich) was 
applied to the cells and left for one minute.  The trypsin-EDTA solution was then removed, 
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and the cells incubated at 37°C for 5 minutes, before being re-suspended in 5mL DMEM at 
37°C and filtered through a sterile needle and syringe.  The sub-culture was then established 
(usually in a 1:5 ratio) in 5mL fresh culture medium at the same temperature.   
When re-suspending cells in culture from 6-well plates, 1mL of each solution was applied 
respectively.  Cells in suspension were counted using a haemocytometer to facilitate 
accurate plate seeding, which is described in greater detail in chapter 4. 
 
 
3.2.2 Small Interfering RNA Transfection Targeting Acid Ceramidase 
 
A set of four siRNAs targeting different regions of the human ASAH1 gene encoding for AC 
was purchased (siGENOME human ASAH1 (427) siRNA, MQ-005228-01-0002, Dharmacon, 
GE Life Sciences, Leicestershire, UK).  The siRNAs were re-suspended according to 
manufacturer’s instructions in RNase-free water to create 20µM stock solutions, aliquoted, 
and stored at -20°C. 
Initial assessment of siRNA transfection was performed in 12-well Nunc™ (Thermo Fisher 
Scientific) cell culture plates, seeded with HCT116 cells at a density of 2x105 in 1mL antibiotic-
free culture medium.  The cells were allowed to adhere overnight, and a subsequent forward 
transfection with each of the siRNAs was performed.  2µL of LipofectamineTM RNAiMAX 
(Invitrogen Life Technologies, Cheshire, UK) in 100µL Opti-MEM® Reduced Serum Medium 
(Gibco Life Technologies) was mixed respectively with 1.2µL of each siRNA stock solution in 
100µL Opti-MEM®, and incubated at room temperature for 15 minutes, prior to adding to 
the cells in culture and gentle mixing.  A vehicle control for the transfection consisted of the 
same transfection reagents but with the addition of a non-coding siRNA (siGENOME non-
targeting siRNA pool #1, D-001206-13-05, Dharmacon, GE Life Sciences) at the same 
concentration.  The final siRNA concentration for each transfection was 20nM, and the 
transfected cells were incubated at 37°C for 48 hours prior to assessment of transfection 
efficiency.   
RT-PCR to detect AC mRNA expression, and Western blotting to assess AC protein expression 
were initially considered in the assessment of siRNA transfection efficiency. 
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3.2.3 Reverse Transcription Polymerase Chain Reaction Detection of Acid Ceramidase 
mRNA 
 
Subsequent to siRNA transfection and incubation, the culture medium along with remaining 
transfection reagents was aspirated, and the cells washed with x1 phosphate buffered saline 
(Invitrogen).  RNA extraction was performed using the miRNeasy Mini Kit (Qiagen, Venlo, 
Netherlands) in accordance with manufacturer’s instruction, prior to RNA quantification and 
quality control using the Nanodrop™ spectrophotometer (Thermo Fisher Scientific).  
Complimentary DNA (cDNA) was reverse transcribed using the QuantiTect® Reverse 
Transcription Kit (Qiagen), again in accordance with manufacturer’s instruction. 
Specific primers were designed for AC (N-acylsphingosine amidohydrolase, ASAH1 gene), as 
well as β-actin (ACTB gene) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH gene) 
for use as housekeeper controls, using the primer designing tool available at 
http://tools.invitrogen.com/content.cfm?pageid=9716 and Primer Blast available at 
http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome. 
The criteria for design of the primers was as follows; a) primer size (bases): minimum 18, 
optimal 20, maximum 27; b) primer melting temperature (°C): minimum 57, optimal 60, 
maximum 63; c) primer guanine/cytosine content (%): minimum 40, optimal 50, maximum 
60; d) product size (nucleotides): minimum 100, maximum 150; e) salt concentration (mM): 
50; f) primer concentration (nM): 50. 
The primers designed for AC were specific for all four transcript variants of the gene 
(NM_001127505.2, NM_004315.5, NM_177924.4, XM_005273504.2) and nothing else.  All 
primers were assessed for self-complementarity, hairpins, and dimerization using 
http://www.basic.northwestern.edu/biotools/oligocalc.html, and were found to be suitable.  
Table 3.1 below details the specific sequences generated. 
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Primer Target Primer Sequence (5’ to 3’) 
ASAH1 
Forward – TGC CCT GAC CCT TGT ATA GG 
Reverse – CCG CGA GTC TTA GTC TTT GG 
ACTB 
Forward – GAT GAG ATT GGC ATG GCT TT 
Reverse – CAC CTT CAC CGT TCC AGT TT 
GAPDH 
Forward – GGC CTC CAA GGA GTA AGA CC 
Reverse – AGG GGT CTA CAT GGC AAC TG 
 
Table 3.1 – Forward and reverse primer sequences generated for the gene of interest (ASAH1) and 
reference genes (ACTB and GAPDH). 
 
The custom primers were synthesized by and purchased from Invitrogen Life Technologies, 
and were reconstituted according to manufacturer’s instruction in Tris-EDTA buffer (10mM 
Tris-HCl (pH 8.0), 1mM EDTA) to create stock primer solutions of 100µM, which were 
aliquoted and stored at -20°C. 
RT-PCR was performed in 96-well PCR plates (Starlab, Milton Keynes, UK), using SYBR® Green 
JumpStart™ Taq ReadyMix™ (Sigma-Aldrich) as per the manufacturer’s instruction.  ASAH1 
primer concentrations were optimized prior to undertaking RT-PCR with experimental 
samples, with optimal concentrations of 250nM in the reaction mix for both forward and 
reverse primers determined by appropriate product accumulation and melt curve analysis.  
Template DNA was loaded at the same mass in each well within each RT-PCR run but varied 
between experimental runs (10-50ng) dependent on the total mass available for the number 
of reactions to be performed.  Relative gene expression was quantified in triplicate samples 
in each run, and negative control samples consisted of the same reaction mix in the absence 
of template DNA.  Cycle threshold (Ct) values indicating product formation were not 
observed in negative control samples with any of the primers.  RT-PCR was performed using 
the ABI PRISM® 7000 Sequence Detection System (Applied Biosystems, Waltham, 
Massachusetts, USA).  Thermal cycling was undertaken with an initial denaturation at 94°C 
for 2 minutes, followed by 40 cycles of denaturation at 94°C for 15 seconds and annealing, 
extension and read fluorescence at 60°C for 1 minute. 
Ct values for the gene of interest (GoI) and housekeeper (HK) genes were observed from the 
exponential phase of product accumulation, and relative quantification of the GoI calculated 
using the formula 2-ΔΔCt, as published by Livak and Schmittgen (2001).  ΔCt can be considered 
as Ct(GoI) – Ct(HK) (where HK in this instance was the mean of the two housekeeper Ct values) 
for each treatment group, and ΔΔCt is ΔCt – ΔCt(Ref) (where Ref = reference sample). 
116 
 
Subsequent to the initial siRNA transfection as detailed in section 3.2.2 and assessment of 
relative gene expression using RT-PCR, it was determined that siRNA number 3 (out of the 
set of four siRNAs tested) provided the greatest inhibition of mRNA production.  This siRNA 
(siRNA3) was therefore selected for further optimization of reagent dosing.  This was 
undertaken in an attempt to maximize therapeutic inhibition of AC with consideration of 
limiting potential off target effects.  In brief, this consisted of assessing the response to siRNA 
transfection across a range of Lipofectamine™ RNAiMAX doses (0.5, 1, 2 and 4µL per well in 
a 12-well plate respectively), and a range of siRNA3 final concentration per well (1.25, 2.5, 5, 
10, 20 and 40nM) over a series of experiments following the same transfection protocol. 
 
 
 
3.2.4 Western Blotting for Acid Ceramidase 
 
The functional effect of siRNA transfection to inhibit ASAH1 mRNA production needed to be 
determined.  Equally, the intended small molecule inhibition of AC at the protein level with 
carmofur, as proposed as part of the experimental plan, would not be assessed by RT-PCR.  
Western blotting for AC to quantify expression at the protein level was therefore deemed to 
be appropriate. 
 
3.2.4.1 Sample preparation 
Cells in culture were prepared for assessment of protein content on Western blotting by use 
of Radio-Immunoprecipitation Assay buffer (RIPA buffer, Sigma Aldrich), to enable efficient 
cell lysis and protein solubilisation, whilst avoiding protein degradation and interference with 
the proteins’ immunoreactivity and biological activity.  Following experimental treatment in 
culture plates, cells were washed with x1 phosphate buffered saline (PBS, Sigma-Aldrich), 
then RIPA buffer was applied (50µL and 100µL in 12-well and 6-well plates respectively) and 
incubated at room temperature for 5 minutes.  Cells were scraped from the well, and the 
lysate centrifuged at 15,000rpm at 4°C for 15 minutes.  Protein quantification of the resultant 
supernatant was performed on Bradford assay, and then prepared for use in Western 
blotting. 
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Mouse heart tissue (obtained and kindly provided fresh frozen as a by-product from existing 
work in the department by Mr Philip Roberts, Department of Molecular and Clinical 
Pharmacology, The University of Liverpool) and a rectal cancer tissue sample known to 
relatively over-express AC (previously obtained and fresh frozen under continuing research 
ethics approval (as detailed in chapter 2), and kindly provided by Mr Paul Sutton, Department 
of Molecular and Clinical Cancer Medicine, The University of Liverpool) were also prepared 
for use as positive controls for Western blotting.  A combination of mechanical and ultrasonic 
homogenisation of the tissue in PBS was performed, prior to centrifugation as per the cell 
lysate.  The resultant supernatant was used for Western blotting, again after protein 
quantification on Bradford assay. 
An AC protein fragment was purchased (ab114948, Abcam) for use as a positive control and 
to identify relevant bands in the HCT116 cell samples, subsequent to initial difficulties with 
antibody specificity as discussed in section 3.3.2 below. 
 
3.2.4.2 Bradford assay (Bradford, 1976) 
Standard protein concentrations of bovine serum albumin (BSA, Sigma Aldrich) were 
prepared at 0, 0.05, 0.1, 0.2, 0.4, 0.6, 0.8 and 1mg/ml in distilled water (dH2O), and 20µL of 
each placed in duplicate to the first two columns of a 96-well plate in increasing 
concentration.  Serial dilutions of samples for protein quantification were prepared at 
concentrations of 1:10, 1:20, 1:50 and 1:100 in dH20, and 20µL of each concentration placed 
in duplicate in adjacent paired wells on the plate.  Bradford reagent (Bio-Rad, Hemel 
Hempstead, UK) was diluted in a 1:5 ratio with dH2O, and 200µL placed in each of the wells 
and then mixed.  Absorbance at 570nm was measured using the Dynex MRX microplate 
reader (Magellan Biosciences, Chelmsford, UK), and protein concentration of the samples 
calculated by comparison to the standard curve. 
When quantifying protein concentration in samples prepared with RIPA buffer, specifically 
in the higher concentration sample dilutions of 1:10 and 1:20, the standard protein 
concentrations of BSA were also prepared to contain the same concentration of RIPA buffer 
as the samples being investigated. 
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3.2.4.3 Western blotting 
Samples containing 15µg of total protein were prepared for Western blotting by mixing in a 
2:1 ratio with Laemmli buffer (Bio-Rad) prepared with β-mercaptoethanol (as a reducing 
agent) as per the manufacturer’s instruction.  The samples were then denatured by heating 
at 85°C for 5 minutes, before loading onto SDS-PAGE (sodium dodecyl sulphate-
polyacrylamide gel electrophoresis) gels to undergo electrophoresis in running buffer at 
150V for 1 hour.  The Precision Plus Protein™ Kaleidoscope (Bio-Rad) molecular weight 
marker was loaded into one of the wells in the gel to assist with analysis of the molecular 
weight of the protein samples.  10% SDS-PAGE gels were prepared for proteins anticipated 
to be detected at 40-50kDa, and 12% gels for proteins of a lower molecular weight. 
Subsequent to electrophoresis, the protein in the gel was transferred to a Hybond-ECL 
nitrocellulose membrane (GE Life Sciences, Buckinghamshire, UK), within a blotting sandwich 
in a transfer unit containing transfer buffer, at 230A for 1 hour.  The membrane was briefly 
washed in 1xTBST (20mM Tris-Cl pH 7.6, 150mM NaCl, 0.1% Tween 20), and the quality of 
the transfer assessed with a Ponceau S solution (Sigma Aldrich).  The stain was removed with 
1xTBST, and the membrane blocked overnight in 10% non-fat dry milk blotting-grade blocker 
(Bio-Rad) in 1xTBST with constant agitation at 4°C. 
Three primary antibodies for AC were ultimately optimised by experimentation for use in 
Western blotting, as was one for β-actin which was used as a protein loading control.  The 
final conditions used are shown in table 3.2 below.  All primary antibodies were diluted in 
2% non-fat dry milk blotting grade blocker (Bio-Rad) in 1xTBST, and incubated overnight with 
constant agitation at 4°C. 
Following primary antibody incubation, membranes were washed three times for 10 minutes 
each in 1xTBST with constant agitation, prior to incubation for one hour with the relevant 
HRP-conjugated secondary antibody as shown in table 3.2, diluted in 2% non-fat dry milk 
blotting grade blocker.  A further 3 x 10 minute cycles of washes in 1xTBST with constant 
agitation was undertaken, before applying an enhanced luminol-based chemiluminescent 
substrate (ECL) (Western Lightning® Plus-ECL, PerkinElmer®, Waltham, Massachusetts, USA) 
to the membrane, for the detection of HRP conjugates, as per the manufacturer’s instruction. 
The prepared membrane was then sealed in transparent wallet, and chemiluminescence film 
(Amersham Hyperfilm™ ECL, GE Healthcare, Buckinghamshire, UK) exposed to the 
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membrane, the duration of which was dependent on protein band intensity, visualised on 
development and fixation of the film. 
 
Primary Antibody Secondary Antibody 
Name 
Manufacturer 
& Reference 
Final Dilution 
Host 
Species 
Manufacturer 
& Reference 
Final Dilution 
Anti-AC, Rb 
monoclonal 
Abcam 
ab174828 
1:1000 
Gt anti-Rb  
IgG 
Sigma 
A9169 
1:10,000 
Anti-AC, Rb 
polyclonal 
Abcam 
ab74469 
1:2500 
Gt anti-Rb 
IgG 
Sigma 
A9169 
1:10,000 
Anti-AC, Ms 
monoclonal 
BD Biosciences 
BD612302 
1:250 
Rb anti-Ms 
IgG 
Sigma 
A9044 
1:10,000 
Anti-β-actin, Ms 
monoclonal 
Abcam  
ab8226 
1:10,000 
Rb anti-Ms 
IgG 
Sigma 
A9044 
1:10,000 
 
Table 3.2 – Antibodies used in Western blotting for the detection and quantification of AC protein 
expression.  Rb = rabbit, Ms = mouse, Gt = goat. 
 
 
3.2.4.4 Experimental conditions investigated on Western blotting 
Subsequent to initial procedural Western blotting optimisation (not described or presented), 
the samples in the first three blots presented in section 3.3.2 were obtained as described in 
3.2.4. 
Following the observation of RT-PCR data described in 3.3.1, where siRNA3 at 10nM was 
selected for future transfection in HCT116 cells, samples for the assessment of protein 
expression at 12, 24, 36 and 48 following siRNA3 transfection were collected and prepared 
as previously described, and compared primarily alongside non-coding siRNA transfected cell 
samples collected at the same time points. 
Upon establishing inhibition of AC activity, as described in sections 3.2.5 and 3.3.3, and with 
developing confidence in determining AC antibody specificity on Western blotting as 
described in section 3.3.2, it was deemed prudent to assess the effect of a non-toxic dose of 
carmofur on AC protein expression.  A parallel set of plates to those used for incubation of 
the 2µM samples in the final described experiment in 3.2.5.3 were created for the purpose 
of sample collection for Western blotting.  The effect of dosing with 2µM carmofur in HCT116 
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cells was therefore assessed at 0.75, 1.5, 3 and 5 hours post incubation, and compared to 
0.05% DMSO vehicle control and untreated culture medium only samples. 
 
3.2.4.5 Densitometry 
Semi-quantitative analysis of selected Western blots was undertaken by performing 
densitometry of visualised bands using ImageJ version 1.48 (National Institutes of Health, 
Bethesda, Maryland, USA).  Density measurements of β-actin bands for samples across the 
blot were normalised to a selected standard, and the measurements from the protein of 
interest adjusted according to these normalised values.  Comparison of the relative 
expression of the protein of interest was undertaken between experimental samples and 
their respective controls, and expressed as a percentage of the control value. 
 
 
3.2.5 Acid Ceramidase Activity Assay 
 
The Rbm14-12 substrate (chemical formula C26H39NO6, molecular weight 461.59g/mol) was 
purchased from The Research Unit on Bioactive Molecules at The University of Barcelona.  
0.5mg of the substrate was dissolved in 270.8µL of ethanol to produce a 4mM solution, which 
was protected from light and stored at -20°C.  The assay was performed as per the Bedia et 
al (2010) paper, and is described below. 
To measure AC activity, cultured cells were re-suspended as described in section 3.2.1, and 
washed with x1 PBS.  Cell pellets were re-suspended in 100µL of a 0.2M sucrose solution, 
and then sonicated.  Cell homogenates were centrifuged at 15,000g for 3 minutes.  The 
supernatant was collected and used for protein quantification (Bradford assay as described 
previously, albeit compared against standards containing the same concentration of sucrose 
solution as the samples in this instance) to work with equal amounts of protein between 
samples.  The enzymatic assay was carried out in 96-well plates. 
Each well contained a mixture of 74.5µL of 25mM sodium acetate buffer (pH4.5), 0.5µL of 
4mM Rbm14-12 substrate solution in ethanol (substrate final concentration 20µM, ethanol 
final concentration 0.5%), and a fixed amount of protein in a volume of 25µL of a 0.2M 
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sucrose solution.  Negative control samples consisted in the same incubation mixture in the 
absence of protein extracts.  The plate was incubated at 37°C for 3 hours without agitation. 
The enzymatic reaction was stopped by first adding 50µL of methanol, and then 100µL of a 
fresh 2.5mg/ml sodium periodate solution in 100mM glycine/sodium hydroxide buffer (pH 
10.6) to each well.  The plate was protected from light for 2 hours and the released 
fluorescence was subsequently quantified using a microplate fluorescence reader at λex 
360nm, λem 446nm (Varioskan Flash, Thermo Fisher Scientific, Massachusetts, USA). 
 
3.2.5.1 Umbelliferone calibration for acid ceramidase activity assay 
To validate the fluorescence of umbelliferone, and therefore its use as a marker of activity 
with the Rbm14-12 substrate, a calibration was performed, as per the protocol received from 
The University of Barcelona and described below. 
A 10mM solution of umbelliferone (molecular weight 162.14g/mol) in ethanol was prepared 
(8.1mg umbelliferone in 5mL ethanol).  2µL of this 10mM solution was mixed with 198µL of 
a 25mM sodium acetate buffer (pH 4.5) to give a 100µM umbelliferone solution.  150µL of 
this 100µM solution was then mixed with a further 850µL of the 25mM sodium acetate 
buffer, to produce a 15µM umbelliferone solution.  Serial 1:2 dilutions of this 15µM solution 
with the 25mM sodium acetate buffer generated umbelliferone solution concentrations of 
15, 7.5, 3.75, 1.88, 0.94, 0.47, 0.23 and 0.12µM respectively.  100µL of each of these solutions 
were dispensed in triplicate in a 96-well plate, as was the 25mM sodium acetate buffer as an 
umbelliferone negative control.  50µL of methanol and then 100µL of 100mM 
glycine/sodium hydroxide buffer (pH 10.6) were added to all wells.  Fluorescence was read 
after 15 minutes using the Varioskan Flash at λex 360nm, λem 446nm. 
 
3.2.5.2 Protein loading validation for acid ceramidase activity assay 
The mass of validated protein loading in the Bedia et al. (2010) paper for the AC activity assay 
was 10-25µg but this was derived from two Farber disease fibroblast cell lines that were 
deficient in and manipulated to overexpress AC respectively.  It was therefore imperative to 
determine appropriate protein loading in the selected HCT116 cell line. 
Untreated HCT116 cells in culture and approaching confluence were collected as described 
previously, and protein extraction and quantification performed as described in section 
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3.2.4.  0, 5, 10, 15, 20, 25, 30, 35, 40, 45 and 50µg protein samples per 25µL of 0.2M sucrose 
were prepared in triplicate and the AC activity assay was performed as above. 
Mean fluorescence values were adjusted accordingly to account for the background 
fluorescence from the negative control (0µg) sample, such that 0µg protein = 0 fluorescence. 
 
3.2.5.3 Chemotherapeutic inhibition of acid ceramidase activity 
It was necessary to investigate the drug dose response characteristics on AC activity in the 
HCT116 cell line with carmofur and 5-FU, both in relation to drug concentration applied to 
the cells and the duration of incubation, in order to establish optimal AC activity inhibition.  
The work performed by Realini et al. (2013) demonstrated significant inhibition of AC activity 
with carmofur in the human SW403 colonic adenocarcinoma cell line (to approximately 1/3 
against vehicle control, p<0.001), which approached maximal inhibition at a dose of 3µM, 
occurring at around 3 hours.  Similar results were seen in the human prostate 
adenocarcinoma cell line LNCaP, albeit with a lower dose of 1µM carmofur.   
The main limitation in performing the activity assay was in the cost and availability of the 
Rbm14-12 substrate.  0.5mg (allowing for ≈540 individual reactions, equivalent to ≈180 
samples or ≈5½ 96-well plates) was purchased from The University of Barcelona for €650.  
Given that each sample required triplicate reaction replicates, allowing for vehicle and 
negative control samples for each assay run, and in the absence of infinite financial resource, 
it was necessary to be selective with optimisation experiments. 
A test dose of 2.5µM carmofur was determined from MTS proliferation assay data (as 
detailed in chapter 4) as non-toxic, whilst considering a likely effect on AC activity in view of 
the data from Realini et al (2013).  After demonstrating initial inhibition of AC activity with 
this dose, an experiment to determine the time of peak inhibition was performed.  A 5mM 
solution of carmofur (molecular weight 257.3g/mol, Abcam) was prepared by dissolving 
2.4mg of the drug in 1866µL of DMSO.  5µL of this solution was mixed with 10mL of DMEM 
to give the required experimental concentration of 2.5µM (DMSO final concentration 0.05%).  
HCT116 cells in exponential growth phase were plated out at 1x106 in 2mL media in 6-well 
plates, and allowed to adhere overnight.  The cells were then incubated with 2.5µM carmofur 
by replacing the media in the wells with 2mL of media containing the drug in solution.  
Sample preparation as described above was performed for cell groups collected from 
individual wells at 0, 0.5, 1, 2, 3.5 and 7 hours respectively.  20µg of total protein (as the 
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optimal mass of protein for HCT116 cells, determined by the results in section 3.3.3.2) was 
used in triplicate wells for each sample group for the activity assay.  Fluorescence values 
obtained were adjusted according to the negative control value, then standardised according 
to the 0 hour time point. 
It was subsequently determined to ascertain the maximal AC activity inhibition achievable 
with carmofur at a single time point following incubation.  The effect of drug dosing with a 
range of concentrations of carmofur (including the highest concentration achievable, whilst 
allowing for a final non-toxic DMSO concentration of 0.05%) at the 2 hour time point was 
studied.  This time point minimised potential cell toxicity from a longer incubation, whilst 
likely achieving maximal activity inhibition, and the range of carmofur concentrations 
allowed for determination of an appropriately therapeutic dose.  AC activity with 5-FU drug 
dosing was also compared at this stage, as this formed a key component of the intended 
direct comparison of radio-sensitisation with carmofur.  An assumption was made that if 5-
FU were to inhibit AC, then this would likely occur to some degree by or at the same time as 
carmofur. 
Carmofur is soluble in DMSO to 50mM according to the manufacturer’s safety datasheet, 
therefore the maximal final carmofur concentration achievable in media (with a final 0.05% 
DMSO concentration) is 25µM.  This was applied to the cells in this experiment, alongside 
concentrations of 10, 1, 0.1, 0.01 and 0.001µM respectively, achieved by serial dilution in 
DMSO of the 50mM carmofur stock, prior to mixing with media.   5-FU (molecular weight 
130.1g/mol, Sigma-Aldrich) is soluble in DMSO to 50mg/mL according to the manufacturer’s 
safety datasheet, allowing for a stock solution of up to 384mM, and a potential maximal final 
incubation concentration of 192µM (again accounting for a maximal final DMSO 
concentration of 0.05%).  This was considered excessively high in comparison with the 
maximal 25µM carmofur concentration being applied.  Given 5-FU itself had not 
demonstrated inhibition of AC in SW403 cells at a concentration of 3µM (Realini et al, 2013), 
it was considered that test concentrations higher than this were appropriate, and final 5-FU 
concentrations applied to the cells were 100, 32 and 8µM.  A 200mM stock solution of 5-FU 
was prepared by dissolving 48mg of the drug in 1845µL DMSO, yielding a 100µM 
concentration to be added to cells in the well, when 5µL is mixed with 10mL media.  Other 
concentrations were achieved by serial dilution of the 200mM stock with DMSO (final DMSO 
concentration 0.05% in all treatment groups). 
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HCT116 cells were cultured and plated in 6-well plates as above, and the drug concentrations 
applied accordingly and incubated for 2 hours.  Cell collection and sample preparation was 
performed according to the activity assay protocol.  20µg of protein from each sample group 
was used, with results again adjusted to account for background fluorescence.  Fluorescence 
values were then normalised relative to a vehicle control sample group (0.05% DMSO in 
media), collected at the same time point to enable direct comparison. 
Following this drug dose response analysis, it was considered appropriate to perform longer 
time-profile responses of AC activity inhibition across a range of potentially therapeutic 
concentrations of carmofur.  2, 4 and 8µM carmofur (ranging from non-toxic to relatively 
non-toxic as per the MTS data presented in chapter 4) were studied.  HCT116 cells were 
seeded in 6-well plates as previously described, to enable cell groups exposed to these 
concentrations of carmofur to be collected at 2, 8 and 24 hours post incubation.  Carmofur 
was dissolved in DMSO comparable with previous descriptions to yield the desired final 
concentrations in media (with a final DMSO concentration of 0.05%), with 0.05% DMSO 
vehicle control groups included at the respective time points. 
It was also considered pertinent to quantify the effect of combined carmofur and 5-FU dosing 
on AC activity, given the original proteomic profiling (demonstrating differential AC 
expression separating responders and non-responders to neoadjuvant CRT) was in a patient 
group treated with capecitabine (as a 5-FU prodrug).  It may be that carmofur (or another 
small molecule inhibitor of AC) in combination with standard 5-FU therapy enhances radio-
sensitivity whereas carmofur (or isolated AC activity inhibition) does not.   
A further AC activity assay was undertaken, with treatment groups being exposed to 2µM 
carmofur and 2µM 5-fluorouracil both individually and combined (maximum DMSO 
concentration 0.05% in all groups), compared against 0.05% DMSO treated vehicle control 
groups.  These doses were selected as non-toxic concentrations both individually and when 
combined based on MTS proliferation data as detailed in chapter 4, and with increasing 
toxicity at higher concentrations.  Cells were collected and processed as previously 
described, following incubation in the respective drug concentrations for 0.75, 1.5, 3 and 6 
hours.  A 20µg sample of protein from each treatment group was plated in triplicate for the 
purposes of the activity assay. 
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3.2.5.4 Small interfering RNA inhibition of acid ceramidase activity 
siRNA was utilised to provide a more permanent inhibition of AC activity for the purposes of 
experimental modelling.  The optimisation of siRNA dosing has been described in section 
3.3.1 but it was necessary to evaluate the AC activity inhibition profile following application 
of siRNA, to ascertain the magnitude and timing of activity inhibition. 
HCT116 cells in exponential growth phase in culture were collected and plated out in 6-well 
plates at a density of 5x105 in 2mL of antibiotic-free media.  Cells were incubated overnight 
to adhere prior to forward transfection with siRNA.  For each transfected well, 4µL of 
LipofectamineTM RNAiMAX in 200µL Opti-MEM® Reduced Serum Medium was mixed with 
1.2µL of a 20µM stock of siRNA3 in 200µL Opti-MEM®.  This mixture was incubated at room 
temperature for 15 minutes, before adding to each well and gently mixing (final siRNA 
concentration 10nM).  Vehicle control groups underwent the same transfection process with 
the non-coding siRNA at the same concentration. 
Following transfection, cell groups were collected at 24, 48 and 72 hours to assess for AC 
activity as previously described, again using 20µg protein per well on the activity assay plate. 
 
 
 
3.2.6 Statistical analysis 
 
Statistical analysis was undertaken using SPSS® Statistics version 22 (IBM®, New York, USA), 
with specific tests used as detailed in the relevant sections. 
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3.3 Results 
 
 
3.3.1 Reverse Transcription Polymerase Chain Reaction Assessment of ASAH1 mRNA 
Expression 
 
 
Figure 3.3 – siRNA inhibition of ASAH1 mRNA expression in HCT116 cells with the set of four siRNAs 
coding for AC (MQ-005228-01-0002, Dharmacon), numbered sequentially as samples 1-4 in the 
graph.  siRNAs were applied at a final concentration of 20nM in the well, including a non-coding 
siRNA (NC, D-001206-13-05, Dharmacon), and incubated for 48 hours.  M represents a non-
transfected media only cell sample.  Ct data has been obtained in triplicate RT-PCR sample reactions 
for each mRNA and used to calculate expression of the GoI relative to HK controls.  Results are 
expressed as a percentage normalised to the non-transfected (M) sample, with error bars 
representing one standard deviation (SD). 
 
Inhibition of AC mRNA expression was observed and considered significant with transfection 
of two of the four siRNAs targeting ASAH1 (siRNAs 3 and 4) as depicted in figure 3.3; mRNA 
expression with siRNA3 was calculated to be 13.1% of that of the non-transfected media only 
control and was selected for to be further validated and optimised.   
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a)                                                              
b)  
Figure 3.4 – Dose optimisation of siRNA3 transfection in HCT116 cells.  ASAH1 mRNA expression was 
analysed by RT-PCR 48 hours after transfection, using 2µL Lipofectamine™ RNAiMAX per well across 
a range of siRNA3 concentrations in two experiments.  Graph a) demonstrates mRNA expression 
with final siRNA3 concentrations in the range 1.25-10nM, compared to 10-40nM in graph b).  Ct data 
has been adjusted relative to HK mRNA expression, with results in the charts expressed as a 
percentage and normalised to the non-coding siRNA vehicle control (NC).  Error bars represent one 
SD of triplicate RT-PCR reactions for each treatment group. 
 
Suppression of ASAH1 mRNA expression was observed with all siRNA3 concentration 
treatment groups (1.25-40nM) when compared to non-coding siRNA transfected cells as a 
vehicle control.  Greatest suppression was observed with the 10nM concentration in both 
experiments, as depicted in figure 3.4.  Although triplicate experiments were not performed 
across the range of doses, and therefore not statistically analysed, the 10nM concentration 
produced ASAH1 mRNA expressions of 10.4% and 9.3% when compared to vehicle control in 
the two experiments respectively.  A lower concentration did not seem to have as great an 
effect, and interestingly, a higher concentration did not seem to have an increased effect. 
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Figure 3.5 – Dose optimisation of Lipofectamine™ RNAiMAX in ASAH1 siRNA transfection in HCT116 
cells.  ASAH1 mRNA expression was quantified by RT-PCR 48 hours after siRNA transfection across a 
range of Lipofectamine™ RNAiMAX doses (0.5-4µL per well) in a 12-well plate, with a constant 
siRNA3 concentration (2nM).  mRNA expression was also observed in treatment groups where the 
same transfection procedure was followed but in the absence of Lipofectamine™ RNAiMAX (0µL) 
and in the absence of siRNA3 with 2µL Lipofectamine™ RNAiMAX (0nM siRNA3).  Ct data has been 
adjusted relative to HK mRNA expression, with results in the charts expressed as a percentage and 
normalised to the non-coding siRNA vehicle control (NC).  Error bars represent one SD of triplicate 
RT-PCR reactions for each treatment group. 
 
ASAH1 mRNA expression was universally reduced compared to vehicle control (NC), when 
the transfection process was undertaken across a range of Lipofectamine™ RNAiMAX doses 
(0.5-4µL).  A 1:600 ratio as the final concentration in the well in subsequent transfections 
was selected (represented by the 2µL sample in figure 3.5), as this concentration is at the 
lower limit of the manufacturer’s recommendation for use in HCT116 cells 
(http://tools.thermofisher.com/downloads/HCT116_RNAiMAX.pdf) and produced at least 
equivalent results.  There was no difference in ASAH1 mRNA expression between non-coding 
siRNA transfected cells, and when the transfection process was followed but in the absence 
of either Lipofectamine™ RNAiMAX or siRNA (NC, 0µL and 0nM siRNA3 treatments groups 
respectively as shown in figure 3.5). 
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Table 3.3 – Mean Ct values (of triplicate replicates) for ASAH1, ACTB and GAPDH observed at RT-PCR 
48 hours following siRNA transfection targeting ASAH1 in HCT116 cells in triplicate experiments (1, 2 
and 3).  10nM of coding (siRNA3), and non-coding (NC) siRNA was present in the final transfection 
mixtures in each experiment and compared to untreated cells in culture medium only (M) as the 
reference sample.  Relative ASAH1 gene expression is calculated using 2-ΔΔCt and expressed as a 
percentage of the reference sample for each experiment. 
 
Crude mean Ct values in the ranges demonstrated in table 3.3 (all of which are below 30) are 
strong positive reactions indicative of abundant target nucleic acid in the samples. 
 
 
 
  Ct Value   
   ASAH1 ACTB GAPDH 2^-ΔΔCt % Expression 
1 
M 28.43 25.70 29.01 1.00 100.0 
NC 24.24 21.49 19.82 5.70 17.5 
siRNA3 29.65 23.19 22.07 61.82 1.6 
        
2 
M 24.92 20.45 20.89 1.00 100.0 
NC 23.66 19.26 18.17 1.61 62.0 
siRNA3 26.68 19.17 17.75 15.62 6.4 
        
3 
M 21.59 19.77 17.73 1.00 100.0 
NC 22.16 18.27 17.85 2.39 41.8 
siRNA3 26.66 19.82 18.66 23.92 4.2 
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Figure 3.6 – ASAH1 mRNA expression in HCT116 cells 48 hours following siRNA transfection.  The 
depicted results are mean values of the percentage expressions from the triplicated data 
demonstrated from the experiments in table 3.3, for cells in culture medium only (M, as an 
untreated control), and those transfected with non-coding (NC, as a vehicle control for the 
transfection) and the chosen ASAH1 coding (siRNA3) siRNAs at 10nM concentration.  Error bars 
represent one standard deviation of the means. 
 
ASAH1 mRNA expression in HCT116 cells following siRNA transfection with siRNA3 was 
observed to be significantly lower when compared to both a non-transfected cell population 
(4.1% vs 100%, p<0.001), and to a non-coding siRNA transfected cell population (4.1% vs. 
40.4%, p=0.032) as depicted in figure 3.6.  Interestingly there was a statistically significant 
difference between the non-coding siRNA transfected and non-transfected cell populations 
(40.4% vs. 100%, p=0.003), implicating the transfection process itself.  Statistical analysis has 
been undertaken using one-way ANOVA followed by Tukey’s test. 
In spite of a seeming off-target effect with siRNA-NC (or the transfection process), it was 
considered that in view of significant inhibition of mRNA expression following transfection 
with siRNA3 when compared with siRNA-NC, further experiments can be interpreted 
accounting for this effect. 
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3.3.2 Western Blotting for Acid Ceramidase 
 
    
Figure 3.7 – Whole membrane films of a Western blot performed on a 10% SDS-PAGE gel, with 
ab74469 (Abcam, rabbit polyclonal) anti-AC primary antibody at a concentration of 1:2500, following 
ASAH1 siRNA transfection in HCT116 cells.  Four different siRNAs targeting ASAH1 were incubated at 
20nM final concentration for 48 hours.  15µg of extracted protein per sample was prepared and 
loaded, along with vehicle and positive controls respectively.  The images demonstrate film 
exposures at two time points for the same blot; 2s on the left, and 60s on the right, with band 
molecular weight (kDa) indicated in red centrally.  The blue arrow in the left image highlights a band 
at around 53kDa, thought to potentially be the precursor AC protein, whereas the orange arrow in 
the right image demonstrates the band in the HCT116 cells of the same molecular weight as the 
dominant band originating from the AC positive rectal cancer. 
 
The AC protein originates as a 53kDa precursor molecule, which is cleaved into an active α 
sub-unit of 13kDa, and a 40kDa β sub-unit (Koch et al, 1997).  The Western blot in figure 3.7 
shows two dominant bands at around the 53 and 40kDa molecular weights in the HCT116 
cell samples in the film taken at 2s on the left.  Of particular interest in this blot following 
siRNA transfection, are the bands at ≈53kDa highlighted by the blue arrow representing 
siRNAs 1, 3 and 4 from the set of four siRNAs targeting ASAH1.  It was initially thought that 
this may represent knockdown of the protein following transfection, albeit with only a partial 
response as the half-life of AC auto-cleavage into its respective sub-units is 17 hours 
(Shtraizent et al, 2008).  Neither of these bands is at the exact molecular weight of the 
dominant bands demonstrated from the positive controls (mouse heart, which replicates the 
positive control blot for this antibody as demonstrated on the manufacturer’s website 
http://www.abcam.com/asah1-antibody-ab74469.html, or the AC positive rectal cancer). 
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The dominant band demonstrated by the AC positive rectal cancer at ≈50kDa, highlighted to 
the left of the orange arrow in the right image, becomes visible in the HCT116 cell samples 
to the right of the arrow at this intended prolonged exposure.  This band is difficult to 
interpret however, as the film becomes over-exposed from the two dominant bands seen in 
the 2s exposure on the left.  Furthermore, subsequent Western blots performed with this 
antibody (Abcam, ab74469) following siRNA3 transfection with optimised conditions as per 
the RT-PCR data, did not replicate any reduction in band density.  Recognition of the AC 
protein fragment was equally not achieved with this antibody and it was therefore 
considered too non-specific to pursue further for Western blotting with HCT116 cells. 
 
 
Figure 3.8 – Whole membrane film of a Western blot performed on a 10% SDS-PAGE gel, with 
ab174828 (Abcam, RabMAb®, rabbit monoclonal) anti-AC primary antibody at a concentration of 
1:1000, following ASAH1 siRNA transfection in HCT116 cells.  Sample loading in the blot is a replicate 
of that described in the detail for figure 3.7, for the same samples.  The molecular weights of protein 
bands are indicated in red to the left of the film, which was exposed for 60s.  The orange arrow 
indicates a faint band in the HCT116 cell samples at the same molecular weight as a dominant band 
in the AC positive rectal cancer just under the 50kDa marker. 
 
The datasheet provided for the antibody used to produce the Western blot in figure 3.8 
(Abcam, RabMAb®, ab174828) demonstrates a band at ≈65kDa but states the predicted band 
size is 45kDa (http://www.abcam.com/asah1-antibody-epr12108-
ab174828.html#description_images_1).  In the demonstrated blot the most dominant band 
in the AC positive rectal cancer sample is ≈65kDa but without any bands visible in the HCT116 
cell samples.  The most dominant band in the cell samples is ≈100kDa, where strong bands 
are also present in both positive controls but it not possible to conclude that this band 
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represents AC as it is likely too high molecular weight, and there is equally no evidence of 
protein knockdown in the siRNA treated HCT116 cell samples.  The band highlighted in 
orange is potentially at the 45kDa molecular weight as stated on the antibody datasheet as 
being the predicted band weight for AC but again there is no conclusive evidence of protein 
knockdown in the siRNA treated HCT116 cell samples. 
Previous optimisation blots with this antibody had not demonstrated better specificity to 
ascertain that any band truly represented AC, and recognition of the AC protein fragment 
was again not achieved.  Further optimisation of the antibody for its use in Western blotting 
with HCT116 cells was not pursued. 
 
 
Figure 3.9 – Whole membrane film of a Western blot performed on a 10% SDS-PAGE gel, with 
BD612302 (BD Transduction Laboratories, mouse monoclonal) anti-AC primary antibody at a 
concentration of 1:500, following ASAH1 siRNA transfection in HCT116 cells.  Sample loading in the 
blot is a replicate of that described in the detail for figures 3.7 and 3.8, for the same samples, with 
the addition of the AC protein fragment.  The molecular weights in red to the left of the film indicate 
the position of the standards of the molecular weight marker, and the film was exposed for 60s.  The 
orange arrow indicates bands in the HCT116 cell samples at the same molecular weight as the 
dominant band in the AC positive rectal cancer, whereas the green arrow does the same but for the 
AC protein fragment. 
 
The antibody used to produce the Western blot in figure 3.9 was selected from one of the 
few papers in the literature where use of a specific anti-AC antibody has been detailed (Liu 
et al, 2006), after not establishing specificity for AC in the HCT116 cells with the previously 
described antibodies.  The product datasheet describes the identification a band 
representing AC at 13kDa, which will represent the α sub-unit of the protein 
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(http://www.bdbiosciences.com/eu/reagents/research/antibodies-buffers/cell-biology-
reagents/cell-biology-antibodies/purified-mouse-anti-acid-ceramidase-23acid-
ceramidase/p/612302).  The 10% SDS-PAGE gel depicted in figure 3.9 was prepared in 
parallel with those demonstrated in figures 3.7 and 3.8 and did not facilitate interrogation 
for AC at the 13kDa molecular weight but does demonstrate some encouraging observations. 
Firstly, the AC protein fragment has been identified at ≈37kDa.  This is at the predicted 
molecular weight from the product datasheet (http://www.abcam.com/human-asah1-
protein-fragment-ab114948.html), with a corresponding faint band in the HCT116 cell 
samples at the same molecular weight, as indicated by the green arrow in figure 3.9.  In 
isolation this band does not provide evidence of protein knockdown following siRNA 
transfection but there is a suspicion of reduced expression in this band representing siRNAs 
1, 3 and 4 from the set of four siRNAs targeting ASAH1, as described in section 3.2.2.  
Complimentary to this is the appearance of similarly reduced protein expression in the faint 
band ≈50kDa in the same lanes, at the same molecular weight as the most dominant band in 
the AC positive rectal cancer sample, as indicated by the orange arrow in the image.  It was 
considered that these bands may represent the 53kDa precursor AC protein, and the 40kDa 
β-subunit.  Prolonged film exposure to the membrane did not produce improved 
development of these bands however. 
The most dominant band in the cell samples at ≈70kDa is of uncertain aetiology, and the 
Western blot was not probed for β-actin to formally validate equivalent protein loading.  In 
spite of this, further optimisation of the antibody was deemed to be justified, and was 
performed on 12% SDS-PAGE gels to facilitate visualisation of a potential 13kDa band, and in 
combination with an optimised transfection process with siRNA3, as previously described. 
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Figure 3.10 – Western blot on a 12% SDS-PAGE gel with BD612302 (BD Transduction Laboratories, 
mouse monoclonal) anti-AC primary antibody at a concentration of 1:250, following siRNA3 
transfection of HCT116 cells.  Protein expression was assessed at 12, 24, 36 and 48 hours following 
transfection with 10nM siRNA3 and a non-coding siRNA, with a sample at each of these time points 
demonstrated from left to right in the bracketed treatment groups in the image.  The membrane 
was cut to probe for AC specifically at 13kDa, and β-actin was equally assessed as a protein loading 
control.  Untreated cells in culture medium (M), and an AC positive rectal cancer sample (Can), were 
also utilised as reference and positive controls respectively. 
 
Protein expression in the bracketed siRNA3 treatment samples is reduced at the predicted 
13kDa molecular weight in figure 3.10, when compared to non-coding siRNA treated cells at 
all time points, and the reference control (M).  There is equally very strong expression in the 
AC positive rectal cancer sample at this molecular weight, compared to all cell samples and 
relative to comparable β-actin expression across all samples.  In combination with the 
appearance of reduced protein expression following ASAH1 siRNA transfection, it is 
reasonable to conclude that the protein band at 13kDa does indeed represent AC. 
On densitometry analysis, the protein expression of this AC band at 13kDa following siRNA3 
transfection in HCT116 cells was 57.2, 18.1, 17.3 and 10.8% at 12, 24, 36 and 48 hours 
respectively, when compared to protein expression in non-coding siRNA treated cells (and 
following normalisation to β-actin expression). 
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Figure 3.11 – Whole membrane film of a Western blot on a 12% SDS-PAGE gel with BD612302 (BD 
Transduction Laboratories, mouse monoclonal) anti-AC primary antibody at a concentration of 
1:250.  The lanes in the blot from left to right depict HCT116 cell samples treated with 2µM carmofur 
at 0.75, 1.5, 3 and 5 hours (Carmofur), an untreated cell sample in culture medium only (M), 0.05% 
DMSO drug vehicle control treated cell sample (V), siRNA3 (final concentration 10nM) transfected 
cell samples at 24, 48 and 72 hours (siRNA3), non-coding transfected cell samples at 24 and 48 hours 
(NC-siRNA), and an AC positive rectal cancer sample (Can).  Molecular weight of the bands is 
indicated by the figures in red to the right of the image – in this instance the molecular weight 
marker used was the Kaleidoscope™ Prestained Standards (Bio-Rad).  The highlighted bands (ringed 
in orange) in the image demonstrate a relative absence of protein in siRNA3 transfected cells 
compared to non-coding transfected cells, at the same molecular weight as a dominant band in the 
AC positive rectal cancer sample. 
 
It was considered pertinent to assess a whole membrane blot (incorporating the 13kDa band) 
in order to further validate the specificity of this antibody.  This was also an opportunity to 
perform a parallel assessment of protein expression after dosing the HCT116 cells with 
carmofur, alongside siRNA3 transfection. 
The striking feature in the Western blot depicted in figure 3.11 is the relative absence of 
three bands pertaining to siRNA3 transfected HCT116 cells, compared to non-coding siRNA 
transfected cells (as highlighted by the orange ring), at ≈53kDa and of the same molecular 
weight as a dominant band in the AC positive rectal cancer.  This molecular weight band is 
therefore highly likely to represent the 53kDa AC precursor protein. 
The 13kDa band observed in figure 3.9 is not visualised in this blot in the cell samples but the 
dominant band in the positive control sample (Can) remains strongly visible at this weight.  
The most dominant band across the cell samples (but that is not visible in the Can positive 
control) runs at ≈78kDa.  Whilst both these observations potentially suggest lower antibody 
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specificity, with the relative absence of the 53kDa band in siRNA3 transfected samples 
replicating and complimenting previous results, it remains reasonable to conclude that the 
antibody is still able to determine reduced AC protein expression. 
In relation to the samples from cells dosed with carmofur there may be a reduced protein 
expression of the 53kDa band at the earlier time points demonstrated, relative to untreated 
(M) and vehicle (V) control samples.  Protein loading for this blot was performed identically 
and in parallel to the cut membrane demonstrated in figure 3.12, where equivalent β-actin 
loading (at 42kDa) can be observed. 
 
 
Figure 3.12 – Western blot from a 12% SDS-PAGE gel demonstrating AC protein expression at 13kDa 
in HCT116 cells following drug inhibition with carmofur and siRNA transfection, and respective 
vehicle controls.  The membrane was incubated with BD612302 (BD Transduction Laboratories, 
mouse monoclonal) anti-AC primary antibody at a concentration of 1:250.  The lanes in the blot from 
left to right depict HCT116 cell samples treated with 2µM carmofur at 0.75, 1.5, 3 and 5 hours 
(Carmofur), an untreated cell sample in culture medium only (M), 0.05% DMSO drug vehicle control 
treated cell sample (V), siRNA3 (final concentration 10nM) transfected cell samples at 24, 48 and 72 
hours (siRNA3), non-coding transfected cell samples at 24 and 48 hours (NC-siRNA), and an AC 
positive rectal cancer sample (Can). 
 
Reduced AC expression at 13kDa was observed in carmofur treated HCT116 cells at 0.75, 1.5 
and 3 hours following incubation, when compared to 0.05% DMSO vehicle control.  
Expression on densitometry (normalised to β-actin) was 53.0, 24.6 and 69.9% of vehicle 
control expression at these time points respectively and returned to an above baseline 
125.3% at 5 hours following incubation.  These findings could be artefactual but may suggest 
carmofur interacts with the α-subunit of the AC protein, and may suggest inhibition with 
2µM carmofur to be optimal at some point between 0.75 and 3 hours following incubation.  
Reduced AC expression is again demonstrated subsequent to siRNA transfection.  A band is 
not visible for the sample collected 72 hours following transfection although there is no 
corresponding non-coding siRNA transfected vehicle control sample for comparison.  In spite 
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of this, isolated densitometry analysis of the 24 and 48 hour time points (normalised to β-
actin) demonstrate likely significant reduction in AC expression (quantified as 17.5 and 4.3% 
respectively), relative to control values. 
The relative expression on densitometry of the 13kDa AC protein at basal level in HCT116 
cells is 28.7%, when compared to the AC positive rectal cancer.  This basal level is represented 
by the untreated cells in culture medium only (M), following normalisation to respective β-
actin expression, and combines data from the Western blots depicted in figures 3.10 and 
3.12. The M band in figure 3.12 is seemingly disproportionately prominent, when compared 
to other bands representing controls and in respect to previous blots, and so may even 
overestimate the basal expression.  The strikingly dominant bands from the cancer (Can) 
sample, the initial difficulty of detecting AC on Western blotting, and considering the band 
density detected with the BD612302 mouse monoclonal antibody, may indicate a relatively 
low basal AC expression in HCT116 cells.  The functional significance of this potentially low 
expression remains to be determined. 
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3.3.3 Acid Ceramidase Activity Assay 
 
3.3.3.1 Umbelliferone calibration for acid ceramidase activity assay 
 
 
Figure 3.13 – Calibration of umbelliferone fluorescence.  Umbelliferone was diluted in ethanol / 
25mM sodium acetate buffer (pH 4.5) at a range of concentrations (0-15µM).  Fluorescence at these 
concentrations was measured following the addition of methanol and 100mM glycine/sodium 
hydroxide buffer (pH 10.6).  Mean values are plotted (blue dots), with error bars representing the 
standard deviation of triplicate experiments.  The dashed line represents a line of best fit (linear) 
across the data points. 
 
Fluorescence was observed to increase with increasing umbelliferone concentration as 
depicted in figure 3.13, and with very strong linear correlation (r=0.997, p<0.001, Pearson 
correlation), thus validating the use of umbelliferone as a fluorescent marker in the assay. 
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3.3.3.2 Protein loading calibration for acid ceramidase activity assay 
 
 
Figure 3.14 – Calibration of protein loading for AC activity in HCT116 cells.  Protein samples derived 
from untreated HCT116 cell lysate were assessed for AC activity across a range of protein masses (0-
50µg).  Fluorescence was measured and mean values plotted (blue dots), with error bars 
representing the SD of triplicate samples.  Values have been adjusted according to the background 
negative control sample, so that 0µg protein = 0 fluorescence.  The orange dashed line represents a 
line of best fit across all data points, plotted against a red dashed line of best fit (linear and 
extrapolated) pertaining to 0-20µg protein loading. 
 
Fluorescence was equally observed to increase with increased protein loading.  There was a 
very strong linear correlation with a protein mass up to 20µg (r=0.998, p<0.001, Pearson 
correlation), as depicted by the extrapolated red dashed line in figure 3.14.  A further 
increase in protein load resulted in an increase in fluorescence but this increase started to 
plateau above 40µg of protein, as visualised with the orange dashed line.  The finite mass of 
substrate (and therefore umbelliferone) used in the activity assay would appear to be a rate 
limiting step, certainly when the mass of protein sample originating from untreated HCT116 
cell lysate is above 30µg.  It was therefore determined that protein loading for subsequent 
activity assay experiments should be 20µg.  The crude fluorescence values for this calibration 
(≤160 relative light units (RLU)), is well within the linear range observed with the 
umbelliferone calibration (≤1500 RLU), and it is therefore appropriate to conclude that a 
proportional increase in protein loading (up to 20µg) yields a proportional mass of 
umbelliferone from the Rbm14-12 substrate due to AC activity, producing a proportional 
increase in fluorescence. 
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3.3.3.3 Chemotherapeutic inhibition of acid ceramidase activity 
 
 
Figure 3.15 – AC activity in HCT116 cells 2 hours after dosing with 2.5µM carmofur, compared to 
untreated cells.  Fluorescence was measured in triplicate samples with values adjusted for 
background fluorescence and then according to the untreated samples.  Mean values are plotted, 
with error bars representing one SD. 
 
AC activity in HCT116 cells 2 hours after dosing with 2.5µM carmofur was observed to be 
6.6% (+/- 4.6%) when compared to untreated cells as depicted in figure 3.15.  Statistical 
analysis was not undertaken as three independent experiments were not performed but the 
result was considered to represent sufficient evidence of AC activity inhibition in cells dosed 
with carmofur, to justify further experiments. 
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Figure 3.16 – Time profile of AC activity in HCT116 cells in response to dosing with 2.5µM carmofur.  
Fluorescence was measured in triplicate samples with values adjusted for background fluorescence 
and then normalised according to the 0-hour time point.  Mean values are plotted, with error bars 
representing one SD. 
 
Inhibition of AC activity was observed in HCT116 cells at the first time point, 30 minutes after 
incubation in 2.5µM carmofur (figure 3.16).  Maximal activity inhibition occurs at and after 2 
hours, with activity at 27.2% of baseline observed 3.5 hours after incubation.  AC activity 
seems to increase subsequently, although activity was significantly inhibited at all time 
points compared to baseline (p<0.001, one-way ANOVA followed by Tukey’s test). 
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a)                                                                       
b)  
Figure 3.17 – Drug dose responses of AC activity in HCT116 cells in relation to carmofur (a) and 5-FU 
(b).  Fluorescence was measured in triplicate samples at 2 hours, following incubation with the 
respective drugs at the determined concentrations.  Values were adjusted for background 
fluorescence, and then standardised relative to a vehicle control group (cells treated with 0.05% 
DMSO).  Mean values are plotted, with error bars representing one SD. 
 
The drug dose responses presented in figure 3.17 demonstrate the following observations.  
There was a significant increase in AC activity observed at very low dose carmofur incubation 
(0.001 and 0.01µM doses, p<0.001), which returned to baseline levels at 0.1µM incubation 
(p=0.988), when compared to the 0.05% DMSO vehicle control groups.  Higher carmofur 
concentrations at and above 1µM resulted in significant AC activity inhibition being 
observed, when compared to the control samples (p<0.001).  There was no statistically 
significant difference in AC activity inhibition between the 10µM and 25µM carmofur treated 
cell groups (p=0.724), therefore treatment above 10µM (which could equally be toxic) was 
considered excessive.  Statistical analysis of carmofur dose response here was performed 
using one-way ANOVA followed by Tukey’s test.  Incubation with 5-FU had no effect on AC 
activity at any of the investigated drug concentrations, with no significant differences 
between groups (p=0.738) on one-way ANOVA. 
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Figure 3.18 – AC activity profiles in relation to potentially therapeutic doses of carmofur.  HCT116 
cells were exposed to carmofur at doses of 2, 4 and 8µM concentrations respectively, and AC activity 
was measured at 2, 8 and 24 hours.  Fluorescence values obtained from triplicate measurements 
were adjusted according to the negative control sample, and then normalised to the fluorescence 
obtained from the 0.05% DMSO vehicle control sample taken at the respective time point.  Mean 
values have been plotted, and error bars represent one SD. 
 
The profiles of AC activity in HCT116 cells in the different carmofur concentration treatment 
groups follow the same pattern (figure 3.18), albeit with increasing inhibition of AC activity 
with increasing carmofur concentration.  Maximal inhibition of activity occurred at the 2-
hour time point in all treatment groups (39.3%, 24.7% and 20.6% with 2, 4 and 8µM carmofur 
respectively).  Subsequent AC activity began to return to that of control sample levels.  At 24 
hours post incubation with carmofur, AC activity had returned to baseline (0.05% DMSO 
vehicle control treatment group levels) in the 2µM carmofur treatment group but inhibition 
of activity persisted with 4 and 8µM treatment groups when compared to controls.  The 
experiment was not replicated, due to the logistical and financial constraints of using the 
activity assay, and therefore statistical analysis has not been undertaken – the pattern of 
response is consistent with previous experiments however, and appears to confirm optimal 
inhibition with carmofur to occur at or soon after 2 hours post incubation. 
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Figure 3.19 – The effect of combined chemotherapeutic dosing on AC activity in HCT116 cells.  
Carmofur and 5-FU were applied individually and in combination to treatment groups at 2µM 
concentration.  Measured fluorescence values pertaining to AC activity were adjusted to account for 
background controls and are normalised to the 0.05% DMSO vehicle control measurements 
obtained at the respective time points.  Plotted data points represent the mean of triplicate 
measurements, with error bars representing one SD. 
 
The profile of AC inhibition in HCT116 cells with carmofur is again comparable to other 
experiments (figure 3.19).  Application of 5-FU in isolation did not appear to significantly alter 
AC activity, nor did it appear to have a significant synergistic effect when combined with 
carmofur.  Peak inhibition of activity was observed at the 1.5-hour time point, and although 
activity was comparable to this at 3 hours, it would appear that inhibition of activity is 
beginning to reduce at this time.  The experiment was not replicated as the profiles of AC 
inhibition with carmofur are consistent with previous results, and for the logistical and 
financial constraints in using the activity assay, therefore statistical analysis has equally not 
been undertaken. 
There is slight variability in the time of peak inhibition with carmofur (observed by the results 
depicted in figures 3.16, 3.18 and 3.19) but is considered to overall represent that significant 
AC inhibition appears to be maximally present at and shortly after 2 hours following 
incubation. 
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3.3.3.4 Small interfering RNA inhibition of acid ceramidase activity 
 
 
Figure 3.20 – The effect of siRNA3 on AC activity in HCT116 cells.  AC activity was quantified at 24, 48 
and 72 hours subsequent to forward transfection with siRNA3 at 10nM.  Fluorescence values have 
been adjusted to account for background control results, and then normalised to the non-coding 
siRNA value for each time point.  Data points represent the mean of triplicate samples, with error 
bars representing one SD. 
 
Application of siRNA3 at 10nM final concentration, inhibits AC activity in HCT116 cells as 
depicted in figure 3.20.  This inhibition is evident at 24 hours but greater inhibition is 
observed at and after 48 hours (24.4% of the vehicle control activity), subsequent to which 
the effect appears to plateau.  Later time points were not assessed to determine when 
normalisation of activity inhibition occurs. 
Triplicate samples were obtained from different experiments at 72 hours following siRNA3 
transfection.  Mean AC activity in siRNA3 transfected groups was 15.5% of that observed in 
non-coding siRNA transfected groups (95% CI, 8.1-22.9%) at this time point, which is 
statistically significantly reduced (p<0.001).  There was no difference in AC activity between 
the non-coding siRNA transfected groups and untreated cells at this time point (100% vs 
88.6% respectively, p=0.18).  Statistical analysis has again been performed using one-way 
ANOVA followed by Tukey’s test. 
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3.4 Discussion 
 
 
3.4.1 Summary of Aims 
 
The aims of the experimental work presented were to establish inhibition of AC in the 
HCT116 CRC cell line, and to provide quantitative evidence of this inhibition.  siRNA 
transfection and pharmacological inhibition with carmofur were performed.  ASAH1 mRNA 
expression following siRNA transfection was quantified using RT-PCR, AC protein expression 
following transfection and drug dosing was assessed by Western blotting, and the functional 
effects of treatments were quantified using a direct AC activity assay.  Dosing parameters in 
terms of reagent concentrations and timing of application were profiled using the activity 
assay to determine optimal and maximal inhibition of AC in order to facilitate the further 
development of radio-sensitivity modelling in the cell line.  
 
 
3.4.2 Summary of Results 
 
ASAH1 mRNA expression on RT-PCR was initially used to determine that siRNA3 produced 
the greatest effect of the set of four siRNAs obtained.  Subsequent experiments produced 
consistent suppression of mRNA expression with use of siRNA3, and dosing parameters for 
the siRNA and Lipofectamine™ RNAiMAX were optimised.  A 10nM concentration of the 
siRNA in the final transfection mix was optimised, producing suppression of mRNA to 4.1% 
of that of an untreated cell population (p<0.001) 48 hours after transfection.   
The non-coding siRNA transfected cells also displayed reduced ASAH1 mRNA expression to 
40.4% of that of the untreated cell population (p=0.003) at 48 hours.  This was demonstrated 
to likely be due to the presence of Opti-MEM® Reduced Serum Medium, and not the other 
transfection reagents, and suggests this product is activating alternative pathways that are 
then affecting AC expression, for example apoptosis, growth arrest or senescence as 
discussed. 
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The effect of ASAH1 siRNA transfection was ultimately used to determine the specific bands 
that represent AC on Western blotting, in combination with appropriate positive control 
samples.  Reduced band expression was observed at ≈53kDa and ≈13kDa across the blots 
with the mouse monoclonal antibody from BD Biosciences (BD612302), representing the 
molecular weights of the precursor AC protein, and the α-subunit. The protein expression of 
AC following siRNA transfection was assessed semi-quantitatively with densitometry but not 
replicated sufficiently to allow for statistical analysis.  Interpretation of the densitometry 
analysis from the Western blots depicted in figures 3.10 and 3.12 however may suggest 
protein expression of AC 24 and 48 hours after transfection with siRNA3 to be 17.8% and 
7.6% respectively. 
Protein expression of AC subsequent to dosing with carmofur was also able to be assessed 
on Western blotting when relevant bands had been determined.  Alterations in band 
densities were potentially observed at ≈53 and ≈13kDa.  Densitometry expression of the 
13kDa subunit was 53.0%, 24.6%, 69.9% and 125.3% at 0.75, 1.5, 3 and 5 hours following 
2µM carmofur dosing in the HCT116 cells.  These data were not replicated sufficiently for 
statistical analysis but may represent carmofur interaction with the α-subunit of AC, and are 
consistent with the AC activity assay data. 
The functional effect of siRNA3 transfection and pharmacological inhibition of AC was 
quantified by direct activity assay.  The assay was validated for its use of umbelliferone as a 
fluorescent marker, and optimised in the HCT116 cells for protein loading.  A very strong 
linear correlation was observed between umbelliferone concentration and fluorescence on 
calibration (r=0.997, p<0.001), and between protein loading up to 20µg and fluorescence in 
assay optimisation (r=0.998, p<0.001). 
Maximal AC activity inhibition on assay was quantified at 15.5% of the vehicle control value 
72 hours following siRNA3 transfection (p<0.001).  Dosing the HCT116 cells with carmofur 
equally produced a significant AC activity inhibition of 15.2% albeit with a potentially toxic 
25µM concentration.  Activity inhibition with carmofur occurred maximally at or soon after 
2 hours following drug incubation dependent on the experimental run performed.  
Significant activity inhibition persisted 8 hours following drug incubation but had normalised 
by 24 hours with a 2µM carmofur dose.  5-FU produced no discernible inhibition of AC 
activity, and there was no additive effect of combined therapy. 
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3.4.3 Strengths and Limitations 
 
The data presented to demonstrate expression and activity of AC encompass genomic mRNA 
expression, protein expression and protein activity, i.e. from post-transcriptional to 
functional level.  There are consistencies both within and between the two treatment 
modalities applied to the HCT116 cells (siRNA transfection and pharmacological inhibition) 
from RT-PCR mRNA expression, protein expression on Western blotting, and protein activity 
on direct assay, thus providing cross-validation of the detection techniques as well as the 
methods of AC inhibition. 
RT-PCR produced reproducible data, and indicated significantly reduced ASAH1 mRNA 
expression with siRNA transfection.  Observed Ct values were consistent with abundant 
target nucleic acid in the samples, and the primers were specific without any product 
formation observed in negative control reactions, indicating reliability.  ASAH1 mRNA 
expression was not anticipated to change after pharmacological manipulation but was not 
assessed. 
The results observed are comparable to the limited literature evidence of siRNA inhibition of 
AC.  Morales et al (2007) demonstrated siRNA inhibition to reduce ASAH1 mRNA expression 
to 18% of control at 36 hours post-transfection in  the Hep-G2 hepatoma cell line, and Bedia 
et al (2011) demonstrated ASAH1 mRNA expression reduced to 15% of control at 72 hours 
in the A375 melanoma cell line, compared to 4% at 48 hours in this study.  Roh et al (2016) 
used short hairpin RNA instead of siRNA, and Elojeimy et al (2007) and Mahdy et al (2009) 
simply demonstrated reduced (non-quantified) AC expression on Western blotting without 
assessing mRNA expression. 
ASAH1 mRNA suppression was also observed significantly with non-coding siRNA 
transfection, although was significantly further suppressed in ASAH1 coding transfection.  
Given the data presented in figure 3.5, where comparable results were observed in 
transfection processes in the absence of either Lipofectamine™ RNAiMAX or siRNA, when 
compared to non-coding siRNA transfection, this would seem to be explained by the 
transfection process and in particular, the presence of Opti-MEM® Reduced Serum Medium. 
This is not reported in the Morales et al (2007) or Bedia et al (2011) studies where results 
are presented against a scrambled siRNA control in isolation.  One hypothesis to explain this 
finding may be due to the implicated involvement of ceramide in apoptosis, cell growth 
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arrest and senescence (Kolesnick and Fuks, 2003).   Reduced ASAH1 mRNA (and subsequent 
protein) expression would lead to intra-cellular ceramide accumulation, indicating a 
potential stress response to incubation with the reduced serum medium. 
Antibody specificity was an initial problem in identifying AC on Western blotting but was 
ultimately overcome with observation of reduced band density at the expected molecular 
weights with siRNA transfection, alongside positive control samples, and with the third 
antibody used.  Consequently, Western blotting was not performed in sufficient replicates 
to enable formal statistical analysis but qualitatively provided data consistent with RT-PCR 
and the activity assay. 
Reduced AC band density following inhibition with siRNA transfection can be explained by 
loss of translation due to reduced mRNA expression.  The reduced band density observed at 
13kDa and potentially 53kDa may be as a consequence of interaction of carmofur with the 
13kDa α-subunit in its precursor or active form.  This interaction may alter the molecular 
weight of a potential carmofur-AC molecule, or may competitively inhibit antibody binding 
and subsequent detection.  In a recent study (Dementiev et al, 2019), have characterised 
carmofur to contain an electrophilic carbonyl group that targets the catalytic cysteine 
residue on AC, forming a covalent complex. 
The approach to the AC activity assay was limited to some degree by the financial and 
logistical constraints in obtaining the Rbm14-12 substrate, and the experimental approach 
was therefore focussed to determine the timing of maximal inhibition following carmofur 
dosing, alongside refining a non-toxic but therapeutic dose.  Umbelliferone and protein 
loading calibrations were undertaken to internally validate the assay, which in itself is not a 
commercially available product, and has not been widely validated but produced consistent 
and seemingly specific results within and between experimental runs, and significant 
inhibition of AC activity was observed.  In the optimisation of the assay, Bedia et al (2011) 
demonstrate a linear response with up to 25μg of protein obtained from the FD1 fibroblast 
cell line over-expressing AC, consistent with my optimisation in the HCT116 cells, where a 
linear response was observed to 20μg. 
The inhibitory profile of carmofur on AC activity is also comparable to the results presented 
by Bedia et al (2011) in the SW403 colon and LNCaP prostate cancer cell lines, with significant 
activity inhibition between 45 minutes and 3 hours, reversal of activity inhibition by 12 hours, 
and maximal AC activity inhibition with a 3μM dose of carmofur at 30-40% of control activity.  
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There was equally no effect on AC activity with 5-FU in the cell lines in this study, consistent 
with the results observed in the HCT116 cells. 
 
3.4.4 Conclusion 
 
In relation to the hypotheses set at the origin of the chapter: 
 
• Expression of AC can be inhibited by siRNA transfection in the HCT116 CRC cell line, 
subsequently inhibiting protein activity – PROVEN 
 
Data has been observed to demonstrate significantly reduced; mRNA expression on RT-PCR, 
protein expression on Western blotting, and protein activity on direct assay.  The optimal 
concentration for transfection with siRNA3 is 10nM, with maximal inhibition of AC activity 
occurring from 48 following transfections.   
 
 
• AC activity +/- expression can be inhibited by the chemotherapeutic carmofur in the 
HCT116 CRC cell line – PROVEN 
Data has been observed to demonstrate significantly reduced; protein expression on 
Western blotting, and protein activity on direct assay.  Whilst maximal inhibition of AC 
activity was achieved with a 25µM dose, a non-toxic 2µM dose produced inhibition to ≈25% 
of baseline activity. 
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Chapter 4 
 
Development of an in vitro Model of Acid Ceramidase Dependent 
Sensitivity to Chemoradiotherapy in Rectal Cancer 
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4.1 Introduction 
 
 
4.1.1 Background 
 
4.1.1.1 Cell survival assays 
A colony forming (or clonogenic) cell survival assay is a technique that evaluates the ability 
of single cells to survive and reproduce, and is quantified by how many of a predetermined 
number of seeded cells in a plate go on to form colonies after 7-12 days.  The assay is 
considered as a gold standard for assessment of cell survival after exposure to cytotoxic 
agents, as it measures the sum of all modes of cell death, and accounts for delayed growth 
arrest (Mirzayans et al, 2007) due to the longer incubation period involved.  One limitation 
of the assay though is that it cannot measure the impact of cell-cell interaction on 
proliferation, as cells are plated at low density. 
Acute cytotoxicity can be measured with a number of non-clonogenic assays.  Enzyme 
release assays assess the activity of soluble, cytosolic enzymes in culture supernatant, 
released proportionally to loss of cell membrane integrity due to direct damage or cell death.  
The GAPDH release assay is considered amongst the most sensitive due to the coupled 
luminescent signal-amplification system yielding a strong signal for even small amounts of 
released enzyme (Corey et al, 1997), although no enzyme release assay provides insight into 
the mechanism underlying the observed cytotoxicity. 
Cell viability can be simply measured by the Trypan Blue exclusion method, as a direct 
measure of early cytotoxicity.  The stain permeates the membrane of dead cells but is 
excluded by living cells.  The traditional manual cell counting using a haemocytometer has 
been developed to allow for automated processes (Louis et al, 2011), although assessing this 
viability does not assess for reduced cell proliferation or survival. 
The major assays to quantify cell survival primarily use colourimetric methods to assess a 
single intracellular end point.  The ease, sensitivity, rapidity and low cost have made MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) or MTS (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assays amongst the 
most widely used for quantifying cytotoxicity in short-term cell cultures over a 24 to 96-hour 
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period (Sumantran, 2011).  MTT is a yellow tetrazole that is reduced to purple formazan in 
living cells (Mosmann, 1983).  MTS in the presence of phenazine methosulphate, produces a 
coloured formazan product which has an absorbance maximum at 490-500 nm, with 
measured absorbance of the formazan product being proportional to cell viability.  The 
solubility of the product reduces the need for detergents, and the rapid colour change and 
ease of storage make it desirable for this use (Buttke et al, 1993). 
Tetrazolium dye reduction is dependent on reduced nicotinamide adenine dinucleotide 
(NAD(P)H)-dependent oxidoreductase enzymes, largely in the cytosolic compartment of the 
cell, and is a measure of mitochondrial function.  Reduction of MTT or MTS therefore 
depends on cellular metabolic activity due to NAD(P)H flux (Berridge et al, 2005).  As well as 
reflecting the number of viable cells present, tetrazolium dye assays can also be used to 
quantify cytotoxicity or cytostatic activity.  The MTS assay is described as a 'one-step' MTT 
assay, offering the convenience of adding the reagent straight to cells in culture without the 
intermediate steps required in an MTT assay.  This convenience can be limited by 
colourimetric interference from traces of coloured compounds normally removed by the 
stages of the MTT assay but can be overcome by correlation with qualitative assessment 
using light microscopy (Cory et al, 1991). 
Cell death occurs either via apoptosis, as an energy-dependent and programmed process 
involving the activation of caspases, or by necrosis, as an energy-independent process often 
involving direct damage to the cell membrane.  Morphological and biochemical features of 
the two processes can overlap but cell death assays to detect both early and late features of 
apoptosis can determine that cell death is occurring via apoptosis (Elmore, 2007).  Early 
apoptosis can be assessed by detection of caspase activation, quantified sensitively and 
definitively by action on fluorescent or luciferin labelled substrates (Gurtu et al, 1997).  Later 
hallmarks of apoptosis are commonly assessed using flow and image cytometry, including 
assessment of mitochondrial transmembrane potential, DNA fragmentation, and plasma 
membrane alterations (Wlodkowic et al, 2011). 
The MTS assay was selected for convenience to be trialled in assessment of short-term 
cytotoxicity in chemotherapeutic dosing optimisation, and could potentially be employed 
alongside the gold-standard clonogenic assay to compliment assessment of survivability / 
reproducibility after cell irradiation. 
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4.1.1.2 Chemotherapeutic selection 
The original mass spectrometry data upon which this thesis is based, determining differential 
expression of AC to separate relative responders and non-responders to CRT, was 
undertaken in a group of patients that had all received 5-FU based chemotherapy with 
capecitabine as a radio-sensitiser.  It was therefore pertinent to assess in vitro whether any 
changes in response to irradiation, based upon genetic or pharmacological inhibition of AC, 
were equally dependent upon the presence of 5-FU.   
The work presented in chapter 3 details the optimisation of inhibition of AC in the HCT116 
CRC cell line, both genetically with siRNA, and pharmacologically with carmofur.  Carmofur 
was selected for this purpose as a known 5-FU prodrug, in addition to its observed potent 
inhibition of AC.  5-FU itself does not inhibit AC, therefore carmofur offers a potentially 
translational model of AC dependent sensitivity to CRT in rectal cancer. 
 
 
4.1.2 Hypotheses 
 
• HCT116 cell radio-sensitivity can be increased by the pharmacological inhibition of 
AC activity using the chemotherapeutic carmofur 
• HCT116 cell radio-sensitivity can be increased by the genetic suppression of AC 
expression (and subsequent activity) using siRNA transfection 
• Any increase in cell radio-sensitivity based on inhibition of AC is independent of the 
presence of 5-FU 
 
 
4.1.3 Aims and Study Design 
 
• Perform dose-response analysis in the HCT116 cells subsequent to exposure to 5-FU, 
capecitabine and carmofur, both individually and in combination 
o MTS assay to assess cell viability / survivability subsequent to 
chemotherapeutic exposure 
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• Establish the effect on TS in the HCT116 cells as the primary target for 5-FU based 
therapy, subsequent to exposure to 5-FU, capecitabine and carmofur 
o Western blotting for TS subsequent to chemotherapeutic exposure 
• Establish a dosing strategy that facilitates optimal inhibition of AC in the HCT116 cells 
at the point of irradiation, with consideration for chemotherapeutic radio-
sensitisation 
• Clonogenic assay and MTS assay to assess cell reproducibility and viability 
subsequent to exposure to irradiation 
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4.2 Methods 
 
 
4.2.1 MTS Assay 
 
Cell proliferation and viability in response to chemotherapeutic dosing was assessed using 
MTS assay.  20µL of MTS reagent (Promega) was applied to each experimental well on the 
96-well plates, to cells in culture 72 hours after exposure to treatment.  Plates were then 
incubated for two hours before absorbance at 490nm was measured using the Varioskan 
Flash.  Absorbance values were adjusted according to background control wells on each plate 
(culture medium without cells, at the same 200µL volume as added when seeding cells), and 
then normalised to absorbance from cell wells treated with 0.05% DMSO in culture medium 
as a vehicle control, to facilitate direct comparison. 
The dose-response on the basis of MTS assay in the HCT116 cells to capecitabine, 5-FU and 
carmofur was assessed primarily.  Optimisation experiments to define an appropriate range 
of concentrations for accurate determination of the IC50 was undertaken.  2,500 HCT116 cells 
in 200µL DMEM were seeded per well of a 96-well Nunc™ plate (Thermo Fisher Scientific) 
and incubated overnight to adhere.  The chemotherapeutics were dissolved in DMSO and 
mixed with DMEM, and this mixture was then exchanged for the existing culture medium in 
the wells of the plate thus dosing the adherent cells. 
Initial concentrations of 5-FU and carmofur resulted in the observation that the IC50 was likely 
to lie in the 2-8µM range, and therefore further experiments assessing the response to 1, 2, 
4, 8, and 16µM concentrations of these drugs was performed in triplicate wells in three 
independent experiments to establish an accurate IC50.  Capecitabine (molecular weight 
359.35g/mol, Sigma Aldrich) was applied to the HCT116 cells at a range of concentrations 
from 1-400µM but demonstrated no toxicity (see section 4.3.1 below) in three independent 
experiments and was therefore not considered further for use as a 5-FU based control in the 
experimental design. 
32mM stock concentrations of 5-FU (molecular weight 130.1g/mol, Sigma Aldrich) and 
carmofur (molecular weight 257.3g/mol, Sigma Aldrich) were prepared by dissolving 8.2mg 
of 5-FU in 1,970µL DMSO, and 10.5mg of carmofur in 638µL DMSO.  The 32mM stock 
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solutions were serially dilute 1:1 with DMSO to generate further concentrations of 16, 8, 4, 
and 2mM.  5µL of each of these solutions mixed with 5mL of DMEM produced 16, 8, 4, 2 and 
1µM concentrations of the drugs (final DMSO concentration 0.05%) which were applied to 
adherent cells in the 96 well plates in triplicate wells in three independent experiments. 
Combined application of carmofur and 5-FU was also assessed, in parallel to designing the 
clonogenic model.  This was in attempt to establish an equivalent control effect of 5-FU, 
under the assumption that the 5-FU based effect of carmofur and 5-FU itself are not 
necessarily equivalent.  2.5µL of the same concentration drug solution (i.e. 2.5µL of 32mM 
5-FU and 2.5µL of 32mM carmofur) was combined in 5mL DMEM for the 32, 16, 8 and 4mM 
stock solutions, generating combined 8, 4, 2 and 1µM solutions with a final 0.05% DMSO 
concentration.  5µL of each 32mM stock in 5mL culture medium produced a combined 16µM 
concentration but with a final 0.1% DMSO concentration.  Adherent cells in triplicate wells 
were again dosed with these concentrations in three independent experiments. 
 
 
4.2.2 Clonogenic Model Development 
 
The fundamental basis for the development of the clonogenic model surrounds AC inhibition.  
It was considered that for the treatment groups in the model, exposing cells to irradiation at 
the point of maximal inhibition of AC was a reasonable starting point.  Pharmacological 
inhibition of AC activity has been observed in chapter 3 to return to baseline 24 hours after 
dosing.  Although the clonogenic assay was planned to run for 7-12 days, and that ongoing 
pharmacological AC activity inhibition would therefore not be maintained, it was considered 
that re-dosing cells at seeding in the clonogenic plates, or that re-dosing the seeded cells 
over the course of the clonogenic assay risked affecting the outcome significantly, either by 
altering the ability of the cells to adhere in the clonogenic plate, or by washing cells or 
colonies away.  Equally cells should enter apoptosis within this 24 hour period, and re-dosing 
should not be necessary.  The effect of siRNA inhibition of AC on activity was observed in 
chapter 3 to persist maximally 72 hours subsequent to transfection, and therefore ongoing 
significant AC inhibition in these treatment groups, which may potentially affect sensitivity 
to irradiation, would be likely.  The application of pharmacological manipulation could be 
further optimised if needed, dependent on these results. 
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Given the original proteomic data separating relative responders and non-responders to CRT 
was in the context of radio-sensitisation with 5-FU based capecitabine, it was considered that 
it would be prudent to incorporate 5-FU treatment into the modelling.  Genetic inhibition of 
AC with siRNA, and pharmacological inhibition of AC with carmofur was planned to be 
compared both against and in combination with standard 5-FU radio-sensitisation.  This 
design allows potentially for any AC inhibition specific radio-sensitivity differences to be 
observed over and above any benefit from the modelled standard 5-FU control treatment.  
The resultant 11 experimental treatment groups, including vehicle controls for both 
transfection and pharmacological manipulation, are detailed in table 4.1 below. 
 
Genetic Manipulation (siRNA) Pharmacological Manipulation  
ASAH1 siRNA Non-coding siRNA Chemotherapeutic Control 
+ Media 
(3,M) 
+ Media 
(NC,M) 
Carmofur 
(C) 
Media 
(M) 
+ DMSO 
(3,D) 
+ DMSO 
(NC,D) 
5-fluorouracil 
(5) 
DMSO 
(D) 
+ 5-fluorouracil 
(3,5) 
+ 5-fluorouracil 
(NC,5) 
Carmofur + 5-fluorouracil 
(C,5) 
 
Table 4.1 – Experimental treatment groups to compare genetic and pharmacological manipulation of 
AC as radio-sensitisation in an in vitro clonogenic based model, incorporating 5-FU as a standard 
treatment control, and vehicle controls for transfection and chemotherapeutic application. 
 
The concentration / volume of transfection reagents was optimised as described in section 
3.3.  The concentrations for pharmacological treatment required determination and 
potential further optimisation but a 2µM concentration of carmofur and 5-FU was selected 
initially in the clonogenic model for the following reasons. 
Administration of this concentration of the drugs either individually or in combination 
demonstrated no significant variation in proliferation/viability of the HCT116 cells on MTS 
assay compared to vehicle control (as demonstrated later in figure 4.8), whereas higher 
individual concentrations decreased cell proliferation, and increasingly so when combined.  
3µM 5-FU is considered to be a biologically equivalent concentration to that observed in 
plasma in the clinical setting in patients receiving 5-FU in CRT (Spitzner et al, 2010) - 2µM is 
a reasonably similar concentration, and the intention is for a 5-FU based effect in this model 
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to be that of radio-sensitisation, and not for it to directly affect viability.  Carmofur was 
equally observed to significantly decrease AC activity in the HCT116 cells at a concentration 
of 2µM (as described in section 3.3.3.3). 
The experimental plan, as depicted in figure 4.1 below, was therefore designed.  Cells would 
be originally seeded at 2x105 in 2mL culture medium in individual 35mm CellBIND® cell 
culture dishes (Corning®, New York, USA), and incubated overnight to adhere.  Transfection 
would be undertaken in pertinent groups, with irradiation planned two days later to facilitate 
maximal inhibition of AC at that point.  Cell groups not undergoing transfection would remain 
incubated in culture for this time.  The media in all groups would be changed two hours prior 
to irradiation to deliver the desired pharmacological treatment, to optimise inhibition of AC 
activity with carmofur at the point of irradiation, and to establish an equivalent volume of 
culture medium in each plate at irradiation. 
Cell irradiation was undertaken in a different laboratory.  To facilitate this process the cells 
in their individual lidded dishes were placed on ice, covered, and transported (walked) to the 
irradiator.  The individual dishes were removed from ice briefly to undertake the desired 
irradiation, and placed back on ice before being transported back to the parent laboratory 
for cell resuspension, counting and re-seeding into the clonogenic plates. 
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Figure 4.1 – A schematic demonstrating the experimental process undertaken to assess irradiation 
response in the HCT116 cells across all treatment groups.  The process was designed to facilitate 
irradiation delivery at the point of maximal AC activity inhibition.  Cells were initially seeded in 
individual 35mm cell culture dishes and incubated overnight to adhere.  siRNA (final concentration 
10nM) transfection was undertaken (siRNA3 and non-coding control) after 24 hours in relevant cell 
groups by adding the transfection mix to the dishes, whereas pharmacologically-only treated groups 
(not undergoing transfection) remained in culture.  At 72 hours the respective pharmacological 
treatments (including 0.05% DMSO vehicle controls) were applied to the cells in both groups, 
undertaken by exchanging the existing culture medium for dosed DMEM.  In those groups where a 
pharmacological treatment was not applied, the culture medium was equally exchanged at this 
point.  Following incubation with the pharmacological treatments for two hours, the cells in the 
dishes were placed on ice and irradiated across the range of experimental doses, then re-seeded 
into 6-well cell culture plates for the clonogenic assay.  Formed cell colonies were fixed and stained 
in the plates after incubation for 9 days, and subsequently counted. 
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4.2.3 Cell Counting and Plate Seeding 
 
It was crucial that seeding of the clonogenic plates particularly was performed as accurately 
as possible.  The specific procedure undertaken for cell counting and plate seeding is 
therefore described.   
The range of treatments to be assessed on clonogenic and MTS proliferation assays were 
applied to adherent cells in 35mm cell culture dishes.  Subsequent to irradiation, the cells in 
each dish were collected and re-suspended as described in section 3.2.1 but using 1mL of 
each respective reagent, and taking care to re-suspend all possible cells.  The resultant 1mL 
of DMEM containing the re-suspended cells was added to a further 4mL of DMEM and 
appropriately mixed.  A 100µL aliquot of this 5mL cell suspension was then mixed with 100µL 
of 0.4% trypan-blue (Sigma-Aldrich), and a further aliquot of this resultant mixture applied 
to a haemocytometer under a cover slip as depicted in figure 4.2.   
 
             
Figure 4.2 – Haemocytometer cell counting performed for the determination of accurate plate 
seeding.  The left side of the figure depicts the haemocytometer grid (adapted from 
https://en.wikipedia.org/wiki/File:Haemocytometer_grid.svg), with a corner square representing 
1x1mm (and containing a further 4x4 grid) highlighted in red.  The right side of the figure 
demonstrates a near-complete image of this 1x1mm square taken from a performed cell count.  An 
aliquot of cells in suspension and appropriately mixed, is mixed 1:1 with 0.4% trypan-blue and 
applied to the haemocytometer under a cover slip at 0.1mm depth.  Cells are counted in each of the 
four corner 1x1mm squares, the total count divided by 4, and this number (representing the number 
of cells in 100nL) multiplied by 20,000 (as the original cell solution was diluted 50:50 with trypan-
blue) to give the cell count per mL of the original suspension.  In the demonstrated image, 7 live cells 
(seen as white dots, where trypan-blue has not permeated the cell membrane) can be observed. 
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A manual cell count was performed by counting observed live cells in each of the four 1x1mm 
corner squares on the haemocytometer.  The total live cell count was divided by 4 to 
represent the number of live cells in 100nL of the cell/trypan-blue mixture, and this number 
was multiplied by 20,000 to give the live cell count per mL of the 5mL cell suspension. 
Once the live cell count of the 5mL cell suspension had been calculated, further calculations 
were performed to ascertain the required volumes of this suspension to be diluted for 
seeding the 6-well Nunc plates for the clonogenic assay, and the 96-well Nunc plates for the 
MTS proliferation assay. 
Seeding for the clonogenic assay was optimised by irradiation of untreated HCT116 cells (as 
described in section 4.2.6), and related to the radiation dose administered as demonstrated 
in table 4.2 below, to account for reduced plating efficiencies with higher doses. 
 
Irradiation Dose (Gy) 
Clonogenic Plate Seeding (cells/well 
on a 6-well plate) 
0 200 (x3) & 400 (x3) 
0.5 200 (x3) & 400 (x3) 
1 400 (x3) & 800 (x3) 
2 400 (x3) & 800 (x3) 
4 800 (x3) & 1,600 (x3) 
 
Table 4.2 – Seeding of the clonogenic assay plate.  A 6-well cell culture plate was seeded at two 
densities (each in triplicate) for each treatment group at each irradiation dose.  The seeding was 
determined from the colony count (surviving fraction) observed with untreated HCT116 cells 
irradiated at that dose. 
 
The 5mL cell suspension was mixed again prior to diluting the required volume (to account 
for the lower of each paired seeding number for that irradiation dose to be present per mL) 
in a final volume of 20mL DMEM.  After further mixing, 1mL of this final volume was added 
with 1mL of DMEM in triplicate to a 6-well cell culture plate, and 2mL of this final volume 
was added in triplicate to the remaining wells.  This allowed for the required seeding 
numbers to be present in triplicate in a volume of 2mL culture medium per well on each 
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plate.  The plate was gently swirled to distribute the cells in the culture medium prior to 
undisturbed incubation at 37°C and 5% CO2 for nine days. 
The 96-well MTS proliferation assay plate was seeded in triplicate at 2,500 cells per well, 
irrespective of irradiation dose for each treatment group.  The 5mL cell suspension was again 
mixed, prior to diluting a volume calculated to contain 62,500 cells in a final 5mL volume of 
culture medium.  This final volume was mixed before pipetting 200µL (containing 2,500 cells) 
in triplicate on the 96-well plate, which was subsequently incubated under the same 
conditions as above for three days. 
 
 
4.2.4 Colony Staining 
 
The duration of incubation for the clonogenic assay was optimised in non-irradiated and 
untreated HCT116 cells, and was determined to be nine days.  After this time colonies were 
observed to become increasingly confluent, and accurate interpretation of the clonogenic 
assay would not have been possible. 
To stain the clonogenic plates, the culture medium in each well was aspirated, and the wells 
gently washed individually with 1mL of cold PBS.  The wash was aspirated, prior to the 
addition of 1mL of cold methanol to fix the colonies, which was left for 15 minutes.  This was 
then aspirated, before 1mL of a 0.5% crystal violet solution was added as a stain.  After a 
further 15 minutes, the excess stain solution was aspirated before the plate was washed in 
a water bath, and then left to air dry.  Each aspiration was performed by the careful 
introduction of a pipette tip at the 6 o’clock position of the well whilst tipping the plate 
towards that point, and the careful addition of each reagent was performed at the same 
point, again whilst tipping the plate.  It was observed that this technique did not result in cell 
colonies being washed away. 
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4.2.5 Colony Counting 
 
Colony counting was undertaken using the GelCount™ (Oxford-Optronix, Abingdon, UK) 
automated colony counter, which facilitates consistent analysis and counting across multiple 
plates.  The system acquires a digital image of the clonogenic plate, which is then analysed.  
Colony detection parameters (predominantly colony size, density and shape) were optimised 
and integrated into the Compact Hough and Radial Map (CHARM™) processing algorithm at 
the outset, to detect colonies of more than 50 cells that had been characterised initially 
under light microscopy. 
The areas of the 6-well plates analysed was also defined at the outset by a designated ‘mask’, 
based on the specification of the loaded plate, such that the entire area of each well on the 
plate is encompassed.  This was visually checked for each analysed plate, and corrected if 
minor adjustments were required based on slight variation of the position of the plate in the 
GelCount™ scanner at the point of image acquisition.  Figure 4.3 demonstrates these 
processes in one of the experimental clonogenic plates. 
 
      
Figure 4.3 – Colony detection using the GelCount™ automated colony counter.  The image on the 
left depicts the digitally acquired image obtained by the system and demonstrates a single well from 
one of the 6-well experimental plates used.  The section of the area highlighted by the red box (as 
magnified in the right side of the figure) demonstrates the automated analysis of the digital image.  
A ‘mask’ is applied to the image (as demonstrated by the circumferential green line) to determine 
the areas for analysis in relation to the specification of the plate loaded, encompassing the area of 
each well individually.  CHARM™ settings are then optimised based primarily on cell colony density 
and for the size of colonies for detection, and the system identifies the colonies (as demonstrated by 
the red triangles, with each triangle counting as one colony) within the designated ‘mask’ for each 
experimental well. 
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As can be observed in the right-sided image in figure 4.3, insignificant debris within the well 
is not identifed.  The pre-determined settings allow for consistent analysis across multiple 
plates. 
 
 
4.2.6 Cell Irradiation Delivery 
 
Cells in culture were subjected to radiation using the CellRad (Faxitron, Tucson, Arizona, USA) 
benchtop irradiator.  The irradiator delivers a consistent beam of x-rays across a 30cm 
diameter field, although all cells in our experiments were irradiated in 35mm tissue culture 
dishes placed in the same position at the centre of the field.  Equivalent irradiation doses are 
achieved with the irradiator between experimental runs due to the internal calibration of 
the system, and the ability to programme delivery of a desired dose.  A dose rate of 3 Gy/min 
was used throughout. 
Optimisation of irradiation dosing was performed at 0, 0.5, 1, 2, 4 and 8Gy in HCT116 cells in 
culture (results not presented), with negligible colony formation following 8Gy irradiation, 
and minimal reduction in surviving fraction at 0.5Gy.  Experimental treatment groups were 
therefore exposed to 0, 1, 2 and 4Gy irradiation, although the model was later refined to 
include a 0.5Gy irradiation dose in selected groups, when it became apparent that radiation 
specific differences were more likely to be observed at this dose in the experimental groups. 
 
 
4.2.7 Western Blotting for Thymidylate Synthetase 
 
Western blotting was performed as described in section 3.2.4, albeit with the use of an HRP-
conjugated anti-TS primary antibody (ab198599, rabbit monoclonal, Abcam) at a final 
concentration of 1:5000 as per the manufacturer’s instruction 
(http://www.abcam.com/thymidylate-synthase-antibody-epr4545-hrp-ab198599.html), 
and obviating the need for incubation with a HRP-conjugated secondary antibody. 
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4.2.7.1 Experimental conditions investigated on Western blotting 
The MTS proliferation data assessing drug dose response to 5-FU and carmofur (as described 
in section 4.3.1) was observed to demonstrate that a 2µM incubation with each drug did not 
result in significant toxicity in HCT116 cells.  Significant AC activity inhibition occurred in the 
cells with carmofur (as described in section 3.3.3.3) at this concentration, and therefore it 
was considered that 2µM was the optimal dose of the drugs to take forward for the 
modelling of AC dependent sensitivity to CRT.  It was considered prudent to assess the effect 
of the drugs at this concentration on their primary target (TS) in attempt to demonstrate an 
approximation of their 5-FU based effect, and therefore isolate any AC specific effect. 
HCT116 cells were seeded in 6-well Nunc plates at a density of 1x106 and allowed to adhere 
overnight.  The cells were then incubated with a 2µM concentration of carmofur or 5-FU in 
DMEM, alongside untreated cells and 0.05% DMSO vehicle control groups, with samples at 
1, 2, 4, 8, 16, and 24 hours following incubation, collected and processed as described in 
section 3.2.4. 
 
 
4.2.8 Post-Clonogenic Evaluation of Treatment Group Characteristics 
 
Subsequent to performing clonogenic assay across all treatment groups and over the range 
of irradiation doses, it was observed on the basis of the baseline (0Gy) surviving fraction that 
there were likely fundamental differences between pre-irradiation treatment groups; ASAH1 
siRNA transfected vs. non-coding siRNA transfected vs. non-transfected (see section 4.3.4 
below).  The original hypotheses did not encompass this eventuality but it was considered 
that further investigation of these differences was valid.  It was further hypothesised that 
the differences observed could relate to cell proliferation rate, the ability to adhere as 
individual cells in the clonogenic plate on re-seeding, apoptotic predisposition, or to a 
combination of these factors. 
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4.2.8.1 Evaluation of cell proliferation 
Data concerning cell proliferation to the point immediately after delivery of irradiation had 
already been collected in a surrogate capacity, when the cells were re-suspended and 
counted upon re-seeding into the clonogenic plates.  2x105 cells had been plated at the 
outset in all groups, with the only significant variability between treatment groups being the 
application of the transfection reagents 48 hours prior.  The observed cell counts at this point 
therefore reflected the effect of application of siRNA3 transfection vs. siRNA-NC transfection 
vs. no transfection. 
It was considered that evaluation of proliferation subsequent to re-seeding after transfection 
was more pertinent.  This data had also been collected in a surrogate capacity on MTS assay 
in the non-irradiated cell groups, with the crude absorbance values obtained at 72 hours 
being directly comparable between groups. 
In attempt to validate this surrogate data, a further post-transfection assessment of 
proliferation was undertaken in a HCT116 cell population that had undergone plasmid 
transfection to stably express luciferase under the influence of Zeocin™.  This cell line had 
been validated to exhibit luminescence proportional to cell viability in the presence of 
luciferin (data not provided) and was generously provided by Mr Jonathan Evans, 
Department of Molecular and Clinical Cancer Medicine, The University of Liverpool.  
Quantification of luminescence (to reflect viability) in this cell population over time, both 
with and without transfection, would assess proliferation in the different treatment groups. 
2x105 luciferase expressing HCT116 cells were seeded into 6-well Nunc cell culture plates in 
2mL DMEM and incubated overnight to adhere.  ASAH1 siRNA transfection and non-coding 
siRNA transfection (as previously described) was undertaken in two wells respectively, with 
a third non-transfected well remaining.  48 hours subsequent to transfection, the cells in all 
experimental groups were individually re-suspended and re-seeded at 2,500 cells per well 
into white-bottomed 96-well cell culture plates (Sigma-Aldrich) in 200µL culture medium in 
triplicate. 
A stock solution of VivoGlo™ firefly luciferin (Promega, Southampton, UK) was created by 
diluting the purchased powder to 15mg/ml in 1x PBS.  This stock solution was further diluted 
100-fold to 150µg/ml in DMEM and 100µl added to the cells in culture on parallel plates at 
0, 27, 53 and 72 hours subsequent to re-seeding.  Plates were incubated at 37°C for 2 hours 
before luminescence was quantified using the Varioskan Flash.  Results were adjusted for 
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background luminescence from negative control wells (culture medium without cells), and 
three independent experiments were performed. 
 
4.2.8.2 Evaluation of caspase 3/7 activity 
The execution phase of apoptosis is characterized by the activation of effector caspases, such 
as caspase-3 and caspase-7, which cleave key regulatory or structural proteins and in 
particular activate apoptotic nucleases (Vaughan et al, 2002).  The Caspase-Glo® 3/7 assay 
(Promega) provides a luminogenic caspase 3/7 substrate, which when added to adherent 
cells or those in suspension results in cell lysis, followed by caspase cleavage of the substrate, 
and generation of luminescent signal produced by luciferase.  The assay substrate is specific 
for caspase 3/7, and luminescence observed is proportional to caspase activity (Bayascas et 
al, 2002).  Caspase 3/7 activity in ASAH1 siRNA transfected, non-coding siRNA transfected 
and non-transfected cell populations could therefore indicate apoptotic predisposition. 
2x105 HCT116 cells were seeded into 6-well cell culture plates in 2mL culture medium, and 
incubated overnight to adhere.  ASAH1 siRNA transfection and non-coding siRNA 
transfection (as previously described) was undertaken in two wells respectively, with a third 
non-transfected well remaining.  48 hours subsequent to transfection, the cells in all 
experimental groups were individually re-suspended and re-seeded at 10,000 cells per well 
into white-bottomed 96-well cell culture plates in 100µL culture medium in triplicate.  100µL 
of Caspase-Glo® 3/7 reagent (reconstituted as per manufacturer’s instruction) was added to 
each well on parallel plates at 0, 2.5, 7 and 24 hours subsequent to re-seeding.  Plates were 
incubated at 37°C for 2 hours before luminescence was quantified using the Varioskan Flash.  
Results were adjusted for background luminescence from negative control wells (culture 
medium without cells), and three independent experiments were performed. 
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4.2.9 Statistical Analysis 
 
IC50 values were calculated with GraphPad Prism version 5 (GraphPad Software Inc., La Jolla, 
California, USA), using nonlinear regression modelling of ‘log(inhibitor) vs. response’. 
Other statistical analysis was undertaken using SPSS® Statistics version 22 (IBM®, New York, 
USA), with specific tests used as detailed in the relevant sections. 
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4.3 Results 
 
 
4.3.1 MTS Assay – Chemotherapeutic Dose-Response 
 
 
Figure 4.4 – Dose-response to capecitabine in HCT116 cells, evaluated on MTS proliferation assay.  
Absorbance at 490nm was quantified from triplicate samples in three independent experiments, 72 
hours after dosing with the demonstrated range of concentrations of the drug.  Data was adjusted to 
account for background absorbance and has been normalised to absorbance of vehicle control 
samples (0.05% DMSO).  Mean values are plotted with error bars representing one SD. 
 
No toxicity was observed subsequent to dosing with capecitabine in the HCT116 cells, even 
at a maximal concentration of 400µM.  An IC50 value is therefore not presented. 
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Figure 4.5 – Dose-response to 5-FU in HCT116 cells, evaluated on MTS proliferation assay.  
Absorbance at 490nm was quantified from triplicate samples in five independent experiments, 72 
hours after dosing with the demonstrated range of concentrations of the drug.  Data was adjusted to 
account for background absorbance and has been normalised to absorbance of vehicle control 
samples (0.05% DMSO).  Mean values are plotted with error bars representing one SD. 
 
Toxicity was observed in the HCT116 cells subsequent to dosing with 5-FU at concentrations 
above 2µM.  The IC50 for the drug is calculated to be 5.48µM (95%CI 4.11-7.31, R2=0.875). 
 
 
Figure 4.6 – Dose-response to carmofur in HCT116 cells, evaluated on MTS proliferation assay.  
Absorbance at 490nm was quantified from triplicate samples in five independent experiments, 72 
hours after dosing with the demonstrated range of concentrations of the drug.  Data was adjusted to 
account for background absorbance and has been normalised to absorbance of vehicle control 
samples (0.05% DMSO).  Mean values are plotted with error bars representing one SD. 
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Toxicity was observed in the HCT116 cells subsequent to dosing with carmofur at 
concentrations above 2µM.  The IC50 for the drug is calculated to be 7.48µM (95%CI 5.96-
9.38, R2=0.843). 
 
   
Figure 4.7 – Dose-response to combining carmofur and 5-FU in HCT116 cells, evaluated on MTS 
proliferation assay.  Absorbance at 490nm was quantified from triplicate samples in five 
independent experiments, 72 hours after dosing with the demonstrated range of concentrations of 
the drugs in combination.  Data was adjusted to account for background absorbance and has been 
normalised to absorbance of vehicle control samples (0.05% DMSO).  Mean values are plotted with 
error bars representing one SD. 
 
Toxicity was observed in the HCT116 cells, subsequent to dosing with combination carmofur 
and 5-FU, at concentrations of each drug above 2µM.  The IC50 when combining the drugs is 
calculated to be 3.95µM for each drug (95%CI 3.64-4.29, R2=0.930). 
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Figure 4.8 – Dose-response profiles of 5-FU, carmofur, and carmofur & 5-FU, evaluated on MTS 
proliferation assay.  The graph depicts the data presented in figures 4.5, 4.6 and 4.7 to facilitate 
direct comparison. 
 
The dose-reponse to application of 5-FU and carmofur to HCT116 cells individually is 
observed to be comparable, both graphically as demonstrated in figure 4.8 and on the basis 
of overlapping 95% CI for their IC50 values (4.11-7.31µM and 5.96-9.38µM respectively).  The 
IC50 value for combined application of the drugs is lower (3.95µM), although a comparable 
effect is observed between the drugs individually and in combination at a concentration of 
2µM.  The effect of treatment at this 2µM concentration is not statistically significantly 
different between any groups or in relation to baseline (p=0.465, one-way ANOVA). 
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4.3.2 Western Blotting for Thymidylate Synthetase 
 
 
Figure 4.9 – Whole membrane film of a Western blot performed on a 10% SDS-PAGE gel, with 
ab198599 (Abcam, RabMAb®, rabbit monoclonal) anti-TS primary antibody at a concentration of 
1:5000.  The green dots represent the position of the bands from the molecular weight marker, as 
per the weights depicted to the right of the film.  The grouped bands from 0.05% DMSO vehicle 
control samples, 2µM carmofur treated samples, and 2µM 5-FU treated samples, were obtained at 
2, 8 and 24 hours following incubation in each group from left to right respectively in HCT116 cells.  
M represents untreated cells incubated in culture medium only. 
 
The film imaged in figure 4.9 demonstrates excellent specificity for a band at ≈36kDa at the 
predicted molecular weight for TS.  A single band is observed in untreated and vehicle control 
treated samples, whereas the band is duplicated in HCT116 cells treated with carmofur 
collected 8 and 24 hours after incubation with the drug, and equally in samples treated with 
5-FU collected 2, 8 and 24 hours after incubation with the drug.  This duplication indicates 
some effect with drug treatment, presumably due to binding of the drug metabolite to TS 
with a shift in its mobility and subsequent increase in protein stability.  The fact this alteration 
is observed only in 5-FU and carmofur treated samples would further validate the observed 
band to be TS. 
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Figure 4.10 – Band specific films of Western blots performed on a 10% SDS-PAGE gel, with ab198599 
(Abcam, RabMAb®, rabbit monoclonal) anti-TS primary antibody at a concentration of 1:5000.  The 
top film represents TS expression (at 36kDa) in HCT116 cells at 1, 2, 4, 8, 16, and 24 hours (from left 
to right respectively in the yellow bracketed bands) subsequent to incubation with 2µM 5-FU, 
compared to expression subsequent to incubation with 2µM carmofur at the same time points (from 
left to right respectively in the green bracketed bands) in the middle film.  The 0.05% DMSO vehicle 
control treated cell samples and untreated culture medium only cell sample (M) are those as 
described in figure 4.9.  Can represents a rectal cancer sample obtained from the original proteomic 
profiling known to have relatively high AC expression.  A β-actin reference band was obtained for the 
carmofur treated samples blot. 
 
Quantitative assessment of the expression of the bands in either figure 4.9 or 4.10 has not 
been undertaken, as a β-actin reference band to normalise protein loading is not universally 
present.  Qualitative assessment of the β-actin band in figure 4.10 would suggest equivalent 
protein loading however.  The functional effect of carmofur and 5-FU on TS expression can 
be observed by the duplication of the bands in the experimental cell samples.  This is 
observed to occur in the 5-FU treated cells 1 hour after incubation and persists to 24 hours.  
Duplication of the band is only faintly observed in the cell sample collected 2 hours after 
incubation with carmofur but again persists thereafter to 24 hours.  The effect on TS of the 
two drugs therefore seems to occur earlier in treatment with 5-FU.  Any potential observed 
increase in radio-sensitivity on clonogenic assay in AC inhibited cells irradiated 2 hours after 
application of a non-toxic dose of carmofur with or without 5-FU, could be argued to be 
independent of the effect on TS. 
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4.3.3 Clonogenic Assay – Post-Irradiation / Acid Ceramidase Inhibition 
 
 
Figure 4.11 – HCT116 cell colonies observed after irradiation (0-4Gy) in the pharmacological 
manipulation arm of the AC dependent model of sensitivity to CRT.  Colony formation was assessed 
9 days after plate seeding, subsequent to irradiation and prior pre-irradiation manipulation of AC 
activity with carmofur.  The treatment groups are those as defined in table 4.1.  The surviving 
fraction for each irradiation dose has been normalised to the non-irradiated (0Gy) control for the 
respective pre-irradiation treatment, to facilitate direct comparison of any radiation specific effect.  
Results are the means of three independent experiments. 
 
The surviving fraction (colonies formed / cells seeded) in all pharmacological treatment 
groups is observed to reduce with increasing radiation dose.  The surviving fraction at 4Gy 
irradiation (normalised to the non-irradiated control for the respective pre-irradiated 
treatment) ranges from 0.010 (M) to 0.022 (C), and as such represents an insignificant 
number of surviving cells to detect a meaningful variation between pre-irradiation 
treatment.  A similar effect is observed at 2Gy irradiation, where the normalised surviving 
fraction ranges from 11.7% (M) to 19.6% (D), and representing crude surviving fractions ≈5-
10%.  At 1Gy irradiation the range of normalised surviving fractions is observed to be even 
closer between pre-irradiation treatment groups (46.7% (C) to 54.4% (C,5)).  Error bars are 
not presented in figure 4.11 as there were no statistically significant differences between 
groups, and to facilitate ease of interpretation. 
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Figure 4.12 – HCT116 cell colonies observed after irradiation (0-4Gy) in the genetic manipulation arm 
of the AC dependent model of sensitivity to CRT.  Colony formation was assessed 9 days after plate 
seeding, subsequent to irradiation and prior pre-irradiation manipulation of AC activity with siRNA3.  
The treatment groups are those as defined in table 4.1.  The surviving fraction for each irradiation 
dose has been normalised to the non-irradiated (0Gy) control for the respective pre-irradiation 
treatment, to facilitate direct comparison of any radiation specific effect.  Results are the means of 
three independent experiments. 
 
The surviving fraction in the genetic manipulation arm of the clonogenic assay is observed to 
reduce in all treatment groups with increasing radiation dose.  An insignificant normalised 
surviving fraction is observed at 4Gy irradiation, with a range from 0.011 (NC,5) to 0.015 
(3,5), and also at 2Gy irradiation, where the range of normalised surviving fractions is 
observed to be 0.073 (NC,5) to 0.139 (NC,D).  A wider range of surviving fraction from 0.285 
(NC,5) to 0.471 (NC,M) at 1Gy is observed when compared with the corresponding results 
from the pharmacological pre-irradiation treatments presented in figure 4.11.  It was for this 
reason that further investigation utilising 0.5Gy was undertaken - the range of normalised 
surviving fraction observed at this radiation dose was 0.505 (3,5) to 0.759 (NC,5).  Error bars 
are not presented in figure 4.12 to facilitate ease of interpretation but a more detailed 
analysis of surviving fractions at 1Gy and 0.5Gy irradiation doses is presented in figures 4.13 
and 4.14 below. 
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Figure 4.13 – Box-and-whisker plots demonstrating the surviving fraction at 1Gy irradiation, across 
all experimental treatment groups investigated on clonogenic assay.  Results have been normalised 
to the non-irradiated (0Gy) control for the respective pre-irradiation treatment to facilitate direct 
comparison of any radiation specific effect.  The treatment groups are those as defined in table 4.1. 
 
The graph in figure 4.13 represents a direct comparison of the outcome of all experimental 
treatment groups at 1Gy irradiation assessed by clonogenic assay.  The lowest normalised 
surviving fraction is 0.285 in the NC,5 treatment group, with the highest being 0.544 in the 
C,5 treatment group.  On Kruskal-Wallis analysis there was no statistically significant 
difference across all treatment groups (p=0.167). 
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Figure 4.14 – Box-and-whisker plots demonstrating the surviving fraction at 0.5Gy irradiation, across 
all transfected treatment groups investigated on clonogenic assay.  Results have been normalised to 
the non-irradiated (0Gy) control for the respective pre-irradiation treatment to facilitate direct 
comparison of any radiation specific effect.  The treatment groups are those as defined in table 4.1. 
 
The graph in figure 4.14 represents the observed normalised surviving fractions for the 
transfected treatment groups, where further investigation at 0.5Gy irradiation was 
undertaken.  The lowest observed normalised surviving fraction is 0.505 in the 3,5 group, 
and a statistically significant difference between all groups was identified on Kruskal-Wallis 
analysis (p=0.048).  On pairwise comparison 3,5 was significantly lower than 3,M (0.737, 
p=0.027), NC,D (0.692, p=0.032) and NC,5 (0.759, p=0.014), as was 3,D (0.530) against NC,5 
(p=0.039).  There was no difference between the normalised surviving fraction of the control 
treatment group NC,M (0.579) with either 3,D (p=0.646) or 3,5 (p=0.400) however, indicating 
no AC inhibition specific effect. 
  
 
 
4.3.4 Baseline Surviving Fraction 
 
Throughout the course of performing the clonogenic assays, it was observed that the crude 
surviving fractions in the baseline non-irradiated (0Gy) control samples was apparently 
different between cell populations that had been transfected with siRNA coding for AC, and 
both those transfected with a non-coding siRNA and non-transfected cell populations.  This 
apparent difference is as depicted in figure 4.15 below. 
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Figure 4.15 – Images acquired by the GelCount™ automated colony counter of two of the 6-well 
experimental clonogenic assay plates.  The comparison demonstrated is to illustrate a representative 
outcome following transfection with siRNA3 (left side) against non-coding siRNA (right side).  The 
cells on both plates were incubated with media only following the respective transfection and are 
the non-irradiated (0Gy) control group for their pre-irradiation treatment.  Cell seeding densities 
were identical between the plates, with each well in the top rows seeded with 200 cells, and 400 
cells seeded into each well in the bottom rows. 
 
 
Fewer colonies are observed in the image of the 6-well plate on the left side of figure 4.15 
on clonogenic assay where the cells had prior been transfected with siRNA coding for AC, 
compared to a greater number of colonies observed in the image of the 6-well plate on the 
right side where the cells had prior been transfected with a non-coding siRNA.  Cell seeding 
into both plates had been identical, and it was considered that further investigation of this 
apparent difference was justified. 
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Figure 4.16 – Box-and-whisker plots demonstrating the observed surviving fraction across all 
experimental treatment groups investigated on clonogenic assay, for the non-irradiated (0Gy) 
control group of the respective pre-irradiation treatment.  The treatment groups are those as 
defined in table 4.1. 
 
Figure 4.16 demonstrates the crude surviving fractions on clonogenic assay of all investigated 
treatment groups in the baseline non-irradiated (0Gy) cell populations.  On Kruskal-Wallis 
analysis there was significant difference across all categories of group (p<0.001), although 
on pairwise comparison there was no difference between cell populations that had been 
transfected with siRNA coding for AC (3,M, 3,D and 3,5), between cell populations 
transfected with a non-coding siRNA (NC,M, NC,D and NC,5), or between non-transfected 
cell populations (M, D, C, 5 and C,5).  It was considered that this represented the 
pharmacological manipulation undertaken prior to re-seeding in the clonogenic plate had 
not affected the inherent viability in these non-irradiated cells, and that any differences were 
due to the siRNA transfection for AC or the transfection process itself. 
A statistical analysis of the baseline surviving fraction in non-irradiated cells was further 
undertaken according to grouping based on transfection, and is presented in figure 4.17 
below. 
 
183 
 
 
Figure 4.17 – Box-and-whisker plots demonstrating the grouped observed surviving fraction at 
baseline (non-irradiated, 0Gy controls) on clonogenic assay between cell populations that had 
undergone ASAH1 siRNA transfection (siRNA3), non-coding siRNA transfection (siRNA-NC) and non-
transfected cells.  The grouped results originate from the data presented in figure 4.16; siRNA3 
combines 3,M, 3,D and 3,5; siRNA-NC combines NC,M, NC,D and NC,5; non-transfected combines M, 
D, 5, C and C,5. 
 
The median baseline surviving fraction on clonogenic assay in non-irradiated cell populations 
subjected to siRNA transfection (siRNA3, n=17) is 0.123 with an interquartile range (IQR) of 
0.141.  This is significantly lower on pairwise comparison following Kruskal-Wallis analysis, 
than both cell populations subjected to transfection with a non-coding siRNA (siRNA-NC, 
n=17) where the median surviving fraction is 0.359 IQR 0.206 (p=0.002), and non-transfected 
cell populations (n=15) where the median surviving fraction is 0.548 IQR 0.211 (p<0.001).  
There was no statistically significant difference between cell populations transfected with a 
non-coding siRNA and non-transfected cell populations (p=0.057). 
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4.3.5 MTS Assay – Post-Irradiation / Acid Ceramidase Inhibition 
 
 
Figure 4.18 – HCT116 cell proliferation after irradiation (0-4Gy) as observed on MTS assay in siRNA 
transfected populations.  Cell populations had undergone pre-irradiation ASAH1 siRNA transfection 
(or non-coding siRNA transfection as control) +/- 5-FU dosing (or respective control).  MTS assay was 
performed 72 hours following the seeding of 2,500 cells from each population in triplicate in 96-well 
plates, with three independent experimental replicates performed.  Absorbance at 490nm was 
measured, data adjusted according to background control samples, then normalised to the 0Gy 
value for each treatment group to facilitate direct comparison.  The treatment groups are those as 
defined in table 4.1. 
 
 
Figure 4.19 – HCT116 cell proliferation after irradiation (0-4Gy) as observed on MTS assay in 
pharmacologically treated populations.  Cell populations had undergone pre-irradiation treatment 
with 5-FU, carmofur, combined treatment or vehicle control.  MTS assay was performed 72 hours 
following the seeding of 2,500 cells from each population in triplicate in 96-well plates, with three 
independent experimental replicates performed.  Absorbance at 490nm was measured, data 
adjusted according to background control samples, then normalised to the 0Gy value for each 
treatment group to facilitate direct comparison.  The treatment groups are those as defined in table 
4.1. 
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The results of the MTS proliferation assay subsequent to irradiation have been split between 
cell populations undergoing transfection prior to irradiation (figure 4.18) and 
pharmacologically-only treated (non-transfected) populations (figure 4.19), to allow for 
relative ease of interpretation but can be directly compared.  HCT116 cell proliferation is 
observed to generally decrease with increasing radiation dose in all treatment groups but 
there is no statistically significant difference (Kruskal Wallis analysis) between any of the 
treatment groups at 1 (p=0.542), 2 (p=0.214) or 4Gy (p=0.515) irradiation respectively.  
Equally, there does not appear to be a consistent trend between treatment groups across 
the range of radiation doses.  Error bars are not presented in figures 4.18 and 4.19 for this 
reason and to facilitate ease of interpretation. 
 
 
4.3.6 Post-Transfection Proliferation 
 
 
Figure 4.20 – Box-and-whisker plots representing the live cell counts observed prior to seeding in the 
clonogenic plates, according to respective grouped treatment.  2x105 cells in 2mL culture medium 
were seeded in each 35mm cell culture dish at the outset, prior to transfection of coding (siRNA3) 
and non-coding (siRNA-NC) siRNA.  Some cell groups were exposed to pharmacological treatment 
only (non-transfected), and control groups were incorporated across the range of treatments as 
described in table 4.1.  All cell groups underwent a change of culture medium (to facilitate 
pharmacological treatment) 2 hours prior to exposure to 0-4Gy irradiation.  The cell counts were 
observed immediately subsequent to irradiation (74 hours following initial seeding) upon re-seeding 
into the clonogenic plates. 
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The cell counts observed prior to seeding into the clonogenic plates, grouped according to 
pre-irradiation treatment (non-transfected n=63, ASAH1 siRNA transfected n=56, and non-
coding siRNA transfected n=56) as demonstrated in figure 4.20, were 347.9 +/- 101.7 x103 
per mL, 192.6 +/- 56.9 x103 per mL, and 228.0 +/- 85.1 x103 per mL respectively.  There was 
a significant difference in the observed cell count between groups on Kruskal-Wallis analysis 
(p<0.001), which was specifically between non-transfected cells and both ASAH1 siRNA 
transfected cells (p<0.001) and non-coding transfected cells (p<0.001) on pairwise 
comparison.  There was no difference in cell count between the two transfected cell groups 
(p=0.105). 
 
 
Figure 4.21 - Box-and-whisker plots representing the crude absorbance values observed on MTS 
assay from non-irradiated cell populations exposed to; siRNA transfection coding for AC (siRNA3), 
non-coding siRNA transfection (siRNA-NC), and non-transfected cells.  Transfection or control 
treatment was undertaken prior to re-seeding the cells in 96-well plates at 2,500 cells per well, and 
MTS was applied after incubation for 72 hours.  The values have been adjusted according the 
background absorbance observed from an equivalent volume of media in wells on the plates and 
represent triplicate values from three independent experiments. 
 
An observation of post-transfection proliferation 72 hours after re-seeding can be obtained 
from the non-irradiated control groups from the MTS assay data, as presented in figures 4.18 
and 4.19.  The crude absorbance values obtained from these experiments are presented in 
figure 4.21, where no statistically significant difference is observed between all groups on 
Kruskal-Wallis analysis (p=0.216). 
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Figure 4.22 – Luminescence observed in luciferase-expressing HCT116 cells comparing ASAH1 siRNA 
transfected (siRNA3), non-coding siRNA transfected (siRNA-NC) and non-transfected (Media) cell 
populations, using VivoGlo™ Luciferin assay (Promega).  Transfection or control treatment was 
undertaken prior to re-seeding the cells in white-bottomed 96-well plates at 2,500 cells per well.  
Luminescence (as a surrogate for cell proliferation) was observed at time points over the subsequent 
72 hours following the application of VivoGlo™ Luciferin.  Triplicate wells were seeded for each time 
point for each population, with three independent experiments performed.  Mean fluorescence 
values observed are plotted with error bars representing one SD. 
 
Cell proliferation, as represented by luminescence in figure 4.22, was observed to be 
comparable at baseline between groups upon re-seeding into the 96-well plate.  This was 
confirmed on Kruskal-Wallis analysis (p=0.463).  The non-transfected group (cells pre-
incubated in culture medium only) began to demonstrate proliferation by 27 hours, at which 
point there was significant variance between treatment groups (p<0.001), which persisted 
to 72 hours (p<0.001).  There was no difference on pairwise comparison between siRNA 
transfected groups (ASAH1 and non-coding) at 27 hours however (p=1.000), which remained 
the case at 72 hours (p=0.105).  Proliferation in these transfected cell groups is observed to 
begin to increase by and after 53 hours but the rate of proliferation is observed to be slower 
than non-transfected cells.  This may be due to an off-target effect of transfection in the 
luminescent population. 
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4.3.7 Post-Transfection Caspase 3/7 Activity 
 
 
Figure 4.23 – Luminescence observed in HCT116 cells subsequent to undertaking the Caspase-Glo® 
3/7 assay (Promega) in ASAH1 siRNA transfected (siRNA3), non-coding siRNA transfected (siRNA-NC) 
and non-transfected (Media) cell populations.  Transfection or control treatment was undertaken 
prior to re-seeding the cells in white-bottomed 96-well plates at 10,000 cells per well.  Luminescence 
(as a marker of caspase 3/7 activity) was observed at 0, 2.5, 7 and 24 hours following the application 
of Caspase-Glo® reagent.  Triplicate wells were seeded for each time point for each population, with 
three independent experiments performed.  Mean fluorescence values observed are plotted, with 
error bars representing one SD. 
 
Caspase 3/7 activity, as represented by luminescence in figure 4.23, was observed to increase 
in all treatment groups over the time points represented, although the rate of increase of 
activity was observed to be greatest initially, particularly in transfected cell populations.  
Highest caspase 3/7 activity was observed in ASAH1 siRNA transfected cells, whereas lowest 
activity was observed in non-transfected cells.  Whilst there was significant variance between 
all treatment groups on Kruskal-Wallis analysis (p<0.001) at all time points, there was no 
difference particularly in caspase 3/7 activity on pairwise comparison between ASAH1 siRNA 
transfected and non-coding siRNA transfected cells at the 0-hour time point (p=0.184) upon 
re-seeding into the 96-well plate, although significant variance had developed by the 2.5-
hour time point (p=0.048), which persisted through to 24 hours (p=0.048). 
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4.4 Discussion 
 
 
4.4.1 Summary of Aims 
 
The overall aim of the work in this chapter was to assess the effect of genetic and 
pharmacological manipulation of AC on the in vitro radio-sensitivity of a CRC cell line.  This 
effect would be assessed using primarily clonogenic assay and MTS viability assay.  To 
facilitate an optimal dosing strategy in the model, it was necessary to perform preliminary 
dose-response analysis with the 5-FU-based potential pharmacological radio-sensitisers, and 
to establish the specific 5-FU based effect of these chemotherapeutics in the cell line, to 
isolate any potential effect based upon AC inhibition. 
Whilst performing the clonogenic assays, it was observed there was a fundamental 
difference in baseline surviving fraction between cell populations subjected to transfection 
with siRNA coding for ASAH1, and both those subjected to non-coding siRNA transfection 
and non-transfected cell populations.  A further aim was developed to assess whether this 
difference could be explained by an alteration in cell proliferation both prior and subsequent 
to re-seeding following transfection, or by apoptotic predisposition, and whether any 
difference was specific to this genetic inhibition of AC expression. 
 
 
4.4.2 Summary of Results 
 
Dose-response analysis with the chemotherapeutics capecitabine, 5-FU and carmofur was 
performed in the HCT116 cell line using MTS assay.  Capecitabine demonstrated no toxicity 
and was not pursued further in the development of the clonogenic model.  The IC50 values 
for 5-FU and carmofur were observed to be 5.48µM (95%CI 4.11-7.31, R2=0.875) and 7.48µM 
(95%CI 5.96-9.38, R2=0.843) respectively, and 3.95µM for each drug (95%CI 3.64-4.29, 
R2=0.930) when in combination.  No significant toxicity was observed at a 2µM concentration 
of these drugs either individually or in combination in the cell line (p=0.465). 
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2µM concentrations of carmofur and 5-FU were assessed for their effect upon TS in the 
HCT116 cells on Western blotting.  Qualitative assessment revealed an earlier effect on TS 
with 5-FU but with some effect on TS following a 2-hour incubation with carmofur. 
These results, combined with the timing for inhibition of AC activity with carmofur as detailed 
in chapter 3, led to the development of the pharmacological dosing strategy in the clonogenic 
model. 
HCT116 cell radio-sensitivity was not demonstrated to be significantly different in either the 
genetic (with or without 5-FU) or pharmacological arms of AC inhibition modelling, either on 
clonogenic or MTS assay.  An insignificant surviving fraction was observed on clonogenic 
assay at both 2Gy and 4Gy irradiation, which did not correlate with MTS assay.   
A significant difference in surviving fraction was observed at baseline between non-
irradiated cell groups on clonogenic assay.  Following siRNA transfection coding for ASAH1, 
a low median baseline surviving fraction of 12.3% was observed.  This was significantly lower 
than in cells transfected with a non-coding siRNA (35.9%, p=0.002) or non-transfected cells 
(54.8%, p<0.001), whereas there was no difference between these latter two groups 
(p=0.057). 
This low baseline surviving fraction was therefore attributable to an AC specific effect, and 
further assessment was undertaken.  There was no difference in the cell count observed prior 
to re-seeding into the clonogenic plates between cell populations subjected to siRNA 
transfection coding for ASAH1 or non-coding siRNA transfection (p=0.105) although both 
groups were lower than for non-transfected cells (p<0.001).  Proliferation after re-seeding 
was assessed using MTS assay data already obtained, where no difference was identified 
between either transfection groups or non-transfected cells (p=0.216), and based on 
fluorescence observed in a stably-transfected luciferin-expressing HCT116 cell line on 
luciferase assay.  Whilst a significantly higher fluorescence was observed in non-transfected 
cells (p<0.001), there was again no difference between cells transfected with siRNA coding 
for ASAH1 or non-coding siRNA transfected cells (p=0.105). 
Caspase 3/7 assay was undertaken in these groups to assess for a potential apoptotic 
predisposition.  At the point of re-seeding subsequent to transfection, there was no 
difference between cells subjected to siRNA transfection coding for ASAH1 and non-coding 
siRNA transfected cells (p=0.184).  Caspase 3/7 activity increased in all groups over the 24-
hour duration of the assay.  Significantly higher caspase 3/7 activity was observed in the cell 
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population subjected to siRNA transfection coding for ASAH1 at the 2.5-hour time point, 
when compared to non-coding siRNA transfected cells and non-transfected cells, and this 
significant difference persisted to 24 hours (p=0.048). 
  
 
4.4.3 Strengths and Limitations 
 
The HCT116 cell line used for investigation of AC dependent radiotherapy modelling in this 
thesis is p53+/+ (wild type).  The HCT116 p53-/- (deficient) cell line is known to be radio-
resistant (Huerta et al, 2013), therefore it is plausible that the wild type cells used are 
inherently radio-sensitive, and that it is not easily possible to demonstrate significant further 
radio-sensitivity.  p53 was equally not identified as significantly differentially expressed in 
the original proteomic profiling, and as such may not be relevant to our investigation of AC. 
Basal AC expression in the HCT116 cell line was observed to be relatively low (by a factor of 
over 3 - 28.7%) on densitometry when compared to a rectal cancer sample known from the 
work performed in the original proteomic profiling to relatively overexpress AC.  In the 
original proteomic profiling, the relative difference in expression was considered significant 
above a factor of 1.5.  It may therefore be the case that the HCT116 p53+/+ is inherently 
radio-sensitive based on a low expression of AC.  A logical further investigation would be to 
profile basal expression of AC in the HCT116 p53-/- cell line, and to potentially perform the 
same range of experiments as in this thesis, particularly if the basal expression was observed 
to be higher.  Alternatively, it could be possible to upregulate AC in the HCT116 p53+/+ cell 
line using a plasmid vector. 
If the basal expression of AC in the HCT116 p53+/+ cell line is low, then despite the results 
presented in chapter 3 in the cell line demonstrating statistically significant inhibition of AC 
expression and activity, it may be that further inhibition of AC from a potential low 
expression and activity baseline, does not produce any changes in functional effect, and does 
not further alter radio-sensitivity. 
The dosing of carmofur and 5-FU in the clonogenic assay model was performed to facilitate 
an optimal inhibition of AC from carmofur at the point of irradiation delivery, and to 
approximate the 5-FU based effect of both drugs.  It is plausible that their mode of action in 
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facilitating radio-sensitivity occurs later than a therapeutically effective concentration of the 
drug persisted in the cells.  It was considered that either plating the cells out in dosed media 
after irradiation (due to an unquantified potential differential 5-FU based effect between 5-
FU and carmofur) or performing re-dosing of the cells after seeding in the clonogenic plate 
(i.e. daily for the duration of incubation for the clonogenic assay) would introduce a greater 
bias than the risk of the drug not being therapeutic for long enough.  The risk of concern in 
re-dosing the clonogenic plate is that cells or colonies are washed away, and that this would 
occur in an inconsistent manner between wells. 
5-FU was also observed to effect TS protein levels on Western blotting earlier than carmofur.  
This may be explained by the required intra-cellular conversion of carmofur to 5-FU prior to 
its inhibition of TS, which may occur through CYP2A6 comparable to tegafur (El Sayed and 
Sadée, 1983) but is not known.  In one study it has been observed that carmofur-induced 
inhibition of TS activity didn’t alter cellular proliferation in comparison to 5-FU (Nishiyama et 
al, 1988), suggesting a more complex mechanism for its action that potentially involves AC 
(Realini et al, 2013), again potentially explaining the observed later or reduced effect on TS. 
The effect of siRNA inhibition of AC was anticipated to outlast the pharmacological inhibition 
but despite this, it is possible that the AC dependent radio-sensitivity being investigated still 
remains dependent on the presence of 5-FU (all the patients in the original proteomic 
profiling were treated with capecitabine as a radio-sensitiser).  Whilst it may be that the 
effective 5-FU concentration did not last for a sufficient time alongside AC inhibition with 
siRNA to effect radio-sensitivity, the baseline surviving fraction in non-irradiated cells 
subsequent to ASAH1 siRNA transfection was significantly reduced (12.3%) - a further 
significant reduction in surviving fraction based on increased radio-sensitivity may not be 
appreciable. 
Further evaluation of the duration of AC expression and activity inhibition following re-
plating in normal culture medium after siRNA transfection and pharmacological dosing could 
be performed. 
Capecitabine was considered to be used as the standard treatment against which carmofur 
should be compared but capecitabine demonstrated no toxicity in the HCT116 cells even at 
the highest achievable concentration of 400µM – this may reflect that the purchased product 
was not appropriate, or that the HCT116 cells do not express the CES proteins at the levels 
required for the conversion of capecitabine into 5-dFCR, or that another of the required 
proteins upstream of final conversion to 5-FU is not expressed sufficiently.  This was not 
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investigated but offers a potential alternative explanation as to why the HCT116 cells in the 
clonogenic experiments did not display any significantly altered radio-sensitivity, if it is 
treatment in the clinical setting with capecitabine in the presence of a low expression of AC 
that confers radio-sensitivity. 
Another explanation for a lack of alteration in radio-sensitivity but under the assumption of 
appropriate inhibition of AC in the clonogenic model, is that the behaviour of the HCT116 
cell line in culture does not mimic the complex environment of a tumour in situ.  The function 
of AC in the two contexts may be very different, and the importance of AC in the in vitro 
survival or function of the HCT116 cells in either a monolayer in culture or when seeded in 
individual cells to form colonies may be negligible.  Alternative potential routes of 
investigation in an AC dependent model of sensitivity to CRT could be to use primary cell 
culture (particularly in a tumour where AC was overexpressed), 3D cell culture in the HCT116 
p53+/+ cell line to represent a more physiologically accurate environment (Ludwig et al, 
2013), or consideration of the development of a mouse model. 
The data presented to represent cell outcome following irradiation was obtained using both 
MTS viability assay and clonogenic assay.  There would appear to be a disparity in the 
outcomes with these assays, in that the normalised data would seem to under-represent the 
effect of irradiation when using the MTS assay.  At 4Gy irradiation, the normalised surviving 
fraction was only 1-2% of seeded cells on clonogenic assay, whereas viability 3 days after 
seeding on MTS assay was in the range 29-66%.  Combined with the inconsistent and wide-
ranging data observed on MTS assay, it would seem that the irradiation effect at 3 days is 
not complete, and that cells remain viable at this time even though they are ultimately 
unable to proliferate.  This is consistent with the description of these techniques at the outset 
of the chapter (Mirzayans et al, 2007), and MTS assay at this time would seemingly not be 
the optimal modality to determine outcome following irradiation. 
Logistical limitations may have existed in undertaking the clonogenic assay, with irradiation 
being undertaken in a different laboratory and with the requirement to place cells on ice 
whilst transporting them to and from these locations, undertaking irradiation and re-plating.  
The time taken to undertake this process was not specifically recorded but it is likely that cell 
groups were on ice for 1-2 hours.  This may have resulted in the activation of survival 
mechanisms which negated the effect of AC inhibition and irradiation, with evidence to 
suggest that cells, tissues and organs have differing survival strategies to overcome 
environmental extremes (Brockbank et al, 2011). 
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Another potential concern is with regard the validity of the controls used for siRNA 
transfection.  This is in the context of non-significant irradiation-specific results with AC 
inhibition, and with reduced ASAH1 mRNA expression following the transfection process, 
both with the presence and absence of non-coding siRNA.  My conclusion from the data 
presented in chapter 3 is that this wasn’t specific to the non-coding siRNA but there was 
clearly a significant off-target effect which may have impacted on the clonogenic results.  
Alternative non-coding sequences could be examined.  The mechanism of siRNA-mediated 
reduction in cellular proliferation has been considered to be due to either innate immunity 
mechanisms responding to the presence of exogenous RNA molecules (Fedorov et al, 2006), 
or to competitive interactions of the siRNA molecules with endogenous RNAs Liang et al, 
2013). 
The use of luciferase-expressing HCT116 cells was an attempt to provide cross-validation for 
the MTS assay data relating to post-siRNA transfection proliferation, which did not separate 
ASAH1 siRNA transfected, non-coding siRNA transfected and non-transfected cells.  The non-
transfected cells demonstrated significantly greater luminescence (as a surrogate for viability 
/ proliferation) with this assay compared to the transfected cell groups, which is contrary to 
the MTS assay proliferation data presented.  There were no statistically significant 
differences between the transfected cell groups over the course of the assay, although 
luminescence was only observed to begin to increase marginally and much later than in non-
transfected cells.  This may be due to on off-target effect of transfection in the HCT116-luc 
population. 
 
 
4.4.4. Conclusion 
 
• HCT116 cell radio-sensitivity can be increased by the pharmacological inhibition of 
AC activity using the chemotherapeutic carmofur - NOT PROVEN 
No difference in HCT116 cell radio-sensitivity was observed in this study subsequent to 
pharmacological inhibition of AC with carmofur.  Significant limitations may exist with the 
dosing strategy undertaken, or with a low baseline expression of AC in the cell line, which 
could have impacted upon these results.   
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• HCT116 cell radio-sensitivity can be increased by the genetic suppression of AC 
expression (and subsequent activity) using siRNA transfection - NOT PROVEN 
No difference in HCT116 cell radio-sensitivity was observed in this study subsequent to 
genetic manipulation of AC expression with siRNA transfection.  A significantly lower baseline 
surviving fraction was observed on clonogenic assay in non-irradiated cell populations 
subjected to siRNA transfection coding for ASAH1, when compared to non-coding siRNA 
transfected and non-transfected cell populations - a finding which is therefore specific to AC 
inhibition.  This baseline surviving fraction of 12.3% of those cells seeded into the clonogenic 
plates, compared to 54.8% in non-transfected cell populations, represents a significantly 
reduced baseline.  A further irradiation specific effect was not observed relative to genetic 
and/or pharmacological manipulation but this significantly reduced baseline surviving 
fraction with siRNA inhibition of AC, may not have afforded sufficient sensitivity. 
 
• Any increase in cell radio-sensitivity based on inhibition of AC is independent of the 
presence of 5-FU - NOT PROVEN 
It has been demonstrated that carmofur and 5-FU independently produce an effect on TS 
within the dosing window employed in the clonogenic assay.  No increase in cell radio-
sensitivity was observed in the presence of 5-FU, with or without pharmacological inhibition 
of AC with carmofur.  This again may relate to the limitations with the pharmacological 
dosing strategy, or to a low baseline expression of AC in the cell line. 
In the context of genetic manipulation of AC expression with siRNA transfection, increased 
radio-sensitivity was not observed with the presence of 5-FU.  This could relate to the 
pharmacological dosing strategy but may be more likely to be related to the significantly 
reduced baseline surviving fraction following ASAH1 siRNA transfection, as previously 
described. 
 
4.4.4.1 Assessment of reduced baseline surviving fraction post-transfection 
The significantly reduced surviving fraction observed on clonogenic assay in HCT116 cells 
subjected to ASAH1 siRNA transfection was not anticipated but implicates AC in their 
inherent survivability.  This may relate to cell adhesion and/or colony formation and growth, 
or apoptosis.  Whilst cell growth during transfection was reduced in both coding and non-
coding groups compared to non-transfected cells based on cell counts observed upon re-
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seeding into the clonogenic plates, there was no difference between coding and non-coding 
siRNA transfected cell populations.  Equally there was no difference in proliferation between 
these two transfection groups subsequent to re-seeding, observed with MTS and luciferin 
assays. 
Caspase 3/7 activity was higher in both transfection groups compared to non-transfected 
cells at the point of re-seeding but subsequent observations of increased caspase 3/7 activity 
were significantly higher in cells transfected with siRNA coding for ASAH1.  Increased caspase 
3/7 activity suggests apoptotic predisposition, and this significantly higher caspase activity 
with inhibition of AC potentially explains the reduced surviving fraction observed on 
clonogenic assay.  This observation of caspase activity also separates the cell group from the 
non-coding control consistent with the clonogenic data.  It is not possible to determine from 
the work presented if this presumed apoptotic predisposition is; a) a direct consequence of 
siRNA inhibition of AC, or b) related to re-seeding and an inability to adhere to the plate 
subsequent to inhibition of AC, which then triggers apoptosis. 
AC inhibition is therefore implicated in vitro in the survivability of HCT116 CRC cells, and may 
predispose to apoptosis. 
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Chapter 5 
 
Concluding Discussion 
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5.1 Background Summary 
 
The response to CRT in rectal cancer varies from pCR, with associated survival benefit, to 
disease progression.  Predicting response is not currently possible but identifying 
biomarkers which may do this has been highlighted as a priority for research from national 
association strategy.  The ability to predict response would facilitate personalised 
treatment, and minimise morbidity from CRT and prevent delays in the systemic and local 
management of the disease in non-responders.  Therapeutic targets may also be revealed 
with the aim of improving the efficacy of CRT, and further facilitate non-operative or rectal-
preservation strategies.  An initial novel temporal proteomic profiling of rectal cancer has 
revealed differential expression of AC between relative responders and non-responders to 
CRT, and AC is proposed for further evaluation as a potential predictive and/or prognostic 
biomarker of response. 
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5.2 Original Aim 
 
The original aim of this thesis was to attempt to provide further validation of AC as a 
biomarker of response to CRT in rectal cancer with assessment in a wider clinical dataset, 
and to perform an in vitro evaluation of the effect of AC inhibition on radio-sensitivity in a 
CRC cell line. 
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5.3 Initial Research Questions and Study Design 
 
The research questions to be answered by this thesis were: 
• Does AC expression predict response to CRT in clinical rectal cancer samples in a 
larger patient cohort? 
• Does the inhibition of AC in a CRC derived cell line increase radio-sensitivity? 
• Does inhibition of AC increase radio-sensitivity when compared to standard 5-FU 
radio-sensitisation? 
 
It was initially determined to answer these questions with the following study plan: 
• Identify ≥100 rectal cancer cases, whereby surgical resection of the primary tumour 
had been performed following completion of neoadjuvant CRT, and assess TRG in 
these cases 
• Construct TMAs comprising; tissue from the diagnostic biopsy specimen, and normal 
epithelium and cancer site tissue from the resection specimen 
• Assess TMA IHC expression of AC, and correlate with TRG and clinical and 
pathological data 
• Perform genetic inhibition of AC with siRNA in the HCT116 CRC cell line, assessing 
mRNA expression, and protein expression and activity 
• Assess the effect of pharmacological inhibition of AC with carmofur in the HCT116 
CRC cell line on protein expression and activity 
• Establish the effect of carmofur, capecitabine and 5-FU dosing on toxicity and TS 
expression in the HCT116 CRC cell line 
• Assess the effect of AC inhibition on radio-sensitivity in the HCT116 CRC cell line 
 
This study plan was executed in entirety other than for complete evaluation of capecitabine, 
including its effect on radio-sensitivity, upon determining it to be non-toxic in the HCT 116 
cells.  A further experimental plan evolved with closer evaluation of the clonogenic assay 
(when no radiation-specific effects were apparent) where ASAH1 siRNA transfected cells 
were observed to have an inherent reduced survivability: 
• Assess the effect of ASAH1 siRNA transfection in the HCT 116 cells on proliferation 
during and after transfection, and apoptotic predisposition, to potentially explain 
their inherent reduced survivability 
201 
 
5.4 Summary of Results 
 
5.4.1 Chapter 2 
111 consecutive rectal cancer resection cases post-CRT were identified and incorporated into 
TMAs for analysis.  There were 22 patients with pCR (19.8%), which was associated with 
improved estimated mean overall survival against non-pCR regression grades (99.6 vs 74.5 
months, p=0.015).  AC expression in diagnostic biopsy tissue, and in cancer site and normal 
colon epithelium from resection specimens was evaluated in the TMAs, discriminating 
between epithelial and stromal expression.  86-107 of the 111 cases were represented in the 
final analysis, dependent upon the tissue component.  A trend towards higher stromal AC 
expression in the diagnostic biopsies was observed in non-responders (TRG 1) to CRT 
(p=0.075).  Stromal expression at the cancer site post-CRT was significantly associated with 
response, with a lower expression in pCR (p=0.003) and higher expression in non-responders 
(TRG 1, p=0.017).  A higher expression in normal colon epithelium from the resection 
specimen post-CRT was also observed in non-responders (p=0.012).  The incidence of local 
disease recurrence was associated with a higher expression of AC at the cancer site post-CRT 
on both epithelial and stromal assessment (p=0.031 and p=0.038 respectively).  The 
epithelial score here is exclusively in those not achieving pCR. 
 
5.4.2 Chapter 3 
Inhibition of AC by genetic (siRNA) and pharmacological (carmofur) manipulation was 
optimised in the HCT116 CRC cell line.  ASAH1 mRNA expression was significantly inhibited 
to 4.1% (p<0.001) against control at 48 hours following siRNA transfection, with confirmatory 
qualitative assessment of reduced AC expression on Western blotting.  ASAH1 mRNA 
expression was also observed to be significantly inhibited by a non-coding siRNA transfection 
to 40.4% (p=0.003) against control at 48 hours.  AC activity was quantified by direct activity 
assay.  siRNA targeting ASAH1 resulted in maximal AC activity inhibition of 15.5% 72 hours 
following transfection.  Dose-dependent inhibition of AC activity was observed with carmofur 
– maximal inhibition to 15.2% was achieved with a 25µM concentration but statistically 
significant inhibition to 47.2% (p<0.001) was achieved with a 1µM concentration.  Activity 
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inhibition of AC was maximal 2 hours after cell dosing but had normalised by 24 hours.  5-FU 
was observed not to inhibit AC activity in the cell line. 
 
5.4.3 Chapter 4 
Dose-response analysis with the chemotherapeutics capecitabine, 5-FU and carmofur was 
performed in the HCT116 cell line using MTS assay.  Capecitabine demonstrated no toxicity 
and was not pursued further in the development of the clonogenic model.  The IC50 values 
for 5-FU and carmofur were observed to be 5.48µM (95%CI 4.11-7.31, R2=0.875) and 7.48µM 
(95%CI 5.96-9.38, R2=0.843) respectively, and 3.95µM for each drug (95%CI 3.64-4.29, 
R2=0.930) when in combination.  No significant toxicity was observed at a 2µM concentration 
of these drugs either individually or in combination in the cell line (p=0.465).  A comparable 
effect on TS expression was observed on Western blotting with 2µM concentrations of 5-FU 
and carmofur.  No radiation-dependent differences were observed with genetic or 
pharmacological inhibition of AC in HCT 116 cells, either on clonogenic or MTS assay.  Cells 
transfected with ASAH1 siRNA demonstrated a reduced baseline surviving fraction (12.3%), 
compared to non-coding siRNA cells (35.9%, p=0.002) or non-transfected cells (54.8%, 
p<0.001), with no statistical difference between these latter two groups (p=0.057).  The only 
difference observed in the ASAH1 siRNA transfected cells was a potential predisposition to 
apoptosis with significantly higher caspase 3/7 activity observed over both non-coding siRNA 
transfected and non-transfected cells (p=0.048). 
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5.5 Study Limitations and Further Work 
 
A detailed evaluation of the potential limitations with the in vitro experimentation 
performed, which may have impacted on the lack of observed radiation-dependent 
sensitivity with AC inhibition in the HCT 116 (p53+/+) cells has been discussed.  Whilst further 
modifications to dosing strategy and repeated experimentation could be considered, the 
finding of higher caspase 3/7 activity in ASAH1 siRNA transfected cells suggests that AC 
inhibition in these cells predisposes to apoptosis, or further implicates AC in apoptotic 
pathways. 
This conclusion is consistent with the literature presented in the introduction relating to the 
potential for ceramide to predispose to apoptosis, considered to involve activation of 
extrinsic apoptotic pathways through enhanced signalling of pro-apoptotic membrane 
molecules, or via intrinsic pathways by the formation of trans-membrane mitochondrial 
channels which allows the release of apoptosis inducing proteins such as caspase-3 and 
cytochrome c (Siskind et al, 2002).  AC activity removes ceramide or limits its accumulation 
by de-acetylation towards S1P (Garcia-Barros et al, 2014).  S1P has equally been 
demonstrated to initiate the pro-survival PIK3/AKT signalling pathway (Bonnaud et al, 2012), 
which has also been implicated independently in resistance to CRT in rectal cancer (Peng et 
al, 2018).  AC is therefore centrally placed in potentially determining cellular fate in 
regulating the balance between ceramide and S1P. 
These conclusions are also consistent with the literature evidence of over-expression of AC 
in particular in head and neck (Roh et al, 2016) and prostate (Cheng et al, 2013) cancers, both 
of which are commonly treated with radiotherapy.  Its over-expression is also associated with 
melanoma (Realini et al, 2016) and myeloid leukaemia (Tan et al 2016), with in vitro data 
demonstrating AC over-expression conferring resistance to treatment in all these 
malignancies, and with clinical corroboration of this in particular with radiotherapy in 
prostate cancer (Cheng et al, 2013).  Inhibition of AC in vitro in cell lines in head and neck 
cancer (Korbelik et al, 2016), melanoma (Bedia et al, 2011), myeloid leukaemia (Hu et al, 
2011), non-small cell lung cancer (Ramírez de Molina et al, 2012), breast cancer (Flowers et 
al, 2011), hepatoma (Morales et al, 2007) and prostate cancer (Mahdy et al, 2009) is 
demonstrated to improve sensitivity to both irradiation and chemotherapeutic treatments, 
with most studies also demonstrating AC inhibition to result in increased ceramide levels, 
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reduced S1P levels and increased apoptosis.  These pathways could be further investigated 
in the HCT116 cells with a view to evaluating for irradiation-specific effects and mechanisms. 
The reduced ASAH1 mRNA expression observed with non-coding siRNA transfection and/or 
the transfection process is also potentially a product of a stress response on the cell.  A 
mechanism to reduce AC expression and activity, that may increase intra-cellular ceramide 
and activate apoptotic pathways could be a protective response.  This potential mechanism 
should also be investigated to evaluate for other biomolecules that may represent 
therapeutic targets, or to further validate AC. 
An alternative further in vitro evaluation of AC dependent radio-sensitivity could be 
performed in the radio-resistant HCT 116 p53-/- cell line, or other cell lines with inherent 
differential expression of AC.  To this end, a collaboration has been sought with Dr Ultan 
McDermott at the Sanger Institute (Cambridge, UK), who has provided data regarding AC 
protein expression from 10K proteome in 49 colorectal cancer cell lines (data presented in 
appendix C, with values normalised to an internal control line).  Evaluation of radio-sensitivity 
with and without inhibition of AC can be performed using clonogenic assay as the outcome 
measure in a selection of these cell lines.  This may be most relevant in cells which over-
express AC but may also be relevant in cells with a low expression which are dependent on 
the protein. 
The main limitation in this study relates to the implication of tumour heterogeneity, and in 
the tissue targeted for incorporation into the TMAs.  Most tumours are considered to arise 
from a monoclonal cell population but with growth and the accumulation of mutations at 
different rates in different areas, tumours are well known to have diverse cell populations 
with different biological characteristics (Rehemtulla, 2012).  This clearly has implications for 
the targeted tissue from which the TMAs in this study were created.  The diagnostic biopsy 
cores were from a few endoscopic biopsy bites of what will have been superficial tumour.  
Prospectively collected tissue with more extensive mapping of the tumour would likely 
provide the most clinically available and robust mechanism from which to derive information 
regarding the expression and predictive value of any potential protein biomarker, alongside 
standardisation and validation of tissue collection, preservation, storage, processing and 
quantification (Stewart et al, 2017).  The finding of near statistical significance in this study 
for higher stromal AC expression correlating with a poor response to CRT does not validate 
its use as a predictive marker but should be evaluated in a larger prospective study. 
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The correlation of reduced AC expression in epithelial cells with an enhanced response to 
CRT is potentially straightforward to understand as a mechanism.  Whilst the results 
presented only potentially demonstrate a trend towards this observation, the impact of a 
low level or down-regulation of AC in tumour cells in response to the cellular insult, may 
result in a reduction of ceramide cleavage and its subsequent accumulation (Arana et al, 
2010), with ceramide then exerting its influence in mediating cell cycle arrest and apoptosis 
(Garcia-Barros et al, 2014). 
The targeting of residual malignant epithelium at the cancer site is equally inherently biased, 
as by definition this tissue has been resistant to CRT.  Whilst optimal tissue cores were 
obtained from these tissue blocks, triplicate samples remain unlikely to overcome the 
limitations with tumour heterogeneity but were practicably the most viable option.  Lower 
stromal expression of AC in this tissue though was significantly correlated with pCR, and 
higher expression with non-response.  It is not possible to determine if this represents cause 
or effect but demonstrates the likelihood of stromal interaction with AC expression as a 
determinant of response to CRT, with AC representing a potential therapeutic target. 
Correlation of AC expression with outcome data has additionally demonstrated association 
between relatively high epithelial and stromal expression in post-CRT cancer site tissue and 
local recurrence, and poorer survival with relatively low epithelial expression in normal 
colon.  The finding of higher epithelial expression of AC in residual malignancy post-CRT 
correlating with local disease recurrence is consistent with the findings of AC expression, 
treatment resistance (including to radiotherapy), and poorer outcome associated with other 
malignancies as outlined in the introduction in 1.4.4.  This epithelial score from the cancer 
site is exclusively from non-pCR patients and is therefore considered to further validate and 
implicate AC as a likely therapeutic target to improve response to CRT in rectal cancer.  The 
latter finding of relatively low AC expression in normal colon epithelium correlating with 
poorer survival seems contrary to higher expression also correlating with no response to CRT.  
This may be a statistical anomaly or may represent activation of alternative pathways based 
on response to CRT (this tissue was from post-CRT samples) but requires further analysis in 
a prospective dataset obtained from pre-CRT samples. 
The stroma (or tumour micro-environment) is considered to play an essential role in both 
the development of malignancy and in the resistance to treatment.  This environment, 
composed of extracellular matrix, fibroblasts, endothelial cells, and cells of the immune 
system regulates the behaviour of tumour cells and co-evolves (Werb and Lu, 2015).  Cancer 
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cells have been demonstrated to activate and recruit carcinoma-associated fibroblasts, 
which are able to both stimulate cell growth and invasion, as well as inflammation and 
angiogenesis but may also be tumour inhibiting (Kalluri and Zeisberg, 2006).  This process is 
considered to be under the regulation of TGFβ signalling, which itself is primarily activated 
by integrins secreted from both tumour and stromal cells.  In normal tissues TGFβ suppresses 
epithelial cell division but tumour cells can develop escape mechanisms to become resistant 
to TGFβ growth suppression.  In addition, TGFβ drives EMT, increasing the potential for 
metastasis (Khan and Marshall, 2016). 
The host response, through natural killer cells, has also been recently observed as a 
determinant of response to CRT (Alderdice et al, 2017), and gene expression profiles derived 
from the (non-malignant) stroma have been demonstrated to influence the classification of 
CRC molecular subtype (Dunne et al, 2016).  Particularly given the association of higher 
expression of AC in normal colon epithelium (post-CRT) with a poor response to CRT, and 
differential stromal cancer site expression post-CRT correlating with response, it may be AC 
is implicated in mediating radio-resistance through tumour-stroma interaction or host 
response. 
This signalling process may be mediated through ceramide-based lipid rafts, as micro-
domains of regions of the cellular membrane, demonstrated to regulate vesicular traffic, cell 
polarity, and cell signalling pathways (Bieberich, 2018).  They have been found in almost all 
existing experimental cancer models, including CRC, and play key regulatory roles in cell 
migration, metastasis, cell survival and tumour progression (Jahn et al, 2011).  Altered AC 
expression may therefore have central implications for the regulation of ceramide and key 
regulatory inter-cellular signalling between stroma and tumour in response to CRT in rectal 
cancer. 
AC was one of eight proteins identified from the original proteomic profiling as differentially 
expressed between relative responders and non-responders to CRT (appendix A).  It was 
selected individually for further assessment on the basis of the evidence for its implication 
in prostate cancer response to radiotherapy specifically, and the availability of a 
commercially available chemotherapeutic inhibitor.  The proteomic profiling also revealed 
myoferlin as another protein that may be implicated in response to CRT.  Myoferlin is a 
muscle specific protein that has been identified in cancer cells and has been shown to confer 
a poor prognosis in oropharyngeal cancers (Kumar et al, 2016), another tumour group often 
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treated with radiotherapy.  Further work is also needed to assess the role of this protein in 
rectal cancer, which can be undertaken initially using the established TMAs. 
On the basis of the literature review undertaken in 1.3.3, it would also seem reasonable to 
assess TMA protein expression of EGFR, TS, and β-catenin. 
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5.6 Review of Hypotheses 
 
The determined hypotheses at the outset of this thesis have been evaluated by the work 
presented: 
• Differential expression of AC is present in rectal cancer and/or normal colon – 
PROVEN 
Differential expression of AC in rectal cancer has been observed both pre- and post-CRT 
in epithelial and stromal tissue, and in epithelial tissue from normal colon. 
• Expression of AC in rectal cancer and/or normal colonic tissue can predict response 
to neoadjuvant CRT, and/or is a biomarker of response to treatment – PARTIALLY 
PROVEN 
There is a trend towards significance to correlate a high stromal diagnostic biopsy 
expression of AC with non-response to CRT.  Low AC expression post-CRT in cancer site 
stroma correlates with pCR and high expression with non-response to CRT.  High 
epithelial cancer site expression of AC post-CRT also correlates with local disease 
recurrence.  AC therefore at least represents a potential biomarker of response to CRT 
and may represent a therapeutic target. 
• Expression of AC can be inhibited by siRNA transfection in the HCT116 CRC cell line, 
subsequently inhibiting protein activity – PROVEN 
Significant ASAH1 mRNA inhibition, and AC protein expression and activity have been 
demonstrated following siRNA transfection in the cell line. 
• AC activity +/- expression can be inhibited by the chemotherapeutic carmofur in the 
HCT116 CRC cell line – PROVEN 
Reduced AC protein expression and significantly reduced AC activity have been 
demonstrated following carmofur dosing of the cell line. 
• HCT116 cell radio-sensitivity can be increased by the pharmacological inhibition of 
AC activity using the chemotherapeutic carmofur – NOT PROVEN 
No difference in cell radio-sensitivity was observed with pharmacological inhibition of 
AC with carmofur in this study. 
• HCT116 cell radio-sensitivity can be increased by the genetic suppression of AC 
expression (and subsequent activity) using siRNA transfection – NOT PROVEN 
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No difference in cell radio-sensitivity was observed following genetic inhibition of AC by 
siRNA transfection in this study.  These cells did demonstrate an inherently reduced 
survivability. 
• Any increase in cell radio-sensitivity based on inhibition of AC is independent of the 
presence of 5-FU – NOT PROVEN 
Similar to previous, no difference in cell radio-sensitivity was observed in this study, 
irrespective of the presence of 5-FU. 
The inherently reduced survivability of HCT 116 cells following ASAH1 siRNA transfection 
was further demonstrated to likely be induced by a predisposition to apoptosis on the 
basis of significantly raised caspase 3/7 activity. 
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5.7 Conclusion 
 
AC remains a novel potential biomarker of response to CRT in rectal cancer.  It does not in 
isolation represent a predictive biomarker, particularly given the complexity of tumour 
biology and tumour heterogeneity, although further investigation of its implicated role in 
mediating radio-resistance is required.  In vitro genetic inhibition of expression seemingly 
predisposes to apoptosis, consistent with literature evidence for its action.  Given this and 
its expression in radio-sensitive and radio-resistant tumours, it would seem reasonable to 
further consider AC as a potential therapeutic target.  Further evaluation of AC expression in 
rectal cancer in a larger prospective dataset is required for wider validation, as is further in 
vitro evaluation of its mechanism of action, most specifically in a radio-resistant cell line. 
A proposed mechanism for the action of AC is in its regulation of ceramide, both with low 
expression (or reduced in response to CRT) facilitating ceramide accumulation and 
subsequently promoting apoptosis directly within cells, or mediating changes in inter-
cellular signalling (stromal-tumour interaction) through an effect upon ceramide-based 
lipid rafts. 
Carmofur has been demonstrated to directly interact with AC and results in significant 
inhibition of activity.  Its effect on TS as the effector of 5-FU-based therapy in comparison 
to 5-FU itself does not appear equivalent, and therefore is proposed to mediate its effects 
through combined AC and TS inhibition.  Whilst 5-FU does not have an effect on AC 
inhibition, its role in improving response to radiotherapy in the clinical setting suggests that 
TS inhibition is also important, and therefore optimisation of combined TS and AC with 
carmofur or other novel small molecule inhibitors may improve CRT response further. 
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Appendix A – Differentially Expressed Proteins Identified at Original Proteomic 
Profiling 
 
 
 
Accession 
Number 
Name p Value 
Log2 Fold-
Change 
Q9NZM1 Myoferlin 4.35E-02 -1.633 
Q13510 Acid ceramidase 1.17E-02 -1.526 
P09525 Annexin A4 1.93E-02 -1.524 
P41219 Peripherin 2.13E-02 1.583 
P12109 Collagen alpha-1(VI) chain 3.61E-02 1.800 
P80748 Ig lambda chain V-III region LOI 4.82E-02 1.866 
P07602 Proactivator polypeptide 5.90E-04 1.943 
P01860 Ig gamma-3 chain C region 2.74E-02 2.549 
 
Table A1 – Those proteins differentially expressed between relative responders and non-responders 
to chemoradiotherapy on diagnostic samples.  8 proteins were identified, 3 of which were 
downregulated in responders (negative values for fold change) and 5 upregulated (positive values 
for fold change). 
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Accession 
Number 
Name p Value 
Log2 Fold-
Change 
P12109 Collagen alpha-1(VI) chain 1.34E-02 -1.953 
P12429 Annexin A3 9.71E-03 -1.757 
Q1KMD3 Heterogeneous nuclear ribonucleoprotein U-
like protein 2 
3.76E-02 1.521 
P51648 Fatty aldehyde dehydrogenase 1.11E-02 1.525 
Q13162 Peroxiredoxin-4 1.84E-02 1.572 
Q96PD5 N-acetylmuramoyl-L-alanine amidase 3.04E-02 1.686 
P02652 Apolipoprotein A-II 1.02E-02 1.758 
Q9BY50 Signal peptidase complex catalytic subunit 
SEC11C 
1.69E-02 1.760 
Q9Y6R7 IgGFc-binding protein 3.22E-03 1.761 
P01023 Alpha-2-macroglobulin 1.54E-02 1.783 
P01859 Ig gamma-2 chain C region 2.67E-02 1.801 
Q8NBS9 Thioredoxin domain-containing protein 5 1.17E-02 1.823 
P01591 Immunoglobulin J chain 2.57E-02 1.861 
O75795 UDP-glucuronosyltransferase 2B17 3.03E-02 1.946 
P02765 Alpha-2-HS-glycoprotein 2.18E-02 2.105 
P01275 Glucagon 2.77E-04 2.381 
P04114 Apolipoprotein B-100 1.75E-02 2.429 
P10645 Chromogranin-A 6.10E-03 3.357 
 
Table A2 – Those proteins differentially expressed between rectal tumours post chemoradiotherapy 
and diagnostic samples.  18 proteins were identified, 2 of which were downregulated (negative 
values for fold change) and 16 upregulated (positive values for fold change). 
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Accession 
Number 
Name p Value 
Log2 Fold-
Change 
P10645 Chromogranin-A 1.12E-02 -3.430 
P04114 Apolipoprotein B-100 2.22E-02 -2.630 
P01275 Glucagon 4.03E-04 -2.562 
P12532 Creatine kinase U-type, mitochondrial 3.62E-02 -2.427 
O75795 UDP-glucuronosyltransferase 2B17 2.21E-02 -2.293 
Q9Y5M8 Signal recognition particle receptor subunit 
beta 
3.61E-02 -2.226 
Q9Y6R7 IgGFc-binding protein 1.62E-03 -2.095 
P01833 Polymeric immunoglobulin receptor 3.21E-02 -2.078 
P01591 Immunoglobulin J chain 2.99E-02 -1.992 
Q07654 Trefoil factor 3 9.92E-03 -1.952 
P21397 Amine oxidase [flavin-containing] A 4.66E-02 -1.882 
P17931 Galectin-3 3.48E-02 -1.830 
Q16836 Hydroxyacyl-coenzyme A dehydrogenase, 
mitochondrial 
1.91E-02 -1.787 
P00966 Argininosuccinate synthase 2.71E-02 -1.757 
Q96EY8 Cob(I)yrinic acid a,c-diamide 
adenosyltransferase, mitochondrial 
9.12E-03 -1.726 
Q8NBS9 Thioredoxin domain-containing protein 5 3.23E-02 -1.725 
P31930 Cytochrome b-c1 complex subunit 1, 
mitochondrial 
3.25E-02 -1.714 
P38117 Electron transfer flavoprotein subunit beta 2.28E-02 -1.691 
P19075 Tetraspanin-8 3.31E-02 -1.686 
O75874 Isocitrate dehydrogenase [NADP] 
cytoplasmic 
3.49E-02 -1.682 
P80303 Nucleobindin-2 4.17E-02 -1.661 
Q96FQ6 Protein S100-A16 1.44E-02 -1.648 
Q9HAT2 Sialate O-acetylesterase 9.52E-03 -1.626 
P17980 26S protease regulatory subunit 6A 2.19E-02 -1.624 
Q1KMD3 Heterogeneous nuclear ribonucleoprotein U-
like protein 2 
3.93E-02 -1.614 
P51648 Fatty aldehyde dehydrogenase 1.33E-02 -1.596 
P15880 40S ribosomal protein S2 4.52E-02 -1.583 
Q13510 Acid ceramidase 1.35E-02 -1.568 
O96000 NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 10 
2.29E-03 -1.538 
P30049 ATP synthase subunit delta, mitochondrial 1.15E-03 -1.537 
Q16658 Fascin 7.94E-03 1.628 
P61106 Ras-related protein Rab-14 2.03E-02 1.706 
Q9H4M9 EH domain-containing protein 1 2.25E-02 1.769 
P08572 Collagen alpha-2(IV) chain 4.48E-02 2.006 
P12429 Annexin A3 6.90E-03 2.009 
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P98160 Basement membrane-specific heparan 
sulfate proteoglycan core protein 
2.73E-02 2.021 
P12109 Collagen alpha-1(VI) chain 1.45E-02 2.136 
P13674 Prolyl 4-hydroxylase subunit alpha-1 9.64E-03 2.569 
P24821 Tenascin 3.63E-02 3.329 
 
Table A3 – Those proteins differentially expressed between rectal tumours at resection and 
immediately following completion of chemoradiotherapy.  39 proteins were identified, 30 of which 
were downregulated (negative values for fold change) and 9 upregulated (positive values for fold 
change). 
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Accession 
Number 
Name p Value 
Log2 Fold-
Change 
O95881 Thioredoxin domain-containing protein 12 3.98E-02 -2.779 
P16444 Dipeptidase 1 3.35E-02 -2.740 
Q13228 Selenium-binding protein 1 2.03E-02 -2.013 
P05783 Keratin, type I cytoskeletal 18 3.44E-02 -1.835 
Q9BY42 UPF0549 protein C20orf43 2.97E-02 -1.732 
P09874 Poly [ADP-ribose] polymerase 1 5.82E-03 -1.599 
O96008 Mitochondrial import receptor subunit 
TOM40 homolog 
8.41E-03 -1.566 
Q9NX63 Coiled-coil-helix-coiled-coil-helix domain-
containing protein 3, mitochondrial 
4.29E-02 -1.548 
P11940 Polyadenylate-binding protein 1 4.44E-02 -1.530 
P05455 Lupus La protein 3.78E-02 -1.525 
P07099 Epoxide hydrolase 1 4.17E-02 1.504 
O14773 Tripeptidyl-peptidase 1 1.17E-02 1.590 
Q99536 Synaptic vesicle membrane protein VAT-1 
homolog 
2.76E-02 1.644 
Q92930 Ras-related protein Rab-8B 1.03E-02 1.690 
Q9H4M9 EH domain-containing protein 1 1.24E-02 1.714 
Q9UJ70 N-acetyl-D-glucosamine kinase 1.59E-02 1.737 
P08758 Annexin A5 2.30E-02 1.770 
P53004 Biliverdin reductase A 1.61E-02 1.842 
P04271 Protein S100-B 4.74E-02 1.882 
P02765 Alpha-2-HS-glycoprotein 3.26E-02 1.896 
Q9BUF5 Tubulin beta-6 chain 4.44E-02 2.002 
P01824 Ig heavy chain V-II region WAH 1.80E-02 2.073 
P13674 Prolyl 4-hydroxylase subunit alpha-1 1.06E-02 2.141 
B9A064 Immunoglobulin lambda-like polypeptide 5 2.80E-02 2.249 
P01860 Ig gamma-3 chain C region 4.99E-02 2.271 
P08603 Complement factor H 4.15E-02 2.310 
P01008 Antithrombin-III 2.61E-02 2.317 
P01834 Ig kappa chain C region 4.25E-02 2.731 
P10909 Clusterin 4.97E-02 4.945 
 
Table A4 – Those proteins differentially expressed between rectal tumours at resection and at 
diagnosis. 29 proteins were identified, 10 of which were downregulated (negative values for fold 
change) and 19 upregulated (positive values for fold change). 
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Appendix B – Clinical and Pathological Patient Data for Tissue Microarray Analysis 
 
 
 
Patient Age Gender Procedure Regression Adjuvant Follow Up
T N M T N CRM EMVI (Ryan) Therapy (months) Recurrence Metastases Death
1 72 M 3 0 0 APR 3 0 0 Yes 2 Yes 102 No No No
2 57 F 3 1 0 Hartmann's 0 0 0 No 4 No 7 No Yes Yes
3 80 M 3 0 0 AR 0 0 0 No 4 No 104 No No No
4 74 F 3 2 1 AR 4 1 1 No 2 Yes 35 No Yes Yes
5 63 M 3 2 0 AR 2 0 0 No 3 Yes 100 No No No
6 62 M 3 0 0 AR 3 0 0 No 3 Yes 52 No Yes Yes
7 59 F 3 2 0 Exenteration 3 2 2 No 1 Yes 15 No Yes Yes
8 69 M APR 3 0 2 No 2 No 4 No No Yes
9 46 F 3 2 0 AR 3 1 0 No 3 Yes 93 No No No
10 57 M 2 0 0 APR 0 0 0 No 4 No 83 No No No
11 61 M 3 1 0 AR 3 1 0 Yes 2 Yes 90 No Yes No
12 74 M 3 1 0 APR 3 1 0 No 2 Yes 23 No Yes Yes
13 70 M 3 1 0 Hartmann's 3 2 1 Yes 2 Yes 15 Yes Yes Yes
14 60 F 3 1 0 AR 2 1 0 No 2 Yes 88 No No No
15 69 M 3 1 0 APR 2 0 0 No 2 No 52 No Yes Yes
16 58 M APR 3 0 0 No 1 57 No Yes Yes
17 64 F 3 2 0 AR 2 0 0 No 2 Yes 90 No No No
18 65 M 3 1 0 AR 3 2 1 No 2 Yes 30 No Yes Yes
19 72 M 3 1 0 APR 3 0 0 No 2 Yes 89 No No No
20 43 M 4 2 0 AR 3 0 2 No 1 Yes 6 No No Yes
21 46 F 4 2 0 APR 0 0 0 No 4 Yes 90 No No No
22 63 M 3 0 0 APR 1 0 0 No 2 No 28 No No No
23 65 M 2 0 0 APR 2 0 0 No 2 Yes 88 No No No
24 70 M 3 0 1 AR 2 0 0 No 3 No 44 No Yes Yes
25 39 M APR 3 0 0 No 2 27 No No No
26 76 F 3 0 0 APR 2 0 0 No 2 No 81 No No No
27 76 M 3 0 0 Hartmann's 3 0 0 No 3 Yes 38 Yes Yes Yes
28 63 M 3 0 0 APR 0 0 0 No 4 No 69 No No No
29 51 M 2 0 0 APR 2 0 0 No 2 86 No No No
30 56 F 2 0 0 AR 0 0 0 No 4 Yes 75 No No No
31 46 F 3 1 0 AR 3 1 0 No 2 Yes 40 Yes Yes Yes
32 52 M 3 2 0 APR 2 0 0 No 2 Yes 84 Yes Yes No
33 54 F 2 0 0 AR 2 1 0 No 2 Yes 38 No Yes Yes
34 77 M 2 0 0 AR 3 1 0 No 2 Yes 39 No No Yes
35 66 M 3 2 0 AR 2 0 0 No 2 Yes 71 No No No
36 55 F 4 2 0 AR 0 0 0 No 4 Yes 74 No Yes No
37 68 F 3 0 0 AR 0 0 0 No 4 Yes 64 No No No
38 67 M 3 0 0 AR 3 0 0 No 2 No 76 No No No
39 67 F 3 2 0 AR 4 2 2 Yes 1 Yes 25 No Yes Yes
40 54 M 3 1 0 AR 3 0 0 No 2 Yes 35 Yes No Yes
41 63 M 1 0 0 AR 3 0 0 No 2 Yes 69 No No No
42 73 F 3 2 0 AR 2 0 0 No 3 Yes 68 No No No
43 64 F APR 0 0 0 No 4 43 No No No
44 27 F 4 2 0 AR 4 0 0 No 3 Yes 67 No No No
45 76 M 2 0 0 AR 0 0 0 No 4 Yes 67 No No No
46 69 M 3 2 0 AR 3 0 0 No 2 Yes 64 No No No
47 62 M 3 2 0 APR 2 0 0 No 2 Yes 64 No No No
48 55 M 3 2 0 AR 3 0 0 No 2 Yes 61 No No No
49 64 M 3 1 1 APR 2 0 1 No 2 Yes 20 No Yes Yes
50 61 M 3 0 0 APR 2 0 0 No 3 Yes 50 No Yes Yes
51 74 M 3 0 0 Hartmann's 3 1 0 No 2 Yes 23 No Yes Yes
52 74 M APR 3 1 0 Yes 2 Yes 60 No No No
53 72 F 3 2 0 AR 3 0 0 Yes 3 No 9 No Yes Yes
54 47 M 3 1 0 APR 3 0 0 No 2 Yes 60 No No No
55 45 M 3 2 1 AR 3 2 0 No 1 Yes 29 No Yes Yes
56 67 M 2 0 0 Hartmann's 1 0 0 No 1 Yes 57 No No No
57 45 M 3 1 0 APR 2 0 0 No 2 Yes 42 No No No
58 71 M 3 0 0 Hartmann's 0 0 0 No 4 Yes 58 No No No
59 63 M 3 0 0 AR 3 0 0 No 2 Yes 36 No No No
60 70 F 3 2 0 AR 0 0 0 No 4 No 60 No No No
61 86 F 3 0 0 Hartmann's 2 0 0 No 2 No 57 No No No
62 72 M 3 1 0 AR 3 0 0 Yes 2 No 49 No No No
63 57 M 4 0 0 AR 3 2 0 Yes 2 Yes 35 No Yes Yes
64 69 F 3 2 0 Hartmann's 3 1 0 No 3 Yes 58 No Yes No
65 72 M 3 1 0 APR 3 0 0 No 1 Yes 56 No No No
66 55 M 3 1 0 AR 4 2 0 No 2 Yes 54 No Yes No
67 26 M 3 1 0 APR 3 2 0 Yes 1 Yes 26 No No Yes
68 77 M 3 1 0 AR 2 0 0 No 2 No 56 No Yes No
69 51 M 3 1 0 AR 4 2 0 Yes 2 Yes 37 No Yes Yes
70 59 M 3 1 0 AR 3 1 0 No 1 Yes 53 No Yes No
71 56 M 2 0 0 APR 0 0 0 No 4 No 55 No No No
72 68 F 3 0 0 AR 0 0 0 No 4 Yes 52 No No No
73 66 M 3 2 0 APR 3 2 0 No 2 Yes 44 No No No
74 71 M 3 0 0 AR 0 0 0 No 4 Yes 47 No No No
75 75 M 2 0 0 APR 2 0 0 No 2 No 51 No No No
76 76 M 4 0 0 Hartmann's 3 0 0 No 1 No 48 No No No
77 74 M 4 1 0 AR 3 0 0 Yes 2 Yes 49 No No No
78 58 M 3 1 0 AR 1 0 0 No 3 Yes 42 No No No
Pre-CRT Staging (MRI + CT) Histopathology Outcome
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Patient Age Gender Procedure Regression Adjuvant Follow Up
T N M T N CRM EMVI (Ryan) Therapy (months) Recurrence Metastases Death
79 61 F 3 2 0 AR 3 1 0 Yes 2 Yes 48 No No No
80 81 F 4 1 0 Hartmann's 0 0 0 No 4 No 47 No Yes No
81 56 M 3 1 1 Hartmann's 0 0 0 No 4 No 46 No Yes No
82 27 M 3 2 0 Panproctocolectomy3 2 0 Yes 2 Yes 43 No Yes No
83 76 M 4 1 0 AR 2 1 0 Yes 3 Yes 42 No No No
84 60 M 3 2 0 AR 3 2 0 Yes 1 Yes 41 No No No
85 53 M 3 0 0 AR 0 0 0 No 4 Yes 40 No No No
86 74 M 3 2 0 AR 2 0 0 No 2 Yes 31 No No No
87 48 M 2 0 0 APR 4 0 2 No 2 Yes 39 No Yes No
88 75 M 3 0 0 Hartmann's 3 0 0 No 2 No 37 No No No
89 57 F 3 2 0 AR 4 2 1 Yes 1 No 34 Yes Yes Yes
90 72 M 3 0 0 AR 2 0 0 No 1 37 No No No
91 49 M 4 1 0 APR 4 2 2 No 1 Yes 37 Yes Yes No
92 56 M 3 0 0 AR 2 0 0 No 1 No 33 No Yes No
93 76 M 3 0 0 APR 2 0 0 No 3 Yes 29 No No No
94 73 M 3 2 1 APR 4 1 0 Yes 1 Yes 32 No Yes No
95 77 F 4 2 0 Hartmann's 2 1 0 No 2 No 23 No No No
96 66 M 3 1 0 AR 2 0 0 No 2 Yes 22 No No No
97 33 F 3 0 0 AR 3 2 0 No 1 Yes 21 No No No
98 64 M 4 1 1 APR 2 0 0 No 3 Yes 18 No Yes Yes
99 79 M 3 1 1 APR 3 0 0 No 3 No 21 No No No
100 69 M 3 1 0 APR 3 2 0 Yes 1 Yes 19 No No No
101 70 M 3 1 0 Hartmann's 3 0 0 Yes 2 Yes 16 No Yes No
102 55 M 3 2 1 AR 3 1 1 No 1 Yes 18 No Yes No
103 79 F 3 0 0 APR 0 0 0 No 4 No 18 No No No
104 60 M 2 0 0 APR 2 0 0 No 2 No 17 No No No
105 76 M 4 2 0 APR 3 0 0 No 2 Yes 13 No No No
106 77 F 3 2 0 AR 3 1 0 Yes 2 Yes 16 No No No
107 71 M 4 2 0 Hartmann's 2 0 0 No 2 No 14 No No No
108 66 M 3 2 0 APR 0 0 0 No 4 Yes 13 No No No
109 66 M 3 2 0 APR 2 0 0 No 2 Yes 14 No No No
110 67 M 3 1 0 AR 0 0 0 No 4 Yes 11 No No No
111 67 M 3 0 0 APR 0 0 0 No 4 No 9 No No No
Pre-CRT Staging (MRI + CT) Histopathology Outcome
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Appendix C – Acid Ceramidase Expression from 10K Proteome in 49 Colorectal 
Cancer Cell Lines 
 
 
 
Cell Line Relative AC Expression
NCI-H716 -2.060838
GEO -1.451349
HT-29 -1.254239
SNU-61 -1.210463
LoVo -0.959903
COLO-320-HSR -0.920947
SW1116 -0.792969
HCC-56 -0.715943
HT-115 -0.712558
SW620 -0.649576
SW837 -0.649537
HCT-116 -0.633228
HT55 -0.60389
RKO -0.59612
LS-411N -0.5289
T84 -0.472482
HCT-15 -0.471081
SNU-175 -0.470129
LS-1034 -0.350895
SNU-C1 -0.342144
SNU-C2B -0.332953
CL-11 -0.24496
KM12 -0.200412
SW1463 -0.149981
GP5d -0.141356
SW948 -0.090236
SNU-C5 -0.038223
SK-CO-1 -0.00629
NCI-H630 0.172662
HCC2998 0.305689
SNU-407 0.375464
LS-180 0.382029
SNU-1040 0.471951
COLO-205 0.505021
CW-2 0.571851
CCK-81 0.595101
LS-513 0.627615
CL-40 0.666811
LS-123 0.667567
SNU-81 0.67398
DIFI 0.849557
CaR-1 0.988862
COLO-678 1.051976
RCM-1 1.181756
C2BBe1 1.279105
NCI-H747 1.41401
MDST8 1.419318
LIM1215 1.554641
NCI-H508 1.602017
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